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ABSTRACT OF DISSERTATION 
 
 
NEUROPROTECTIVE STRATEGIES FOLLOWING EXPERIMENTAL 
TRAUMATIC BRAIN INJURY: LIPID PEROXIDATION-DERIVED ALDEHYDE 
SCAVENGING AND INHIBITION OF MITOCHONDRIAL PERMEABILITY 
TRANSITION  
 
Traumatic brain injury (TBI) represents a significant health crisis. To date there 
are no FDA-approved pharmacotherapies available to prevent the neurologic deficits 
caused by TBI. Following TBI, dysfunctional mitochondria generate reactive oxygen and 
nitrogen species, initiating lipid peroxidation (LP) and the formation of LP-derived 
neurotoxic aldehydes, which bind mitochondrial proteins, exacerbating dysfunction and 
opening of the mitochondrial permeability pore (mPTP), resulting in extrusion of 
mitochondrial sequestered calcium into the cytosol, and initiating a downstream cascade 
of calpain activation, spectrin degradation, neurodegeneration and neurologic 
impairment.  
As central mediators of the TBI secondary injury cascade, mitochondria and LP-
derived neurotoxic aldehydes make promising therapeutic targets. In fact, Cyclosporine A 
(CsA), an FDA-approved immunosuppressant capable of inhibiting mPTP has been 
shown to be neuroprotective in experimental TBI. Additionally, phenelzine (PZ), an 
FDA-approved non-selective irreversible monoamine oxidase inhibitor (MAOI) class 
antidepressant has also been shown to be neuroprotective in experimental TBI due to the 
presence of a hydrazine (-NH-NH2) moiety allowing for the scavenging of LP-derived 
neurotoxic aldehydes. 
The overall goal of this dissertation is to further examine the neuroprotective 
effects of the mPTP inhibitor, CsA, and the LP-derived neurotoxic aldehyde scavenger, 
PZ, using a severe controlled cortical impact injury (CCI) model in 3-month old male 
Sprague-Dawley rats.  
First, the effects of CsA on cortical synaptic and non-synaptic mitochondria, two 
heterogeneous populations, are examined. Our results indicate that compared to non-
synaptic mitochondria, synaptic mitochondria sustain greater damage 24h following CCI 
and are protected to a greater degree by CsA.  
Second, the neuroprotective effects of a novel 72h continuous subcutaneous 
infusion of CsA combined with PZ are compared to monotherapy. Following CCI, our 
results indicate that individually both CsA and PZ attenuate modification of 
mitochondrial proteins by LP-derived neurotoxic aldehydes, PZ is able to maintain 
mitochondrial respiratory control ratio and cytoskeletal integrity, but together, PZ and 
CsA, are unable to improve and in some cases negate monotherapy neuroprotective 
effects. 
 
 
 
Finally, the effects of PZ (MAOI, aldehyde scavenger), pargyline (PG, MAOI, 
non-aldehyde scavenger) and hydralazine (HZ, non-MAOI, aldehyde scavenger) are 
compared. Our results indicate that PZ, PG, and HZ are unable to improve CCI-induced 
deficits to learning and memory as measured by Morris water maze (post-CCI D3-7). Of 
concern, PZ animals lost a significant amount of weight compared to all other group, 
possibly due to MAOI effects. In fact, in uninjured cortical tissue, PZ administration 
leads to a significant increase in norepinephrine and serotonin. Additionally, although PZ, 
PG, and HZ did not lead to a statistically significant improvement in cortical tissue 
sparing 8 days following CCI, the HZ group saw a 10% improvement over vehicle.  
Overall, these results indicate that pharmacotherapies which improve 
mitochondrial function and decrease lipid peroxidation should continue to be pursued as 
neuroprotective approaches to TBI. However, further pursuit of LP-derived aldehyde 
scavengers for clinical use in TBI may require the development of hydrazine (-NH-NH2)-
compounds which lack additional confounding mechanisms of action.  
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CHAPTER ONE: 
 
Introduction 
 
Epidemiology of Traumatic Brain Injury  
Traumatic brain injury (TBI) represents a significant health crisis in the United 
States and worldwide. Currently there are no FDA-approved pharmacological agents 
capable of attenuating the devastating neurologic consequences that can occur following 
TBI [1]. TBIs range from mild to severe, with at least two and a half million documented 
cases occurring in the United States annually [2]. However, these numbers are 
underestimates because the majority of TBIs are classified as mild [3], and often go 
unreported, especially in sports and military communities [4, 5]. In fact, it is estimated 
that sports-related TBIs alone occur at a rate of 3.8 million annually [6]. Young children 
(0-4 years), older teenagers (15-19 years), the elderly (>65 years), and males across all 
ages groups are at the highest risk of sustaining a TBI [7].  In the US, falls and motor 
vehicle accidents are the leading causes of TBI [7].  
Clinically, TBIs are classified using the Glasgow Coma Scale (GCS: mild 13-15, 
moderate 9-12, severe 3-8) an injury scale which relies on assessments of eye, motor, 
and verbal responses [8] (Fig. 1.1). However, it must be noted that although GCS can 
give a clinical assessment of brain injury, it is unable to characterize injury pathology [9], 
but clinical utilization of imaging can be useful in this regard. For example, amongst TBI 
patients categorized as having a severe TBI by GCS score, CT or MRI scans can 
distinguish between injury pathologies such as epidural hematoma, subdural hematoma, 
subarachnoid hemorrhage, etc. [9].   
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Glasgow Coma Scale 
Response Scale Score 
Eye Opening 
Response 
Eyes open spontaneously  4 
Eyes open to verbal command 3 
Eyes open to pain 2 
No eye opening 1 
Verbal Response 
Oriented 5 
Confused conversation; able to answer questions 4 
Inappropriate responses; words discernable 3 
Incomprehensible speech or sounds 2 
No verbal response 1 
Motor Response 
Obeys movement commands 6 
Purposeful movement to painful stimuli 5 
Withdraws from pain 4 
Spastic flexion; decorticate posture 3 
Rigid extensor response; decerabrate posture 2 
No Motor Response 1 
Mild = 13 - 15, Moderate = 9 - 12, Severe = 3 - 8 
 
Figure 1.1 Glasgow Coma Scale indicating the specific eye opening, verbal and motor 
responses and the corresponding scores utilized for clinical assessment of brain injury 
severity. 
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Although the majority of diagnosed TBIs are classified as mild on the GCS, the 
most severe injuries, those resulting in hospitalization and death, account for ninety 
percent of TBI-associated costs, a staggering amount considering that in 2010 both 
direct and indirect TBI medical costs were estimated to be seventy-five billion dollars [10, 
11].   
Additionally, there are over five million people in the United States living with a 
TBI-related disability [12]. In fact, over fifty percent of persons hospitalized due to TBI, 
will continue to suffer from a TBI-associated disability more than a year following injury 
[13]. Such disabilities can include cognitive, physical, and emotional impairments [12]. 
Animal Models of TBI 
Animal models have been used extensively to model TBI and are able to 
recapitulate several aspects of human TBI neuropathology and behavioral impairment 
[167]. Although large animal (e.g. swine) models of TBI exist, the majority of TBI studies 
utilize rodents [167]. However, there are several anatomic and physiologic differences 
between humans and rodents which must be taken into consideration [168]. For 
example, compared to rodents, human brains contain higher ratios of white to grey 
matter, higher ratios of glia to neurons, sulci, gyri, longer myelinated axons, and a 
denser vascular supply [168]. 
In humans, TBI injury pathology is heterogeneous and as such, several animal 
models of TBI have been developed, including controlled cortical impact injury (CCI), 
fluid percussion injury (FPI), and the Marmarou weight drop (WD) model. In recent 
years, with the growing interest in military and sports-related injuries, models of blast 
injury, mild closed head injury (CHI) and rotational injury have also been developed 
[167]. Due to the clinical heterogeneity of TBI, as well as the failure of TBI clinical trials, 
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many recent pre-clinical TBI studies, such as “Operation Brain Trauma Therapy” are 
screening drugs across multiple animal models of TBI [384]. These studies aim to 
identify drugs that have robust neuroprotective effects across multiple experimental 
injury paradigms, with the hope that such drugs will be clinically translationally for use in 
multiple types of human TBI. On the other hand, these types of studies have the ability 
to identify drugs that only have neuroprotective effects in certain experimental models, a 
finding that can improve future clinical trial designs by limiting the type of human TBI 
such drugs are evaluated in.    
The majority of severe injury studies have utilized the CCI, FPI and WD models, 
all of which have aspects of focal contusion, diffuse axonal injury, and hemorrhage. 
However, WD is often identified as being diffuse, FPI as mixed (focal/diffuse), and CCI 
as focal [167]. Although each model has its advantages and disadvantages, CCI, the 
model utilized in this dissertation, is considered to be more reproducible and have a 
lower mortality rate than both the WD and FPI models [167].  
Traumatic Brain Injury Pathophysiology 
 Primary Injury Mechanisms  
TBI consists of a primary injury followed by a secondary injury cascade. The 
primary injury occurs immediately and is caused by external forces, such as a direct 
impact, rapid acceleration/deceleration, or a blast wave. Primary injury can result in 
contusion, hemorrhage, ischemia, shearing and straining of axons and blood vessels, 
and diffuse axonal injury from the mechanical insult [14-16].  
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Secondary Injury Mechanisms  
Cellular strain and deformation caused by the primary injury results in membrane 
depolarization, mechanoporation of membranes, ionic imbalances, and neurotransmitter 
release, resulting in initiation of the secondary injury cascade, a process which occurs 
hours to weeks following injury [14, 15], and is heavily influenced by alterations in 
calcium homeostasis [16], mitochondrial function [17], and the process of lipid 
peroxidation (LP) [17], but includes additional processes such as neuroinflammation [14, 
18] (Fig. 1.2). The following sections present a simplified description of TBI secondary 
injury mechanisms and focuses on specific aspects of mitochondrial function and LP. 
Although not the main focus of this dissertation, because the drug of interest phenelzine 
(PZ) is classified as a monoamine oxidase inhibitor, dysfunction of monoamine 
neurotransmitter systems following TBI will also be briefly discussed. 
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Figure 1.2 Simplified schematic of the TBI secondary injury cascade. ROS = 
reactive oxygen species, RNS = reactive nitrogen species, PN = peroxynitrite, Mito = 
mitochondria, 4-HNE = 4-hydroxynoneal, ER = endoplasmic reticulum. Adapted from 
Kulbe et al. 2017 [19].  
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TBI-Induced Calcium Influx  
Activation of calcium channels by high levels of extracellular glutamate following 
injury, along with activation of voltage-gated calcium channels, failure of energy-
dependent calcium efflux pumps, and membrane leakage leads to large increases in 
intracellular calcium [16]. As essential regulators of calcium [20, 21], mitochondria 
attempt to maintain calcium homeostasis by taking up excess intracellular calcium, a 
process dependent upon the presence of the mitochondrial calcium uniporter, a calcium 
concentration gradient, and a negative mitochondrial membrane potential [22-24]. 
Additionally, calcium-binding proteins and the endoplasmic reticulum (ER) function to 
sequester calcium following injury [16]. 
Mitochondria: An Introduction 
Mitochondria and Physiologic Calcium 
 In addition to being able to sequester calcium under pathologically high 
intracellular calcium concentrations, mitochondria can regulate calcium homeostasis 
under physiologic conditions as well. Calcium is an activator of the citric acid cycle (TCA) 
enzymes, including pyruvate dehydrogenase, NAD+ dependent isocitrate 
dehydrogenase, and α-ketoglutarate dehydrogenase, therefore increases in calcium can 
induce increases in mitochondrial respiratory rates [21, 25]. Furthermore, the ability of 
mitochondria to cycle calcium allows for fine tuning of calcium concentrations in 
subcellular compartments such as the presynaptic terminal, allowing for tight regulation 
of processes such as neurotransmitter release [21, 25, 26].  
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Mitochondria and Energy Production (Fig. 1.3) 
Although mitochondria serve an important role in maintenance of calcium 
homeostasis under both physiologic and pathologic conditions, mitochondria are 
generally known for their role in adenosine triphosphate (ATP, i.e. energy) production. 
The brain primarily utilizes glucose as its energy source [27], a process which begins 
with cytosolic glycolysis, in which one molecule of glucose, a product of carbohydrate 
metabolism, is catabolized to form two molecules of pyruvate, two molecules of ATP, 
and two molecules of nicotinamide adenine dinucleotide (NADH). Fortunately, 
mitochondria can utilize pyruvate to significantly increase the amount of ATP that can be 
generated from each glucose molecule, through the process of oxidative 
phosphorylation.  
Pyruvate is transported across both the outer and inner mitochondrial 
membranes, into the mitochondrial matrix where it is converted into acetyl-coA before 
entering into the citric acid cycle (TCA). Through a series of oxidation (loss of electrons) 
and reduction (gain of electrons) reactions NADH and flavin adenine diculeotide (FADH2) 
are produced. NADH and FADH2 provide the electrons and protons utilized by the 
electron transport chain (ETC) complexes, located in the inner mitochondrial membrane, 
during the process of oxidative phosphorylation. Complex I (NADH dehydrogenase) 
receives electrons from NADH, while complex II (succinate dehydrogenase) receives 
electrons from FADH2. Complex I and II both pass these electrons on to complex III 
(coenzyme Q-cytochrome c oxidoreductase) through the electron-carrier coenzyme Q 
(ubiquinone).  
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Figure 1.3 Mitochondria electron transport chain. Following glycolysis pyruvate is 
transported into the mitochondrial matrix where it is converted into acetyl-coA before 
entering into the citric acid cycle (TCA). Electrons and protons are passed from NADH to 
complex I and from succinate / FADH2 to complex II. From there electrons are passed 
through coenzyme Q (Q) to complex III and onto complex IV through cytochrome c (C). 
At complex IV the electrons are passed onto the final electron acceptor O2 to generate 
water. As electrons are passed through the electron transport chain H+ are pumped from 
the matrix to the intermembrane space through complex I, III, and IV. Protons flow down 
their gradient at complex V to generate ATP from ADP. 
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From complex III electrons are transferred to cytochrome c before reaching 
complex IV (cytochrome c oxidase) where they are transferred to the ETC’s final 
electron acceptor, O2, resulting in the formation of H2O. 
Importantly, as the initially high energy electrons are passed through the redox 
centers of the ETC, this energy is used to pump protons (H+) from the mitochondrial 
matrix, across the inner mitochondrial membrane at complexes I, III, and IV, into the 
mitochondrial intermembrane space, producing the mitochondrial membrane potential, 
which under physiologic conditions is approximately -150 mV to -180mV [25, 28]. 
Generation of the mitochondrial membrane potential allows for H+ to re-enter the 
relatively negative mitochondrial matrix from the relatively positive mitochondrial 
intermembrane space, through the transmembrane protein ATP synthase, utilizing the 
energy generated as protons flow down their gradient to phosphorylate ADP and 
generate ATP, thus linking the electron transport chain with ATP production (i.e. 
oxidative-phosphorylation).  
Analysis of Mitochondrial Respiration (i.e. Bioenergetics)  
One method of evaluating mitochondrial bioenergetics is through the use of a 
Clark-type oxygen electrode, a device which measures oxygen concentration. 
Mitochondria are added to a 37°C continuously stirred chamber. As O2 is the final 
electron acceptor of the ETC, following addition of ETC substrates, O2 is consumed and 
drops in O2 concentration can be measured to assess respiratory rates. Upon addition of 
several compounds, information can be obtained regarding various individual states of 
mitochondrial respiration (Fig. 1.4).  
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Figure 1.4 Mitochondria states of respiration. (1) The complex I substrates pyruvate 
and malate are added to initiate state II respiration. (2) Next, boluses of ADP are added 
to initiate state III respiration. (3) Following addition of ADP, oligomycin is added to 
inhibit complex V (i.e. ATP synthase), inducing state IV respiration. (4) Next, the 
mitochondrial uncoupler FCCP is added to induce state V(I) respiration. (5) Rotenone is 
added to inhibit complex I, (6) followed by the complex II substrate succinate, initiating 
state V(II). Adapted from Vaishnav et al. 2010 [29].  
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State II respiration occurs after addition of the complex-I substrates pyruvate and 
malate, but before ADP addition, and represents a slow/basal state of respiration. 
State III respiration occurs following the addition of the complex-I substrates 
pyruvate and malate along with ADP, allowing for the formation of ATP (ADP + Pi) as 
protons pumped out of the mitochondrial matrix during electron transport flow back down 
their proton gradient via ATP synthase, thus coupling electron transport with oxidative 
phosphorylation. State III is considered one of the most important states of respiration, 
as decreases in State III respiration can be indicative of both impairments in complex-I 
driven substrate oxidation and/or ATP turnover [30]. 
State IV respiration is measured following addition of the ATP synthase inhibitor 
oligomycin, preventing the flow of protons down their proton gradient through ATP 
synthase. Therefore, the oxygen consumption which occurs following ATP synthase 
inhibition is due to proton leak across the membrane. Consequently, in healthy 
mitochondria state IV respiration should be low, representative of a basal state of 
respiration similar to state II [30, 31]. Intuitively, damaged mitochondria with leaky 
membranes would result in an increase in state IV. However, when damaged 
mitochondria show decreases in state IV, it may represent initial impairments in electron 
flow either due to damage to complex-I or upstream processes, such as to the citric acid 
cycle (TCA) enzymes. For example, damage to complex-I would impair electron flow to 
downstream ETC complexes (Fig. 1.3), resulting in a decrease in all complex-I-
dependent respiration states, including that of state IV. Similarly, damage to TCA 
proteins would impair electron flow into complex-I (and complex-II) (Fig. 1.3), resulting in 
a decrease in all individual respiratory states, including that of state IV.  
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Respiratory control ratio (RCR), the difference in oxygen utilization between 
activation of ATP production (state III) and inhibition of ATP production (state IV), is a 
general measure of mitochondrial health and function. Healthy mitochondria are able to 
generate ATP under minimal proton leak and therefore have high RCR values, whereas 
damaged mitochondria can have relatively lower RCR values, however, there is not a 
single RCR value which can be considered diagnostic of dysfunction [30].  However, as 
RCR is a ratio, equal drops in state III and state IV respiration would result in an 
unchanging RCR value.  
State V(I) is measured following addition of the protonophore, FCCP (carbonyl 
cyanide p-trifluoromethoxyphenylhydrazone), which allows for free flow of protons 
across the inner mitochondrial membrane down their gradient, uncoupling oxidative 
phosphorylation and allowing for complex-I driven maximal respiration, with decreases in 
state V(I) being indicative of deficits in complex-I initiated substrate oxidation [30].  
State V(II) respiration is measured following addition of the complex-I inhibitor, 
rotenone, and the complex-II substrate, succinate, and is a measure of complex-II driven 
maximal respiration. Therefore, decreases in state V(II) represent defects in complex-II 
driven substrate oxidation. 
Heterogeneity of Mitochondria  
Mitochondria are heterogeneous. Brain mitochondria have distinct properties 
compared to mitochondria derived from other organ systems as well as other regions of 
the CNS, such as the spinal cord [32, 33]. Additionally, there exists much heterogeneity 
within brain mitochondria themselves depending on brain region, cell type, and 
subcellular compartment.  
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For example, the activities of respiratory chain complex enzymes vary between 
brain regions (e.g. cortex, hippocampus, striatum), with high enzyme activities being 
seen in the cortex. ETC enzyme activities also vary between synaptic and non-synaptic 
mitochondria [34, 35]. Additionally, mitochondrial sensitivity to calcium-induced 
permeability transition varies between brain regions and between synaptic and non-
synaptic mitochondria, with striatal mitochondria being more sensitive to calcium than 
cortical mitochondria [36], and synaptic mitochondria being more sensitive to calcium 
than non-synaptic mitochondria [37, 38].  It has been proposed that differences in 
calcium sensitivities are in part due to concentrations of cyclophilin D (CyD), a protein 
which interacts with the mitochondrial permeability transition pore (mPTP).  In fact, 
higher concentrations of CyD are found in both striatum and synaptic mitochondria [36, 
38]. Additionally, high concentrations of CyD have been found within the interneurons of 
several brain regions and certain subpopulations of astrocytes [39]. Furthermore, 
heterogeneity in calcium responses have also been reported within non-synaptic 
populations, possibly due to differences in phosphate uptake [40].  
Previous studies have revealed that synaptic mitochondria are more susceptible 
to dysfunction than non-synaptic mitochondria [41-43]. In fact, non-synaptic mitochondria 
can tolerate larger impairments to respiratory complex activity before ATP production is 
significantly decreased [35]. Although the role non-synaptic neuronal mitochondria and 
mitochondria derived from glial subtypes have in brain function should not be dismissed, 
synaptic mitochondria are considered essential for proper neurotransmission and 
synaptic plasticity, [44-46]  processes which are impaired following TBI [47]. Synaptic 
mitochondrial dysfunction has been implicated in neurodegeneration, as well as 
degeneration of synapses and neurons absent overt cell death [37, 48, 49]. However, 
specifically protecting synaptic mitochondria against injury may prove challenging as 
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synaptic and non-synaptic mitochondria have been shown to have differential responses 
to pharmacotherapy [50].   
Currently, in order to examine the differences between synaptic mitochondria and 
non-synaptic mitochondria the populations must be isolated and examined ex-vivo. In 
the isolated mitochondrial preparations utilized in this dissertation, synaptic mitochondria 
consist of pre-synaptic mitochondria located within the synaptosome, whereas non-
synaptic mitochondria consist of neuronal (axonal, somal, dendritic) and non-neuronal 
(glial, vascular, etc.) mitochondria (Fig. 1.5). 
The Role of Mitochondria, Oxidative Stress, Lipid Peroxidation, and Neurotoxic 
Aldehydes in TBI 
Reactive Oxygen Species, Reactive Nitrogen Species, and Peroxynitrite 
Increases in intra-mitochondrial calcium following TBI lead to decreased 
mitochondrial membrane potential, decreased mitochondrial bioenergetics/respiration, 
and increased production of mitochondrial-derived reactive oxygen and nitrogen species 
(ROS/RNS) [23, 51]. Although calcium-induced decreases in the membrane potential 
may initially speed up the ETC in an attempt to maintain membrane potential [25], 
eventually, exceedingly high levels of calcium [52], along with injury-induced damage to 
electron transport complexes and upstream metabolic proteins, leads to ETC 
impairment, and as respiration slows, single electrons leak from complex I (and to a 
lesser degree complex III), and combine with O2, generating superoxide radicals (O2
●-), 
which rapidly react with the nitric oxide (●NO) generated by calcium-activated 
mitochondrial nitric oxide synthase (mtNOS), forming peroxynitrite (PN) anion (ONOO-) 
[53, 54].  
O2
● + ●NO → ONOO-  
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Figure 1.5 Schematic of synaptic mitochondria. Synaptic mitochondria are isolated 
from the presynaptic nerve terminal and represent a purely neuronal population. Non-
synaptic mitochondria are isolated from neuronal (e.g. axonal, somal, dendritic) and non-
neuronal sources such as astrocytes (shown above) and endothelial cells (not shown).  
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Protonation of ONOO- results in peroxynitrious acid (ONOOH) which 
decomposes into nitrogen dioxide (●NO2) and hydroxyl (•OH) radicals. Alternatively, 
ONOO- can react with CO2 to form nitrosoperoxocarbonate (ONOOCO2
-) which 
decomposes into the radicals ●NO2 and (CO
●-
3) [1, 55].  
ONOO- + H+ → ONOOH → ●NO2 + •OH 
ONOO- + CO2 → ONOOCO2
- → ●NO2 + CO
●-
3 
PN is demonstratively increased following brain and spinal cord injury [56-59] 
and because of its unique diffusion radius, mitochondrial-derived PN and its products are 
capable of damaging multiple cellular structures including proteins, lipids and nucleic 
acids [1, 55]. In addition to reactive species derived from the ETC and mtNOS, the outer 
mitochondrial membrane enzyme, monoamine oxidase, which is responsible for 
oxidation of monoamines such as dopamine (DA), serotonin (5-HT), norepinephrine 
(NE), and epinephrine (EPI) can also serve as a source of mitochondrial generated 
reactive species. 
Does Calcium Always Increase Generation of Mitochondria-Derived Reactive 
Species? 
Although increases in intra-mitochondrial calcium have been presented to lead to 
increased production of ROS/RNS, there is some controversy surrounding this topic 
depending on experimental conditions. For example, in naïve mitochondria calcium 
decreases respiration [52] and decreases production of mitochondrial-generated 
ROS/RNS, suggesting that because increases in calcium can immediately induce 
decreases in respiration, increases in mitochondrial generation of ROS/RNS may be a 
secondary event [52]. 
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In fact, calcium-induced increases in mitochondrial generated ROS/RNS may 
require induction of additional pathologies. For example, mitochondrial permeability 
transition (mPT) has been shown to be required for calcium-induced mitochondrial 
production of ROS, possibly because mPT decreases the ability of endogenous 
mitochondria antioxidants, such as glutathione (GSH) and NADH to attenuate ROS 
production [60]. Additionally, inhibition of complex I (NADH dehydrogenase) [61-63] or 
the presence of pro-apoptotic proteins [62] have been shown to be required for calcium 
to induce increases in mitochondrial derived ROS/RNS.  
However, it is difficult to extrapolate the findings of studies which utilized isolated 
mitochondria ex-vivo to in-vivo pathologies, particularly because in-vivo calcium 
regulation is complex and includes additional organelles, such as the endoplasmic 
reticulum [52, 63]. If, in fact, respiratory dysfunction does precede calcium-induced 
increases in mitochondrial ROS/RNS, it is possible that non-mitochondrial sources of 
oxidative stress (see below) may contribute to the initial respiratory deficits. For 
example, PN is capable of inactivating several mitochondria enzymes such as Complex I 
and II, creatine kinase, ATP synthase, aconitase, voltage-dependent anion channel 
(VDAC), and Mn-SOD (mitochondrial superoxide dismutase 2) [52, 54]. Although it is 
likely that mitochondrial generated ROS/RNS exacerbates dysfunction of these 
enzymes, it is possible that their initial dysfunction could be caused by non-mitochondrial 
sources of PN.  
Non-Mitochondrial Sources of Oxidative Stress  
In addition to the O2•
- produced by the mitochondria during oxidative 
phosphorylation, O2•
- is produced during several other processes, including metabolism 
of purines by xanthine oxidase, autoxidation of biogenic amines, metabolism of biogenic 
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amines by monoamine oxidase, and nicotinamide adenine dinucleotide phosphate 
(NAD(P)H) oxidase generation of inflammatory cell oxidative bursts [1, 64]. In fact, in 
addition to mitochondria, glial cells represent a significant source of ROS [64]. 
The metabolism of arachidonic acid, a polyunsaturated fatty acid abundant in 
cellular membranes, also accounts for generation of ROS [1, 64]. Following brain injury, 
phospholipases are activated resulting in the release of arachidonic acid. Arachidonic 
acid is metabolized by cyclooxygenases and lipoxygenases in order to produce a variety 
of signaling molecules, resulting in formation of ROS in the process [64].  
•NO, which reacts with O2•
- to form PN, can also be generated from several non-
mitochondrial sources. For example, calcium-activated endothelial NOS (eNOS) 
neuronal NOS (nNOS), and calcium-insensitive inducible NOS (iNOS) all lead to 
generation of NO• [59]. In fact, increases in NOS expression following experimental TBI 
coincide with PN-induced protein damage [59].  
Endogenous Mitochondrial Antioxidants  
As a major site of ROS/RNS generation under both pathologic and physiologic 
conditions, mitochondria require endogenous antioxidant systems. Although the O2
●- 
generated through mitochondrial respiration can go onto react with NO● to form PN, this 
is not always its fate. O2
●- can spontaneously dismutate to form H2O2, a reaction that is 
catalyzed by superoxide dismutase (SOD) [1, 65]. Mitochondria contain a specific form 
of SOD within their matrix, termed MnSOD or SOD2 [65] as well as the cytosolic Cu,Zn-
SOD or SOD1, within their intermembrane space [66]. Additionally, cytochrome c can act 
as an antioxidant in the removal of O2
●- and H2O2 [66]. Another electron carrier within the 
electron transport chain, ubiquinone, similarly has antioxidant properties [66, 67].  
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Although H2O2 is less reactive than its O2
●- predecessor, it can itself be 
damaging, particularly in the presence of iron, which catalyzes the Fenton reaction, 
resulting in the highly reactive OH•. 
Fe2+ + H2O2 → Fe
3+ + •OH + OH- 
 Fortunately, as glutathione peroxidases (GPx) are present within the 
mitochondria, H2O2 can be reduced to H2O by the glutathione (GSH)/GPx system, which 
is itself also capable of scavenging •OH [66]. Additionally, the reduction of H2O2 to H2O 
can be catalyzed by peroxiredoxins and thioredoxins, enzymes present within brain 
mitochondria, as well as catalase which is present in brain mitochondria, albeit in small 
quantities [66]. Furthermore, NAD(P)H, a hydrogen donor, can participate in the 
regeneration of GSH, as well as directly scavenge both ●NO2 and CO
●-
3 [66]. Additional 
antioxidants located in brain mitochondria include ascorbic acid (i.e. vitamin C) and α-
tocopherol (vitamin E), which is capable of scavenging lipid peroxyl radicals present 
within the mitochondrial membranes [66].  
Lipid Peroxidation (Fig. 1.6) 
Lipid Peroxidation: Initiation 
The highly reactive PN-derived radicals, ●NO2, •OH, CO
●-
3, initiate lipid 
peroxidation (LP) by extracting a hydrogen atom and its electron from a polyunsaturated 
fatty acid, such as arachidonic acid, which is highly enriched in neurons and cellular and 
organelle membranes, forming a lipid radical (L●) [1, 55].  
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Figure 1.6 Phases of lipid peroxidation. Initiation, propagation and termination of lipid 
peroxidation of arachidonic acid, including catalysis of propagation by Fe++, and the 
resulting formation of the lipid peroxidation-derived neurotoxic aldehyde 4-
hydroxynonenal (4-HNE). Adapted from Hall et al. 2010 [1]. 
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Lipid Peroxidation: Propagation 
The lipid radical (L●) allows for self-propagation of lipid peroxidation (LP) to occur 
throughout adjacent polyunsaturated acids, as it first reacts with O2 to form a lipid 
peroxyl radical (LOO●) capable of extracting a hydrogen atom and it’s electron from 
neighboring polyunsaturated acids, generating another lipid radical (L●) able to 
participate in further propagation reactions [1, 55]. Although LP is considered to be a 
self-propagating process, it is also catalyzed by the presence of iron, particularly in the 
acidic tissues of TBI [1]. Following TBI, decreases in pH cause iron to be released from 
the iron storage proteins, ferritin and transferritin, with additional iron being released 
from the hemoglobin deposited during hemorrhages and microbleeds [1].  
Lipid Peroxidation: Termination 
LP terminates upon breakdown of the peroxidized polyunsaturated fatty acids to 
form neurotoxic aldehydic end products, such as 4-hydroxynonenal (4-HNE) and 2-
propenal (acrolein) [1, 55]. It is well-established that oxidative stress, LP, and the LP-
derived aldehydes are increased in several CNS pathologies including TBI [57, 68-73], 
spinal cord injury (SCI) [74, 75], ischemic-reperfusion injury and stroke [64, 76], multiple 
sclerosis [64, 77], neurodegenerative disease [64], epilepsy [64], and psychiatric 
disorders [64], as well as other conditions which involve oxidative stress such 
atherosclerosis, diabetes, and obesity [78]. 
Lipid Peroxidation-Derived Aldehydes: 4-HNE and Acrolein  
Although the breakdown of polyunsaturated fatty acids can result in multiple 
classes of aldehydic end products including α,β-unsaturated aldehydes, di-aldehydes, 
and keto-aldehydes, the α,β-unsaturated aldehydes, namely 4-HNE and acrolein, are 
the most abundant and toxic products of LP [79]. Additionally, as 4-HNE and acrolein 
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were assessed as part of this dissertation work, 4-HNE and acrolein will be the two 
products discussed here by name.  
The neurotoxic aldehydes, 4-HNE and acrolein, are stable, diffusible end-
products, with acrolein being the more reactive of the two [79]. In addition to being a 
product of LP, acrolein is a well-known environmental pollutant and can also be formed 
by other physiologic processes such as the metabolism of spermine or hydroxyl-amino 
acids [79]. 4-HNE and acrolein covalently bind lysine, histidine, arginine and cysteine 
protein residues through both Schiff base and Michael addition reactions (Fig 1.7), and 
have multiple reactive sites which allows for formation of cross-linkage reactions [1, 79-
81]. Neurotoxic aldehydes can be metabolized through conjugation with the endogenous 
antioxidant GSH or through oxidation/reduction of their carbonyl groups by enzymes 
such as alcohol and aldehyde dehydrogenase [79, 82]. However, once neurotoxic 
aldehydes bind proteins, the protein-aldehyde conjugates are often targeted for 
degradation by the proteasome [83].  Additionally, once covalently bound to proteins, 
such as occurs following TBI, LP-derived aldehydes induce protein dysfunction and 
enzyme inactivation, neurotoxicity and cellular death [77, 84-89].  
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Figure 1.7 Acrolein and 4-HNE reactions. The multiple reactive sites of 4-
hydroxynonenal (4-HNE) and 2-propenal (acrolein) can react with various amino acids 
including lysine, histidine, and cysteine through both Schiff base and Michael addition 
reactions. Adapted from Vaishnav et al. 2010 [29]. 
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Although LP-derived aldehydes have been shown to bind and inactivate a vast 
array of cellular proteins [79, 81, 90-96], due to their polyunsaturated fatty acid 
composition and as a major site of PN formation, mitochondria are particularly 
susceptible to attack by LP-derived neurotoxic aldehydes [17, 68, 90, 91]. Binding of 4-
HNE and acrolein to mitochondria results in extensive mitochondrial dysfunction through 
impairment of mitochondrial respiration and enhanced generation of ROS/RNS [29, 71-
73, 97-99]. Following TBI, binding of LP-derived neurotoxic aldehydes to mitochondrial 
proteins further exacerbates TBI-induced impairment of mitochondrial bioenergetics and 
the initial ROS/RNS-LP-aldehyde cascade (Fig 1.8), which combined with high levels of 
intra-mitochondrial calcium concentrations can lead to opening of the mitochondrial 
permeability transition pore (mPTP) [29, 51, 53, 60, 72, 93, 100-102]. 
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Figure 1.8 Downstream effects of mitochondrial dysfunction. Mitochondria 
generated ROS/RNS initiate LP and the formation of the LP-derived neurotoxic 
aldehydes 4-HNE and acrolein. 4-HNE and acrolein exacerbate mitochondrial 
dysfunction and opening of the mPTP. Additionally, 4-HNE and acrolein-induced 
mitochondrial dysfunction increases generation of ROS/RNS, creating a ROS/RNS-LP-
neurotoxic aldehyde-mitochondrial dysfunction-ROS/RNS feedback loop. ROS/RNS = 
reactive oxygen species/reactive nitrogen species, LP = lipid peroxidation, 4-HNE = 4-
hydroxynonenal, mPTP = mitochondrial permeability transition pore.  
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Mitochondrial Permeability Transition Pore  
The mPTP is a non-selective mega channel. Upon formation it forms a pore 
between the inner and outer mitochondrial membranes that is permeable to solutes 
<1.5kDa [51]. Although the structure of the mPTP is not entirely elucidated it has been 
proposed to contain the inner mitochondrial membrane protein adenine nucleotide 
translocase (ANT) and the outer mitochondrial membrane protein VDAC [51]. 
Additionally, more recent studies suggest ATP Synthase is involved in pore formation 
[25].  Although the matrix protein cyclophilin D (CypD) is not a structural component of 
the mPTP, it can induce mPTP formation through interactions or ANT (or possibly with 
ATP Synthase [25]) which results in conformational changes [103]. However, CypD is 
not considered essential for mPTP formation as CypD knock-out mice can still undergo 
permeability transitions when subjected to high concentrations of substrates capable of 
inducing mPTP [103]. Additionally, some forms of permeability transition are considered 
to be insensitive to cyclosporine A (CsA), a compound that inhibits mPTP formation by 
binding CypD and inhibiting its ability to translocate to ANT to induce pore formation 
[103] (Fig. 1.9). Calcium, oxidative stress, a decrease in membrane potential, and 
inorganic phosphate (Pi) can induce mPTP opening, while opening of the channel can 
be inhibited by magnesium (Mg2+), high membrane potential, ADP, or through 
pharmacological means (e.g. CsA) [51].  
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Figure 1.9 Schematic of the mitochondrial permeability transition pore (mPTP). 
CsA binds to the matrix protein cyclophilin D, which prevents cyclophilin D from 
translocating to the inner mitochondrial membrane and binding the mPTP protein ANT, 
thus preventing induction of the confirmation change required for mPTP opening. Figure 
originally adapted from www.mitosciences.com.  
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Under pathologic conditions, opening of the mPTP leads to extrusion of calcium 
back into the cytosol, collapse of the membrane potential, cessation of ATP generation, 
mitochondrial swelling, rupture of the outer mitochondrial membrane, and release of 
cytochrome c and other apoptotic proteins [51, 104]. However, under physiologic 
conditions mPTP functions to produce ROS signaling molecules, as well as to regulate 
calcium concentrations in the microenvironment through transient openings and closings 
[105]. 
Downstream Consequences of Mitochondrial Dysfunction 
ATP Depletion 
Following TBI, neurons are in a state of high energy demand. Upon massive 
depolarization and ionic influx, cellular membrane pumps, such as Na+/K+ ATPase and 
Ca2+ ATPase must utilize ATP in an attempt to restore ionic balance [16]. Neurons 
primarily utilize glucose as an energy source and the initial demand for ATP following 
TBI is met by acute increases in glucose uptake. However, this acute increase is 
followed by a severity-dependent decrease. There are several possibilities for this 
decrease in glucose uptake including decreased cerebral blood flow, impairment of 
glucose transporters, and impairment of glucose metabolic processes upstream of the 
citric acid cycle (TCA), decreasing the overall pool of pyruvate available to the 
mitochondria for ATP generation [27]. Additionally, as calcium influx decreases the 
mitochondrial membrane potential, ATP synthase begins to slow and has the potential to 
run in reverse [25]. With limited substrate available to begin with, calcium-overloaded, 
aldehyde-modified, low membrane potential, dysfunctional mitochondria are unable to 
produce the amount of ATP required to meet the high energy demands of the injured 
brain.  
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Calpain Activation & Necrosis 
Calpain is a calcium-activated protease capable of breaking down a variety of 
cytoskeletal proteins including αII-spectrin [106], a scaffolding protein associated with 
the inner surface of the plasma membrane [107]. As stated previously, following TBI the 
induction of the secondary injury cascade relies heavily on increased intracellular 
calcium levels. Although calpain can be activated by early increases in intracellular 
calcium, calcium homeostatic mechanisms, including sequestration of calcium by the 
mitochondria prevent much of the initial activation. However, once the mPTP opens 
intra-mitochondrial calcium is extruded back into the cytosol where it can again activate 
calpain [51]. Calpain cleavage of the 250kD αII-spectrin protein results in 145kD 
(calpain-only) and 150kD (calpain/caspase 3) spectrin breakdown products (SBDP) 
[106]. Formation of SBDP proceeds neurodegeneration, and SBDP have been used 
extensively to assess post-TBI axonal damage and the efficacy of neuroprotective 
agents [56, 70, 108-112]. In fact, prevention of mPT, inhibition of the ROS/RNS-LP-
aldehyde cascade, and induction of endogenous antioxidant pathways have all been 
shown to attenuate αII-spectrin degradation [70, 109, 110, 113].  In TBI, calpain 
activation is thought to be predominately associated with necrosis [70, 106]. In fact, in 
the rat model of severe controlled cortical impact traumatic brain injury (CCI) utilized 
throughout this dissertation, the 120kD SBDP (caspase/apoptosis-dependent) has been 
shown to not increase with injury [73].  
Caspase Activation & Apoptosis  
Following opening of the mPTP or increases in mitochondria outer membrane 
permeability, mitochondria can release pro-apoptotic proteins such as cytochrome c, 
apoptosis inducing factor (AIF) and Smac/Diablo, leading to a cascade of caspase 
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activation, including activation of the executioner caspase, caspase-3 [51, 106]. In 
addition to DNA-fragmentation, caspase-3 can cleave αII- spectrin, resulting in 150kD 
(calpain/caspase-3) and 120kD fragments [106].   As stated previously, cell death in TBI 
is thought to be predominately necrotic. However, TBI-associated apoptosis has been 
documented, particularly in pathologies involving ischemic injury [106, 114], and 
caspase-3-dependent SBDP have been found to occur in the CSF of rats following 
moderate CCI, albeit inconsistently and to a lesser degree than calpain-dependent 
products [115].  
Neurodegeneration 
In addition to αII-spectrin, calcium-activated calpain can cleave a variety of other 
cytoskeletal proteins including MAP2 (microtubule-associated protein 2) and tau [51, 
104, 106, 116]. One of the consequences of cytoskeletal degradation following TBI is 
impairment of axonal conductance and axonal transport [117]. Impairment of axonal 
transport can result in the accumulation of proteins, such as amyloid precursor protein 
(APP) in axonal varicosities and bulbs of damaged neurons [51, 104, 106, 116]. 
Additionally, cytoskeletal degradation and impairment of axonal transport interfere with 
the transport of organelles, such as the transport of healthy mitochondrion from the cell 
body to the synapse [118], where loss of synaptic mitochondria can result in synaptic 
degeneration [37, 48, 49] and impairment of synaptic plasticity [119]. The degradation of 
the cytoskeleton can further impair mitochondria by interfering with normal mitochondrial 
quality control measures such as fission and fusion, processes essential to maintaining 
mitochondrial health and function, particularly under times of stress such as occurs 
following TBI [120]. 
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Sensitive methods for assessing neurodegeneration, such as de Olmos 
aminocupric silver staining, which specifically stains degenerating neurons and neuronal 
processes have revealed that following experimental TBI neurodegeneration often 
occurs to a much greater than that of overt neuronal loss or cavitation, even in primarily 
focal injury models such unilateral CCI [121].  In fact, following unilateral CCI, 
neurodegeneration has been demonstrated to occur throughout the ipsilateral cortex, 
hippocampus and thalamus, as well as to extend into the contralateral hemisphere [121].  
Previous studies have demonstrated that both mitochondrial dysfunction and LP 
contribute to the neurodegenerative process, as pharmacologic interventions aimed at 
attenuating mitochondrial dysfunction and inhibiting the ROS/RNS-LP-aldehyde cascade 
have been shown to decrease neurodegeneration following injury. For example, 
compounds which target these processes such as CsA and NIM811 [110, 122-124], PZ 
[71, 72], tempol [109], mitochondrial uncouplers [125], and N-acetylcysteine (NAC) [126] 
are all able to attenuate neurodegeneration or neuronal cell death following TBI. 
Time Course of Oxidative Stress, Mitochondrial Dysfunction, and 
Neurodegeneration Following TBI 
 Formation of OH• occurs as early as five minutes following experimental TBI 
[161, 162].  Within 30min, there is a significant decrease in cortical and hippocampal 
mitochondrial respiration, an effect which dissipates 1h post-injury [163]. However, 
because the ability of mitochondria to buffer calcium 30min post-injury remains intact, it 
is speculated that this initial burst of oxidative stress [161, 162] induces mitochondrial 
respiratory dysfunction without inducing permeability transition, allowing mitochondria 
the ability to functionally recover from early incidences of oxidative stress [163].  
However, by 3h post-injury, decreases in mitochondrial respiration reappear and 
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coincide with a decrease in calcium buffering capacity [163]. Although there is some 
evidence to suggest a slight recovery between 3h and 24h, this possibility can be 
explained by the most damaged mitochondria being processed out prior to the 24h time 
point [73, 163]. Beyond 24h, mitochondrial respiratory dysfunction continues to 
deteriorate, reaching peak impairment 72h following severe CCI [73]. By five days post-
CCI, mitochondrial respiration has begun to recover, likely due to further removal of 
impaired mitochondria as damaged tissue continues to degenerate [73]. However, it 
must be noted that decreases in mitochondria respiratory function and membrane 
potential have been documented as far out as two weeks following experimental TBI [22, 
134].  
Increases in cortical or hippocampal 3-nitrotyrosine (3-NT, marker of PN 
damage), 4-HNE, and SBDP have been identified as early as 30-60 min following TBI in 
mice [56, 57]. However, this time course seems to be slightly delayed in the rat [73, 121], 
with small increases in cortical or hippocampal 3-NT, 4-HNE, acrolein and SBDP 
beginning as early as 8h and peaking between 48h and 72h in severe CCI before 
returning to baseline levels 5d to 7d following injury [73]. Regardless of species, these 
processes do precede cortical and hippocampal neurodegeneration, as well as 
increases in cortical lesion volume [121, 164] because although levels of mitochondrial 
dysfunction, LP, and spectrin degradation have returned to baseline by 5-7days 
following severe CCI [73], neurodegeneration and cortical lesion volumes continue to 
progress [56, 121, 164].  In fact, although cortical contusions can be seen early following 
experimental TBI, volumes continue to increase until at least 28 days post-injury [164].  
 Up until this point the process of mitochondrial dysfunction, LP, LP-derived 
aldehyde formation, and spectrin degradation have been presented to occur in a linear 
fashion for simplicities sake. However, time course studies are an important reminder 
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that many of these processes can occur simultaneously. Although significant 
impairments to mitochondrial respiration do appear to occur prior to these other 
processes, the observation that peak dysfunction for many of these processes occurs 
between 48h and 72h following severe CCI [73], reinforces the idea that these 
processes often work synergistically to exacerbate each other’s dysfunction.  
Time Course of Antioxidant Depletion Following TBI 
 Following TBI, increases in ROS/RN, LP, and neurotoxic aldehydes result in the 
depletion of endogenous antioxidants. However, the temporal decrease in antioxidant 
activities is variable across experimental TBI studies [165, 166]. Following unilateral CCI 
decreases in a wide range of antioxidants (e.g. GSH, SOD, catalase, GPx, etc.) have 
been reported to occur in both hemispheres and the hippocampus beginning as early as 
3-6h following injury, with some enzymes remaining significantly decreased out to 4 days 
post-TBI [165, 166].  
Although the body has mechanisms for upregulating endogenous antioxidant 
systems during times of oxidative stress, including through binding of the transcription 
factor, nuclear factor (erythroid-derived 2) (Nrf2), to the antioxidant responsive element 
(ARE), mRNA expression for several of the Nrf-2-ARE regulated antioxidants, such as 
heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NqO1), and glutathione 
S-transferase (GST), do not begin to increase until 24h to 72h following injury [111], 
much later than 3-6h post-injury timeframe in which antioxidants begin to deplete 
following TBI [165, 166].   
Behavioral Impairment 
 In human patients, TBI often results in long-term neurobehavioral dysfunction, 
including cognitive deficits (e.g. attention, memory), aggression, and psychiatric, mood, 
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and anxiety disorders [127], sequelae that can be recapitulated in animal models, 
although most behavioral outcome assessments in experimental TBI have focused on 
motor and sensory dysfunction and impairments to learning and memory.  
It is unsurprising that TBI would have neurobehavioral consequences given the 
widespread neurodegeneration and neuronal dysfunction that is seen in both animal 
models of injury [56, 57, 121, 128] and in human TBI patients [129-131]. Although the 
behavioral impairments that occur following TBI will vary depending on the specific 
neurons, pathways and networks affected by injury, mitochondria dysfunction contributes 
to development of TBI-induced behavioral deficits, and pharmacologic protection of 
mitochondria  and inhibition of downstream consequences of mitochondrial dysfunction 
such as LP and spectrin cytoskeletal degradation are able to attenuate behavioral 
deficits following experimental TBI [109, 110, 123, 125, 126, 132, 133]. Although 
mitochondrial dysfunction has been shown to precede behavioral impairment [134], 
behavioral deficits can be seen as early as one day following injury, particularly in 
regards to motor dysfunction [109, 135-137]. Similarly, although the majority of 
experimental TBI studies begin assessments of cognitive function at least one week 
following injury [135, 138-140], early cognitive deficits have also been reported [141-
144].  
The experimental model of TBI utilized here, a unilateral CCI onto the motor and 
sensory parietal cortex, although not assessed as part of this dissertation work, 
expectedly can produce motor and sensory deficits [109, 110, 145]. However, this type 
of CCI also can induce cognitive impairment. For example, severe unilateral CCI 
produces widespread degeneration throughout the hippocampus [121, 128], a brain 
region involved in forming new memories and in spatial memory [146, 147], and 
throughout the thalamus [121, 128], a subcortical structure through which a variety of 
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important neuronal tracts pass [148, 149]. Additionally, although the prefrontal cortex is 
responsible for the majority of executive functions, neuronal projections involved in 
executive function extend throughout the cortex beyond the pre-frontal region [150, 151]. 
Therefore, injuries sustained in anatomic regions distinct from the pre-frontal cortex, 
such as a CCI onto the sensory-motor cortex, additionally put these projections at risk 
due to Wallerian/anterograde and retrograde degeneration [121]. In fact, unilateral CCI 
to the sensory-motor cortex has been shown to result in executive function (e.g. 
motivation, planning, problem-solving, working memory) related behavioral deficits [152].  
Although there are several behavioral tests available to assess cognitive function 
following experimental TBI, the work in this dissertation utilized the Morris water maze 
(MWM), a task which evaluates spatial, working and reference memory. Briefly, in MWM 
animals are placed into a circular, featureless pool, filled with opaque water, and 
surrounded by visual cues. During the acquisition phase, which assesses working 
memory, animals are allowed 60s to find a submerged platform after which they are 
allowed to remain on the platform for approximately 20s. Animals which do not find the 
platform are manually guided and placed onto the platform. Animals are given several 
trials per day over the course of multiple days, and as the animals learn the location of 
the platform, the time and distance it take to find the platform should decrease [146, 
147]. Following the acquisition phase a probe trial is utilized to test reference memory 
[147]. In the probe trial, the platform is removed and animals are given 30s to search for 
the previously learned platform location [147].  
Overt damage to several distinct brain regions have been shown to impair MWM 
performance, including damage to the hippocampus, cortex, thalamus, raphe nuclei, and 
striatum [146]. However, overt damage to specific anatomical regions is not required to 
induce MWM impairment per se, as dysfunction in the neural communication networks 
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between regions also result in impairments to spatial learning and memory [146]. For 
example, although the hippocampus is necessary for consolidation, storage, acquisition 
and retrieval of spatial memory, spatial navigation is complex and requires coordination 
of several brain regions, including the cortex, as cortical input is required for the planning 
and execution of the task [146]. 
In addition to distinct anatomic regions, specific neurotransmitters, such as 
norepinephrine (NE), serotonin (5-HT), and dopamine (DA) have an important role in 
cognitive and motor function [150, 151, 153-155]. Although not addressed as part of this 
study, the neurotransmitter acetylcholine also plays an important role in cognition [385]. 
In fact, acetylcholinesterase inhibitors, such as donepezil, are often used clinically to 
treat memory disorders, as are NMDA antagonists, such as memantine [385]. In regards 
to the monoaminergic system, stimulants, which modulate the DA system, also are 
clinically used to improve cognition and attention [385]. However, the role each 
monoamine has in spatial learning in memory remains controversial. For example, drugs 
which can modulate these systems (e.g. monoamine oxidase inhibitors (MAOI), selective 
serotonin reuptake inhibitors (SSRI), amphetamines, DA agonists, 5-HT agonists) have 
variously been reported to improve, decrease, or have no effect on spatial learning and 
memory performance [146, 156-159].   
There are several caveats to utilizing MWM in the assessment of spatial learning 
and memory. For example, although the intent of MWM is to evaluate spatial learning 
and working memory by requiring animals to utilize distal cues to locate the platform, 
animals can utilize other strategies such as a learned set of movement sequences or 
use of proximal cues [146]. However, varying the start position of trials each day and 
using featureless pools with opaque surfaces, as was done in the current dissertation 
work, should help to control for these factors. Furthermore, MWM performance is often 
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considered independent of locomotor deficits [147] and probe trial performances have 
been reported to be insensitive to swim speed deficits [147]. However, that assumption 
is not entirely true as sensorimotor deficits can indeed interfere with MWM performance 
[147]. For example, animals with sensorimotor deficits often continually follow the pool 
perimeter without initiating a search pattern, jump off or swim over the platform [147], 
thus reducing the ability of the animal to associate the platform with a means of escape, 
which make it more difficult to accurately assess memory impairments [147]. 
Additionally, visual acuity is required for use of the distal MWM cues, which can be 
concerning considering that visual pathways run through the thalamus [148] and have 
been demonstrably damaged following experimental TBI, although this is more 
commonly seen in closed head injury models [160]. Visual acuity can be assessed 
through use of visual platform cues, such as a platform flag. However, such visual acuity 
assessments were not conducted as part of this dissertation work [386].  
An Introduction to Biogenic Amines  
Biogenic Amines 
Biogenic amines consist of polyamines (e.g. putrescine), trace amines, such as 
phenethylamine (PEA), which exists endogenously as a metabolite of the amino acid 
phenylalanine and as a metabolite of the drug PZ, and the monoamine neurotransmitters 
[151, 169]. The monoamine neurotransmitters include the catecholamines DA, NE, and 
epinephrine (EPI), as well as the non-catecholamines histamine and 5-HT [151, 169]. 
DA, NE, and EPI are synthesized sequentially from the amino acid tyrosine, while 
histamine is derived from the amino acid histidine and 5-HT is derived from the essential 
amino acid tryptophan [151](Fig. 1.10).  
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Figure 1.10 Synthesis of the monoamines. Dopamine, norepinephrine, and 
epinephrine are sequentially synthesized from the amino acid tyrosine. Histamine is 
synthesized from the amino acid histidine, and serotonin (i.e. 5-HT) is synthesized from 
the amino acid tryptophan. 
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Biogenic Amine Anatomic Pathways and Physiologic Functions 
Dopamine 
Within the nervous system DA is involved in a wide range of processes including 
movement, motivation, reward, addiction, memory, stress and mood [154]. Although the 
majority of DA is found within the striatum, DA is found throughout the brain [154]. For 
example, within the mesocorticolimbic system, DA neurons from the ventral tegmental 
area project directly to the hippocampus and prefrontal cortex [153, 170]. Further, 
although the nigrostriatal pathway, predominately involved in movement regulation, 
consists of dopaminergic neurons projecting directly from the substantia nigra to the 
striatum, it is part of complex circuitry that includes input and output to the motor cortex, 
along tracts that pass through the thalamus [153]. As a catecholamine, in addition to 
binding DA receptors, DA can bind adrenergic receptors [154]. Clinically, DA can be 
used as a vasopressor to elevate cerebral perfusion pressure and mean arterial blood 
pressure following severe TBI [154].  
Norepinephrine 
Within the brain NE neurons are concentrated in the locus coeruleus with 
widespread connections to areas including the cortex, limbic system, and thalamus, and 
it is involved in modulation of arousal, attention, mood, cognition and memory [150, 151]. 
As a catecholamine, NE, also known as the “flight or fight” neurotransmitter can bind 
adrenergic receptors and induce sympathetic responses such as vasoconstriction [154, 
171]. As such, similar to DA, NE can be used as vasopressor in clinical TBI [154].   
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Serotonin   
 Within the CNS, 5-HT neurons arise from the raphe nuclei and project 
extensively throughout most of the brain including the cortex, limbic system, and 
thalamus [151], modulating arousal, mood, cognition and memory [155]. Interestingly, 
the majority of 5-HT is found outside the CNS, within the gastrointestinal tract [155]. 
Additionally, 5-HT plays a role in platelet activation, vasodilation, and vasoconstriction 
[172].    
TBI and Acute Monoamine Dysregulation 
Neurobehavioral sequelae following TBI are common and include dysregulation 
of cognition (e.g. attention, memory), mood (e.g. depression, anxiety), and emotion (e.g. 
aggression) [127]. Given the role the monoamines DA, NE, and 5-HT have in modulating 
these domains, sustained neurobehavioral impairments following TBI points to chronic 
dysregulation of monoamine neurotransmitter systems. However, as the goal of this 
dissertation is to evaluate acute neuroprotective pharmacologic strategies, the following 
brief discussion only includes acute changes in the monoamine systems following TBI. 
In general, less is understood about acute effects to monoamine systems 
following TBI, with the majority of work being focused on DA systems [154, 170]. 
Although DA is known to be acutely altered following experimental TBI [154, 170], some 
studies indicate increased DA levels, whereas others report decreased DA levels 
depending on brain region and time point [173, 174]. Additionally, other aspects of the 
dopaminergic system such as DA synthesis, metabolism, and DA transporter protein 
expression, have also been reported to be altered following TBI [175-177].  
Similarly, NE levels and turnover rates have been demonstrated to be acutely 
altered following experimental TBI, with variations again been seen across distinct brain 
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regions [174, 178, 179]. Further, high NE levels have been shown to be associated with 
worse outcomes and/or mortality rates in TBI patients [180, 181]. However, because 
catecholamine levels increase with activation of the sympathetic nervous system, as 
would occur following trauma, it is difficult to determine whether high catecholamine 
levels following TBI are an actual cause or rather an effect of injury severity [181].    
Less data are available regarding acute levels of 5-HT following TBI. However, 
increases in extracellular 5-HT levels have been demonstrated to occur [182]. Similarly, 
at subacute time points 5-HT expression has been shown to be increased [183]. On the 
other hand, at subacute time points 5-HT transport protein expression has been reported 
to decrease [184] and degeneration of 5-HT neurons has been seen following multiple 
types of experimental TBI [185], unsurprising given the widespread projections of 5-HT 
pathways throughout the brain.  
Monoamine Metabolism  
 Monoamines are removed from the synaptic cleft by reuptake into pre-synaptic 
nerve terminals and glial cells [151]. DA has two major metabolites, 3,4 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), both of which are 
measured in this dissertation. The metabolism of DA involves three enzymes, 
monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde 
dehydrogenase (ALDH), and the additional intermediate metabolite 3-methoxytyramine 
(3-MT) [186] (Fig. 1.11).  
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Figure 1.11 Simplified monoamine metabolism pathways. Dopamine is metabolized 
by monoamine oxidase (MAO-A/B), catechol-O-methyl transferase (COMT), and 
aldehyde dehydrogenase (ALDH) to form the metabolites 3,4 dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA), and the intermediate metabolite 3-
methoxytyramine (3-MT). Norepinephrine (NE) is metabolized by MAO-A and COMT. 
Serotonin (5-HT) is metabolized by MOA-A and ALDH to form 5-hydroxyindolacetic acid 
(5-HIAA). 
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MAO is located in the outer mitochondria membrane. MAO requires the presence 
of the cofactor FAD+/FADH2 and oxygen to function [186]. ALDH is also a mitochondrial 
protein, located within the matrix and requires the cofactors NAD+/NADH. COMT is a 
cytosolic enzyme [186]. DA is metabolized by MAO-A/B and ALDH to form DOPAC 
which can be further metabolized to HVA by COMT. Additionally, DA can first be 
metabolized by COMT to form 3-MT before being further metabolized to HVA by MAO-
A/B and ALDH [186]. The metabolism of NE also involves MAO-A and COMT, as well as 
a variety of other enzymes, and results in the formation of metabolites such 
vanillylmandelic acid (VMA) and 3-methyoxy-4-hydroxyphenylglycol (MHPG) [186]. 
However, NE metabolites were not measured as part of this study due to their low 
cortical tissue levels. 5-HT is metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by 
MOA-A and ALDH [186], and is measured as part of this dissertation.  
 As part of this dissertation work the cortical tissue levels of NE, DA, 5-HT and the 
metabolites DOPAC, HVA, 5-HIAA were measured using HPLC [187]. The turnover of 
DA to DOPAC/HVA and the turnover of 5-HT to 5-HIAA were used a surrogate measure 
of MAO inhibition [188].  
Monoamine Oxidase: An Outer Mitochondrial Membrane Protein  
The MAO enzyme exists as two subtypes, MAO-A and MAO-B, both of which are 
located in the outer mitochondrial membrane. MAO contains a flavin group allowing it to 
participate in oxidative deamination reactions [186]. MAO is responsible for the 
metabolism of the monoamine neurotransmitters NE, 5-HT, and DA, measured within 
this dissertation, but additionally participates in the metabolism of EPI, several amino 
acids, and PEA, a trace amine under physiologic conditions, but which is also an active 
metabolite of PZ [186, 189]. MAO-A and MAO-B have differing substrate affinities. For 
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example, MAO-A is selective for NE, 5-HT, and EPI, whereas MAO-B is selective for 
PEA [186]. DA, on the other hand, is metabolized by both MAO-A and MAO-B [186]. 
However, the metabolism of DA by MAO differs between rodents and humans, with DA 
being predominately metabolized by MAO-A in rats and MAO-B in humans [186]. In the 
brain, monoamines are removed from the synaptic cleft by reuptake into pre-synaptic 
nerve terminals and glial cells [151]. In fact, the majority of MAO in the brain is located 
within the glia [190], with the MAO-B isoform predominating in glia as well as in 
serotonergic neurons and platelets [190].   
Monoamine Oxidase Inhibitors  
 Clinically, MAOIs have been used as anti-depressants, as MAO inhibition leads 
to increases in neurotransmitters that are dysregulated in mood and other psychiatric 
disorders. However, MAOIs, particularly irreversible inhibitors, have numerous side 
effects, including several food interactions that can lead to a dangerous tyramine toxicity 
syndrome and hypertensive crisis. With the development of newer class anti-
depressants, MAOIs are no longer considered a first-line therapy for depression [191].  
 Multiple classes of MAOIs exist, including irreversible MAO-A selective inhibitors, 
irreversible MOA-B selective inhibitors (e.g. selegiline, rasagiline), irreversible non-
selective inhibitors (e.g. PZ, isocarboxazide, tranylcypromine, pargyline), and several 
reversible inhibitors, including methamphetamine (MAO-A selective) [191]. PZ, 
isocarboxazide, and tranylcypromine have all been used clinically in the treatment of 
anxiety and depression, while selegiline and rasagiline are currently used clinically to 
treat the symptoms associated with Parkinson’s disease [191].  
 Given their use for the symptomatic treatment of neurodegenerative disease, 
there has been increasing interest in studying the neuroprotective properties of MAOs 
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[192]. However, in theory MAOIs could have both neuroprotective and neurotoxic 
effects. For example, oxidative deamination of monoamine neurotransmitters by MAO, 
generates ROS [193], suggesting that MAO inhibition could reduce ROS and provide a 
therapeutic benefit. However, inhibition of MAO also leads to increases in biogenic 
amines, such as DA, which is capable of directly inhibiting mitochondrial respiration 
[194], and undergoing non-enzymatic autoxidative formation of toxic H2O2 and quinones 
[194], suggesting that MAO inhibition could also lead to increases in neurotoxicity and 
oxidative stress. 
Although the plasma half-lives of the MAOIs vary, irreversible MAOIs have longer 
lasting effects than their plasma half-lives suggest due to the rate of MAO turnover. In 
fact, the half-life of MAO in the rat brain is 10-13 days [195], increasing to 30 days in 
humans [196]. However, it must be noted that because effects on neurotransmitter levels 
and behavior can require 65-80% MAO inhibition, the effective recovery time for MAO in 
the rat brain may be as low as 4 days [186]. However, multiple doses of an MAOI may 
prolong MAO inhibitory effects, as might TBI given the fact that regeneration of MAO 
within presynaptic nerve terminals requires trafficking of MAO and mitochondrion to the 
synapse [191].   
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MAOI Properties of Phenelzine  
 Although PZ is classified as a non-selective MAOI, it is slightly more preferential 
to MAO-A [197]. The structure of PZ contains a hydrazine moiety (-NH-NH2), which 
confers it the ability to scavenge LP-derived neurotoxic aldehydes [72, 198] (Fig. 1.12). 
However, this moiety is also purported to contribute to its ability to act as an irreversible 
MAO inhibitor [199]. As a MAOI, PZ has both anti-depressant and anxiolytic properties 
[169]. However, similar to other MAOIs, PZ is not clinically utilized as a first line therapy 
to treat psychiatric disorders, although it is a choice for the treatment of atypical or 
intractable depression [191].  
In humans, following oral administration the plasma half-life of PZ is 
approximately 11.5 hours [74], although following intraperitoneal administration in rats, 
the half-life could be as short as 30min [74]. However, in regards to PZ’s MAOI 
properties, the plasma half-life is of minimal importance, as the effects of irreversible 
MAO inhibitors are prolonged and based on MAO turnover rates. In rats, the ED50 for 
oral administration of PZ has been reported to be 6 mg/kg for MAO-A and 12 mg/kg for 
MAO-B, resulting in a 2:1 selectivity ratio of MAO-A to MAO-B [197]. 
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Figure 1.12 Chemical structures of phenelzine and pargyline. Phenelzine contains 
an aldehyde-scavenging hydrazine moiety (-NH-NH2, circled in red), while pargyline 
does not. However, PG contains an N-propargyl moiety (circled in blue) 
  
 
 
49 
MAOI Properties of Pargyline 
Pargyline (PG) is similarly structured to PZ, but does not contain the hydrazine 
moiety (-NH-NH2) which gives PZ its aldehyde-scavenging capabilities (Fig. 1.12). 
Instead, PG contains an N-propargyl moiety, which confers its MAOI effects [200]. 
Interestingly, the N-propargyl moiety, itself, has also been suggested to be 
neuroprotective [201]. PG has been both referred to as a non-selective irreversible MAOI 
[191], as well as a MAO-B specific irreversible inhibitor [197], likely based on IC50 values 
of 0.011522 μmol/L for MAO-A and 0.00820 μmol/L for MAO-B [202]. However, in rats, 
the ED50 for oral administration of PG has been reported to be 9.3 mg/kg for MAO-A and 
1.4 mg/kg for MAO-B, resulting in a 6.6:1 selectivity ratio of MAO-B to MAO-A [197].  
Although PG is classified as a MAOI, clinically it was used more frequently as an 
anti-hypertensive than as an anti-depressant [203]. This is somewhat paradoxical as the 
interaction between MAOIs and tyramine-containing foods can induce a hypertensive 
crisis [191]. However, its anti-hypertensive properties are thought to be due to increased 
NE levels acting on inhibitory α2-adrenergic receptors, such as those found in the 
brainstem and periphery [204]. Therefore, it is possible that several other irreversible 
MAOIs may also have anti-hypertensive effects. 
Comparison of Phenelzine and Pargyline MAO Inhibitory Effects on Drug-Induced 
Behavioral Changes  
 The MAOI drug class was developed decades ago. Therefore, recent 
comparisons between PZ and PG are sparse. However, both drugs have been utilized 
within single studies to assess the effects of MAOIs on drug (e.g. nicotine, cocaine, 
ethanol) administration. Whereas it has been shown that PZ, but not PG is able to 
enhance the discriminatory effects of nicotine [205] and nicotine-induced locomotor 
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activity [206], both PZ and PG are able to decrease cocaine [207] and ethanol self-
administration, with PZ requiring lower doses and producing prolonged effects compared 
to PG [208].  
TBI and Neuroprotective Drug Development 
Failure of Clinical TBI Drug Trials 
Guidelines for acute management of severe TBI do exist. However, these 
guidelines contain supportive measures such as monitoring and management of 
intracranial pressure, cerebral perfusion pressure, and systolic blood pressure [209]. 
Although there are interventions available, for example, utilization of decompressive 
craniotomy, CSF drainage, and hyperosmolar therapy for the control of intracranial 
pressure [209], as stated previously, to date there are no FDA-approved 
pharmacological agents capable of attenuating the devastating neurologic 
consequences that can occur following TBI [1]. However, this is not for lack of effort.  
 Recently, large scale clinical trials for progesterone failed to improve outcome 
following TBI [210]. Similarly, glutamate antagonists, steroids, antioxidants, anti-
epileptics, and erythropoietin clinical TBI trials have all failed [211, 212]. Numerous 
reasons have been cited for the failure of neuroprotective compounds in clinical TBI 
studies, such as heterogeneity of injury, lack of consideration for pre-injury and post-
injury factors, reliance on clinical assessments of injury insensitive to injury pathology 
such as GCS score, lack of sensitivity in outcome measures or use of inappropriate 
outcome measures, lack of appropriate subgroup analyses, inadequate pre-clinical 
experimental design, and lack of understanding of secondary injury mechanisms [9, 211, 
213, 214]. However, within the context of pre-clinical experimental design and the 
complexity of the secondary injury cascade, it is conceivable that investigation into 
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innovative pre-clinical neuroprotective pharmacological strategies, such as 
combinational therapies or single drugs with multiple neuroprotective mechanisms of 
action, may improve the success of future clinical trials.  
Review of Selected Neuroprotective Strategies 
 A multitude of neuroprotective strategies have been investigated in experimental 
TBI models, including but not limited to NMDA antagonists, calpain inhibitors, hormonal 
therapy, attenuation of neuroinflammation, stem cell administration, induction of 
neurogenesis, hypothermia, environmental enrichment, and post-injury rehabilitation, 
[215, 216]. Although all have led to a greater understanding of TBI pathophysiology, the 
following discussion will focus on a selection of therapies directed toward attenuation of 
mitochondrial dysfunction and oxidative stress. Use of monoamine modulators will also 
be briefly discussed. 
Targeting of Mitochondrial Dysfunction 
Due to the significant role mitochondria serve in secondary injury processes, they 
have been and continue to be therapeutic targets for neuroprotection following TBI. 
Several strategies have been utilized in attempts to improve mitochondrial function and 
prevent downstream consequences of dysfunction following TBI, including but not limited 
to inhibition of the mPTP, mild uncoupling, and use of alternative energy sources such 
as ketones. 
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Inhibition of mPTP: Cyclosporine A and NIM811 
CsA (Fig. 1.13) is an FDA-approved immunosuppressant, used clinically to 
prevent organ rejection after transplant through a mechanism that involves inhibition of 
calcineurin and T-cell activation [217]. However, CsA also has the ability to bind the 
mitochondrial matrix protein cyclophilin D (CyD) [218, 219], which inhibits its interaction 
with ANT, an inner mitochondrial membrane protein, thus preventing formation of the 
mPTP [220]. Although under normal physiologic conditions CsA is minimally blood brain 
barrier (BBB) penetrable [221], CsA is able to enter the CNS following TBI due to 
increases in BBB permeability following injury [222].  
In experimental TBI, CsA and NIM811, an mPTP inhibitor but non-
immunosuppressive analog of CsA, have been shown to protect against mitochondrial 
dysfunction, decrease production of reactive species and their termination products, 
decrease cytoskeletal degradation, attenuate axonal pathology and neurodegeneration, 
improve cortical tissue sparing, and improve motor and cognitive function [110, 122-124, 
135, 136, 223-227]. 
Although there are studies to suggest that the immunosuppressive properties of 
calcineurin inhibitors (e.g. CsA, tacrilomus) have neuroprotective effects [228-233], the 
ability of NIM811 to recapitulate the neuroprotective effects of CsA, confirms mPTP 
inhibition as a means of neuroprotection. 
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Figure 1.13 Chemical structure of cyclosporine A 
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To date, large scale clinical trials utilizing CsA have not been conducted, 
however, small phase II trials have shown CsA to be safe for use clinically in severe TBI 
patients [234, 235], with the possibility of improved outcomes being seen with a 
continuous infusion dosing paradigm. However, CsA does have some concerning 
properties that could make clinical dosing in the TBI patient population challenging, such 
as a biphasic dose-response curve, [227] and the fact that it is both a substrate and an 
inhibitor of ATP-dependent p-glycoprotein drug efflux pumps [236]. Additionally, 
depending on the concentration and length of dosing, CsA and its vehicle, cremophor, 
have associated toxicities, including neurotoxicities [237-245].  Furthermore, CsA is 
metabolized by Cyp3A4 and therefore has several adverse drug interactions [246]. 
Mild Uncoupling 
Although mitochondria serve an important role in maintaining calcium 
homeostasis following TBI, high concentrations of intra-mitochondrial calcium can lead 
to increased production of ROS, collapse of mitochondrial membrane potential, and 
induction of mPT [125]. Therefore, it is important for mitochondria to maintain an optimal 
balance between the two scenarios, particularly under the stressful conditions that occur 
following TBI. Hence, somewhat counterintuitively, decreasing the mitochondrial 
membrane potential (i.e. a more positive membrane potential) should result in decreased 
uptake of positively charged calcium ions, resulting in decreases in ROS production and 
improved mitochondrial function [125]. One way to decrease mitochondria membrane 
potential is to mildly uncouple the ETC from ATP synthesis, allowing protons to bypass 
ATP synthase, and freely flow down their gradient through the inner mitochondrial 
membrane into the mitochondrial matrix [125]. Although mitochondria endogenously 
express uncoupling proteins [247], uncoupling can also be induced through 
pharmacologic means through use of chemical uncouplers such as 2,4-dinitrophenol 
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(2,4-DNP) and FCCP [125]. In fact, following TBI mild uncoupling can improve 
mitochondrial respiration, decrease ROS production, improve cortical tissue sparing and 
improve motor and cognitive function [125, 248].  
Ketones  
Although the brain relies on glucose as its primary energy source [27], alternative 
energy substrates, such as ketone bodies do exist. Upon depletion of glucose the body 
can shift to catabolism of fatty acids, generating ketones in the process, such as β-
hydroxybutyrate. During the conversion of β-hydroxybutyrate to acetyl-coA, the complex 
II substrate succinate is formed, bypassing the citric acid cycle (TCA). From there, 
acetyl-coA can enter the citric acid cycle (TCA), producing complex I and II substrates, 
while bypassing the need for glycolysis [139]. Ketones can be provided either directly 
through administration of β-hydroxybutyrate, or through ketogenic diets and fasting. In 
TBI, ketones have been shown to improve cortical tissue sparing, decrease cognitive 
impairment, decrease oxidative stress, and improve mitochondrial function [139]. In 
addition to being utilized as an alternative substrate, it is possible ketones also provide 
their neuroprotective effects through direct antioxidant mechanisms and through 
activation of uncoupling proteins [249, 250]. However, the utility of ketones as 
neuroprotectants may be limited to juveniles, as juvenile brains are better able to utilize 
non-glucose energy substrates and use of ketones in TBI seems to be more effective in 
this population [27, 249].  
Targeting of ROS/RNS, LP, and LP-Derived Neurotoxic Aldehydes 
Select Antioxidant Therapies  
 A multitude of antioxidants have been utilized over the decades in an attempt to 
attenuate oxidative stress following TBI [1, 55]. In this context, “antioxidant” will refer to 
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compounds with the ability to scavenge ROS, RNS, lipid peroxyl radicals, alkoxyl 
radicals, or inhibit LP propagation. Presented here are selections of antioxidant agents 
that have been evaluated in TBI. 
Superoxide Dismutase 
 As SOD is an endogenous O2•
- scavenger, it follows that administration of SOD 
following injury should result in neuroprotective effects by reducing oxidative stress. 
Although experimental TBI models were able to show that administration of SOD 
decreases O2•
- induced microvascular dysfunction and that overexpression of SOD1 or 
SOD2 prevents mitochondrial dysfunction and attenuates TBI pathophysiology [1, 55, 
251], clinical trials with PEG-SOD (a more stable form of SOD) failed, possibly due to the 
short half-life of O2•
- and brain penetrability issues [1, 55].  
Lazaroids 
 Lazaroids are compounds structurally related to steroids without having any 
glucocorticoid activity. Examples of lazaroids include tirilazad and the compound U-
83836E. These compounds function to scavenge lipid peroxyl radicals while also 
preventing LP propagation through phospholipid membrane stabilization. U-83836E has 
the added benefit of being structurally comprised of a portion of α-tocopherol (i.e. vitamin 
E) allowing for regeneration of its antioxidant properties through redox reactions with 
ascorbic acid and GSH. Although both compounds showed neuroprotective effects in 
experimental TBI, tirilazad failed clinical trials in the United States. Although, post-hoc 
analysis revealed that tirilizad was able to decrease mortality in a subset of male 
patients with subarachnoid hemorrhage, the design of these trials has been heavily 
criticized, underscoring the importance of appropriate clinical trial design [1, 55]. 
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Spin-Trapping Agents  
 Spin-trapping agents refer to a group of antioxidants which contain a nitroxide 
group, and include agents such tempol. Tempol is capable of scavenging PN-derived 
radicals such as NO●2 and CO
●-
3, as well as other reactive species such as O2•
- and 
H2O2. Tempol has shown to be neuroprotective in experimental TBI, decreasing 
oxidative damage, cytoskeletal and neuronal degeneration, and improving mitochondrial 
function. However, its limited therapeutic window of 1hr makes clinical translation 
unlikely [1, 55].  
Induction of Endogenous Antioxidant Pathways 
Nrf2 
 Neurons contain endogenous antioxidant systems which are activated in times of 
increased oxidative stress, such as occurs in TBI. Many of these systems are regulated 
by binding of the transcription factor Nrf2, which is able to translocate to the nucleus 
under stressful conditions, to ARE, which results in the induction and expression of 
antioxidants such as HO-1, NqO1, and GST. Compounds such as sulforaphane (found 
in broccoli and other cruciferous vegetables) and carnosic acid (found in rosemary and 
sage) are considered Nrf2 activators and have been shown to be neuroprotective in 
experimental TBI, reducing LP-derived aldehyde formation, improving mitochondrial 
bioenergetics, decreasing cytoskeletal and neuronal degeneration, decreasing edema, 
and attenuating motor and cognitive deficits [55, 97, 113, 138, 252].  
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Glutathione Precursors 
In addition to induction of endogenous antioxidant transcription pathways, 
another approach at enhancing endogenous antioxidant activity is through utilization of 
glutathione precursors, such as gamma-glutamylcysteine ethyl ester (GCEE) or NAC 
[126, 253-255]. Following TBI, GCEE is able to attenuate increases in PN and carbonyl 
protein damage and decrease BBB permeability [255]. More impressively, NAC and the 
more membrane permeable, N-acetylcysteine amide (NACA) have been shown to 
reduce PN and 4-HNE protein damage, increase mitochondrial glutathione 
concentration, improve mitochondrial respiration, and attenuate cortical lesion volume 
and cognitive impairment [126, 254].   
Carbonyl Scavenging  
Although LP, itself, is known to directly affect membrane fluidity and destabilize 
membrane integrity [256], the LP-derived aldehydes, including 4-HNE and acrolein are 
known to have directly toxic effects [29, 72, 76, 77, 85-89, 93, 101, 102, 257, 258], with a 
notably devastating effect on mitochondrial function.  
Therefore, scavenging of LP-derived aldehydes, such as 4-HNE and acrolein, the 
stable final breakdown products of LP represents a practical neuroprotective approach to 
TBI [1, 79]. In fact, scavenging of LP-derived aldehydes is more clinically feasible than 
the use of conventional antioxidants, as LP-derived aldehydes are longer lived than their 
highly reactive free radical predecessors [79, 81, 259].  
LP-derived aldehydes, such as 4-HNE and acrolein, are considered strong 
electrophiles [260]. Therefore, strong nucleophiles can be used as scavengers [260]. 
Several classes of compounds have been shown capable of scavenging LP-derived 
aldehydes such as thiol compounds (e.g. NAC, D-penicillamine), histidine containing 
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compounds (e.g. carnosine), and guanidine derivatives (e.g. metformin) [79]. However, 
hydrazine (-NH-NH2) compounds, which react with LP-derived aldehydes to form 
hydrazone derivatives, represent one of the most potent aldehyde scavenging groups 
available (Fig. 1.14) [258, 261].  
Further, hydrazine (-NH-NH2) compounds are able to scavenge both free 
aldehydes and aldehyde-protein conjugates to prevent further cross-linking [79, 262]. 
There are several FDA-approved drugs in current clinical use which contain a hydrazine 
moiety (-NH-NH2) capable of scavenging aldehydes, including the anti-tuberculosis 
agent isoniazid, the anti-hypertensive hydralazine (HZ), and the MAOI PZ [198] (Fig. 
1.15). Of these FDA-approved hydrazine containing (-NH-NH2) compounds, HZ and PZ 
have been the most extensively studied in experimental models of brain and spinal cord 
injury.   
Following brain or spinal cord injury, HZ, clinically used as an anti-hypertensive, 
or PZ, an irreversible non-selective MAOI-class anti-depressant, are able to attenuate 
formation of aldehyde-protein conjugates, enhance tissue sparing and neuronal survival, 
attenuate mitochondrial respiratory dysfunction, and improve behavioral outcomes [71, 
72, 74-76]. Although PZ contains both aldehyde-scavenging and MAOI capabilities, in-
vitro experiments comparing PZ to the similarly structured MAOI pargyline (PG), which 
lacks a hydrazine moiety (-NH-NH2), confirm that the presence of the hydrazine moiety (-
NH-NH2) and not steric hindrance confers PZ’s aldehyde scavenging abilities [72]. 
However, due to the absence of MAO substrate, the cited in-vitro study by Cebak et al. 
did not allow for rigorous assessment of MAOI affects [72]. However, in further support 
of the hydrazine moiety (-NH-NH2) being protective, in-vivo studies show that PZ but not 
PG decrease carbonyl and atherosclerotic plaque formation in experimental models of 
atherosclerosis [198].  
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Figure 1.14 Phenelzine scavenging of lipid peroxidation-derived aldehydes. 
Phenelzine covalently binds 4-HNE (4-hydroxynonenal) and acrolein, leading to the 
formation of phenelzine-aldehyde conjugates. 
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Figure 1.15 Chemical structures of phenelzine and hydralazine. Phenelzine is a 
monoamine oxidase inhibitor class anti-depressant and hydralazine is an anti-
hypertensive. However, both compounds contain hydrazine moieties (-NH-NH2), circled 
in red, which are capable of scavenging lipid peroxidation-derived aldehydes. 
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However, there are some concerns regarding the use of carbonyl scavengers as 
neuroprotective compounds. For example, hydrazine (-NH-NH2) drugs can react with 
physiologically important molecules and enzymes that contain carbonyl groups, such as 
pyridoxal phosphate, a cofactor required for several enzymes involved in the 
biosynthesis of neurotransmitters such as DA, 5-HT, and gamma-aminobutyric acid 
(GABA) [78]. Additionally, it is currently unknown how drug-aldehyde-protein conjugates 
are metabolized or what, if any, the long-term consequences of drug-aldehyde-protein 
conjugate formation are [78]. In fact, there is evidence to suggest that drug-aldehyde-
protein complexes can induce an immune response [258]. For example, the use of 
hydralazine has been linked to development of systemic lupus erythematosus [258]. 
Additional Properties of Phenelzine 
 As stated previously PZ is an irreversible non-selective MAOI which contains an 
aldehyde-scavenging hydrazine moiety (-NH-NH2), and although the plasma half-life of 
PZ, which is 11.5h in humans and possibly as short as 30min in rats [74], is not as 
clinically relevant to its MAOI properties, it likely does have an effect on its role as an 
aldehyde scavenger.   
In general PZ has complex pharmacokinetics which must be considered in 
regards to developing it for clinical use in TBI patients. For example, in addition to being 
a MAO inhibitor, PZ is also a MAO substrate, being metabolized to PEA and 
phenylethyldenehydrazine (PEH). Both PEH and PEA are considered to be active 
metabolites [263]. For example, PEA, is similar to amphetamine and can produce 
stimulatory effects [207], whereas PEH inhibits several transaminases, including GABA 
transaminase (GABA-T), alanine transaminase (ALA-T), and ornithine transaminase 
(ORN-T) [169]. These transaminases serve important physiologic functions. For 
example, GABA-T is responsible for the conversion of the inhibitory neurotransmitter 
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GABA, to succinic semi-aldehyde, which can be further oxidized to succinate [169], a 
substrate of the Krebs cycle and complex II of the ETC. Therefore, inhibition of GABA-T 
could lead to increases in GABA, which can paradoxically cause excitotoxicity following 
neuronal injury through reversal of chloride channels [264], as well as decreases in ETC 
substrates during a time in which there is ongoing mitochondrial dysfunction and ATP 
depletion [22, 25, 51, 73]. Similarly, inhibiting ALA-T, the enzyme which catalyzes the 
reaction of alanine + α-ketoglutarate to form glutamate + pyruvate, could also lead to 
decreased formation of Krebs cycle substrates. Further, ORN-T catalyzes the formation 
of glutamate, from the urea cycle product, ORN. However, inhibition of ORN-T could 
alternately lead to decarboxylation of ORN by ornithine decarboxylase (OCD), the result 
of which is formation of neurotoxic polyamines [169].  
Of additional concern in  regards to clinical translation of PZ is that anti-
depressants can lower seizure threshold [265], a complication for which TBI patients are 
already at increased risk [209], although of all the anti-depressant drug classes, MAOIs 
are at the least risk to do so [265]. Therefore, use of PZ could increase the risk of post-
traumatic seizure in TBI patients. Additionally, it must be noted that although PZ is not 
technically classified as a CYP3A4 inhibitor, there is data to suggest that PZ is capable 
of inhibiting CYP3A4 [266, 267], which could lead to several adverse drug interactions.  
Properties of Hydralazine  
Although HZ’s hydrazine (-NH-NH2) moiety can act as an aldehyde scavenger, 
HZ is an anti-hypertensive, used clinically to treat emergent and essential hypertension, 
eclampsia, and congestive heart failure in African-Americans [268]. In humans, HZ has a 
short plasma half-life of 30-60 minutes, similar to the 60min half-life seen in rats [74, 78]. 
The anti-hypertensive properties of HZ are due to its ability to act as an arteriolar 
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vasodilator. Although the exact mechanism of action remains unknown, it has been 
hypothesized to be due to activation of guanylate cyclase, inhibition of sarcoplasmic 
reticulum calcium release, or increased conductance of calcium-dependent K+ channels 
[258]. Interestingly, in relation to the properties of PZ, there is evidence to suggest that 
HZ may also be able to act as a reversible non-selective MAOI, with a slight preference 
to MAO-A [258, 269]. 
Although HZ’s anti-hypertensive effects could be a barrier to using it clinically in 
TBI patients, in experimental SCI intraperitoneal doses of HZ ranging from 5mg/kg-
25mg/kg, do not induce changes in systolic blood pressure [270]. However, HZ does 
undergo polymorphic acetylation within the liver, which means even an optimized dose 
of HZ could lead to elevated concentrations in patients with slow acetylator phenotypes 
[268].  
Use of Monoamine Agonists, Antagonists, and Monoamine Oxidase Inhibitors in 
TBI 
Although there is a need for more established guidelines for the pharmacological 
treatment of TBI-induced chronic neurobehavioral sequelae, several options do exist 
which work by modulating monoamine neurotransmitter systems, such as 
antidepressants for the treatment of depression and aggression, dopamine enhancers 
and stimulants for the treatment of attention deficits and enhancement of learning and 
memory, and beta blockers for the treatment of aggression [127].  
 In the context of acute TBI, drugs that modulate monoaminergic systems such as 
DA and 5-HT agonists have shown promise as neuroprotective agents [154, 170, 271]. 
However, these drugs often have additional purportedly protective mechanisms of 
action. For example, amantadine, in addition to being a DA agonist is an NMDA 
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glutamate receptor antagonist. Additionally these drugs are often receptor subtype 
specific, such as the D2 agonist bromocriptine and the 5-HT1A agonist buspirone [154, 
170, 271], and therefore would have more specific effects than an overall increase in 
monoamine levels, as would be induced through use of an MAOI.  
Specifically in regards to MAOIs, they have been demonstrated to be 
neuroprotective in both models of stroke and closed head injury [272, 273]. Although 
some studies suggest that inhibition of MAO itself is protective [193], others have shown 
MAOIs can be neuroprotective at concentrations which are too low to inhibit MAO [274, 
275]. Therefore, it is possible that the neuroprotective effects of several similarly 
structured MAOIs such as PG, deprenyl (selegiline), clorgyline, and rasagiline [192, 201, 
276-278] are due to another property such as the presence of an N-propargyl moiety 
[201], which, itself, has been proposed capable of exerting neuroprotective effects 
through a variety of mechanisms ranging from modulation of apoptotic proteins to direct 
targeting of the mPTP [192, 274-276, 278, 279]. 
Combinational Therapies  
 To date, all single agent pharmacotherapy clinical trials for TBI have failed. 
Although there have been numerous reasons cited for these failures, due to the 
heterogeneity of injury and the complexity of the secondary injury cascade, there is 
interest in developing multi-mechanistic combinational therapies for the treatment of TBI 
[213]. Indeed, the need for combinational approaches can be seen in experimental TBI 
models where agents, such as CsA and PZ, are unable to completely restore pre-injury 
function [71, 72, 76, 110, 136].  
In 2008, NIH funded six multi-drug combinational experimental TBI studies. Of 
the six studies, only the combination progesterone and nicotinamide (NAD+ precursor, 
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antioxidant, anti-inflammatory) was able to significantly improve cognitive and motor 
deficits over monotherapy [280].  On the other end of the spectrum, despite studies 
showing that creatine (maintenance of ATP levels)[281] or choline (various mechanisms 
of action, precursor to neurotransmitter synthesis)[140] were protective in experimental 
TBI, combining the two worsened outcomes [280]. 
  However, a recent comprehensive review by Kline and colleagues detailing 
experimental TBI combinational therapy studies is more optimistic [215]. Of the 35 
studies reviewed, all of which included behavioral outcomes, 46% resulted in additive or 
synergistic effects, 35% had neutral outcomes, and only 19% resulted in negative 
interactions [215]. Unlike the six studies that were funded under the NIH “multi-drug 
combinational therapy” funding announcement, several of these studies included non-
drug therapies such as hypothermia, environmental enrichment, exercise, and stem cell 
administration. Although the Kline review focused on distinct categories (inflammation, 
oxidative stress, neurotransmitter dysregulation, neurotrophins, stem cells, and 
rehabilitative therapies), environmental enrichment combinations were utilized the most, 
and the majority of successes were either achieved through a combination of stem cell 
implantation and environmental enrichment [282], or through attenuation of 
neuroinflammation  [215]. Of important note here is that one study, which utilized CsA 
and minocycline (antibiotic, anti-inflammatory), saw a 100% lethality rate in the 
combination group [215, 283]. 
 In general both reviews highlight some of the challenges in developing 
combinational therapies for TBI including optimization of combined dosing paradigms, 
consideration of sub-optimal doses, consideration of altered pharmacokinetics, 
pharmacodynamics, toxicities, and side effects, choice of time point, choice and 
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sensitivity of outcome measures, inclusion of behavioral assessments, use of 
appropriate statistics, and variations in efficacy across outcome measures [215, 280]. 
Overall Dissertation Objective and Specific Aims  
Traumatic brain injury (TBI) represents a significant health crisis in the United 
States. To date there are no FDA-approved pharmacotherapies available to prevent the 
devastating neurologic deficits caused by TBI. Due to the complex pathophysiology 
which occurs following TBI, more robust pharmacological approaches must be 
developed. As central mediators of the TBI secondary injury cascade, mitochondria and 
LP-derived neurotoxic aldehydes make promising therapeutic targets. In fact, 
Cyclosporine A (CsA), an FDA-approved immunosuppressant capable of inhibiting the 
mitochondria permeability transition pore (mPTP) has been shown to be neuroprotective 
in experimental TBI. Additionally, phenelzine (PZ), an FDA-approved non-selective 
irreversible monoamine oxidase inhibitor (MAOI) class antidepressant has also been 
shown to be neuroprotective in experimental TBI due to the presence of a hydrazine (-
NH-NH2) moiety allowing for the scavenging of LP-derived neurotoxic aldehydes.  
 The overall goal of this dissertation is to further examine the neuroprotective 
capabilities of the mPTP inhibitor, CsA, and the LP-derived neurotoxic aldehyde 
scavenger, PZ, using a severe controlled cortical impact injury (CCI) model in 3-month 
old male Sprague-Dawley rats. First, the neuroprotective effects of CsA are examined in 
isolated synaptic and non-synaptic mitochondria, two heterogeneous populations. Next, 
the ability of a novel 72h subcutaneous continuous infusion of PZ combined with CsA to 
improve mitochondrial respiration, attenuate mitochondria-aldehyde conjugate formation, 
and prevent cytoskeletal spectrin degradation is compared to monotherapy. Finally, the 
effects of PZ (MAOI, aldehyde scavenger) on learning and memory and cortical tissue 
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sparing following injury are compared to the effects of pargyline (MAOI, non-aldehyde 
scavenger) and hydralazine (non-MAOI, aldehyde scavenger). 
Specific Aim 1: To test the hypothesis that CsA will have a differential 
neuroprotective effect on isolated synaptic and non-synaptic mitochondrial bioenergetics 
following experimental traumatic brain injury. Following a severe controlled cortical 
impact injury (2.2mm) in 3mo male Sprague-Dawley rats, an intraperitoneal dose of CsA 
(20mg/kg) will be administered 15min following injury. At 24h following injury cortical 
synaptic and non-synaptic mitochondria will be isolated and respiratory rates will be 
measured using a Clark-type oxygen electrode. 
Specific Aim 2: To test the hypothesis that a 72h subcutaneous continuous 
infusion of PZ combined with CsA will improve mitochondrial respiration, attenuate 
formation of LP-derived aldehyde mitochondrial protein conjugates, and maintain 
cytoskeletal integrity following experimental TBI to a greater degree than monotherapy. 
Following a severe controlled cortical impact injury (2.2mm) in 3mo male Sprague-
Dawley rats, subcutaneous osmotic pumps containing PZ (10mg/kg/day/3d) and/or CsA 
(10mg/kg/day/3d) will be implanted. Loading doses of PZ (10mg/kg) and/or CsA 
(20mg/kg) will also be administered 15min following injury. At 72h post-injury 1) cortical 
mitochondria (total) respiratory rates will be assessed using a Clark-type oxygen 
electrode and 2) cortical mitochondria (total) bound 4-HNE and acrolein will be assessed 
using Western blot. Additionally, Western blot will be used to assess cortical tissue for 
145kD (calpain-only) and 150kD (calpain/caspase 3) αII-spectrin breakdown as a marker 
for cytoskeletal integrity. 
Specific Aim 3: To test the hypothesis that PZ, a LP-derived neurotoxic 
aldehyde scavenger and MAOI, and hydralazine (HZ), an LP-derived neurotoxic 
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aldehyde scavenger incapable of inhibiting MAO will improve cognitive function and 
cortical tissue sparing following experimental TBI, whereas pargyline (PG), a MAOI 
incapable of scavenging LP-derived neurotoxic aldehydes, will not. Following severe 
controlled cortical impact injury (2.0mm), 3mo male Sprague-Dawley rats will receive an 
intraperitoneal dose of PZ (15mg/kg), HZ (5mg/kg), or PG (15mg/kg) at 15min, 24h, and 
48h following injury. Morris water maze testing will be conducted on day 3 – day 7, and 
animals will be perfused on day 8 for analysis of cortical tissue sparing. Additionally, the 
effects of the PZ, HZ, and PG dosing paradigms on MAO inhibition and monoamine 
neurotransmitter (NE, 5-HT, DA) tissue levels will be evaluated via HPLC in uninjured 
cortical tissue.  
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CHAPTER TWO: 
 
Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria 
after Traumatic Brain Injury and are Protected by Cyclosporine A 
 
Preface:  Chapter Two has been adapted from: Kulbe JR, Hill RL, Singh IN, Wang JA, 
Hall ED. Synaptic mitochondria sustain more damage than non-synaptic mitochondria 
after traumatic brain injury and are protected by cyclosporine A. Journal of Neurotrauma. 
34(7): 1291-1301 (2017). DOI: 10.1089/neu.2016.4628. (Mary Ann Leibert, Inc., New 
York, NY). Figures have been renumbered and formatted in accordance with University 
of Kentucky Graduate School requirements. 
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Introduction 
Traumatic brain injury (TBI) represents a significant health crisis. In the United 
States, there are over 5 million persons currently living with a disability resulting from a 
TBI [12] with an associated economic burden of 76.5 billion dollars. [10, 11] TBI consists 
of a primary mechanical injury followed by a secondary injury cascade. [14]  Aspects of 
this cascade include increases in excitotoxic amino acids such as glutamate, increases 
in intracellular calcium, mitochondrial dysfunction, production of reactive oxygen and 
nitrogen species (ROS/RNS), initiation and propagation of lipid peroxidation (LP), 
formation of LP-derived neurotoxic aldehydes, activation of calcium-dependent 
proteases such as calpain, cytoskeletal degradation, cell death, and neurologic 
dysfunction. [1, 16, 17, 22, 24, 41, 51, 55, 56, 58, 71, 108, 109, 114, 161-163, 223, 224, 
284-288]  The secondary injury cascade should be amenable to therapeutic intervention. 
Currently, there are no Food and Drug Administration (FDA)-approved 
pharmacotherapies for the treatment of patients with TBI, however. [1] 
Mitochondria play a central role in the secondary injury cascade. Mitochondria 
are essential regulators of calcium homeostasis [20, 21] and buffer increased 
intracellular calcium after TBI. [22] High levels of mitochondrial calcium, however, lead to 
mitochondrial dysfunction, including increased generation of ROS/RNS, decreased 
oxidative phosphorylation and adenosine triphosphate (ATP) production, and induction 
of the mitochondria permeability transition pore (mPTP).  [22, 51, 53, 56, 60, 163, 225, 
251, 289, 290] 
The mPTP is a non-selective mega channel located in the inner mitochondrial 
membrane that is permeable to solutes <1.5 kDa. [51]  Opening of the mPTP leads to 
extrusion of calcium back into the cytosol, mitochondrial swelling, and rupture of the 
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outer mitochondrial membrane. [51, 104] Mitochondrial dysfunction contributes to 
several aspects of the aforementioned injury cascade, including ROS/RNS induction of 
LP and formation of the LP-derived neurotoxic aldehydes 4-hydroxynonenal and 
acrolein, which are capable of covalently binding mitochondrial proteins, further 
exacerbating mitochondrial dysfunction. [29, 69, 71, 77, 101, 113, 163]  Additional 
downstream consequences of mPTP formation include activation of the calcium-
dependent protease calpain, cytoskeletal degradation, cell death, and neurologic 
dysfunction. [1, 17, 29, 51, 55, 56, 58, 69, 70, 84, 93, 98, 99, 110, 163, 226]  Therefore, 
as central mediators of the secondary injury cascade, mitochondria are promising 
therapeutic targets for prevention of cellular death and dysfunction after TBI.  
Several therapies targeting mitochondria have been shown to be neuroprotective 
in experimental models of TBI, including mild uncoupling, [125, 248] ketogenic diets, 
[249, 291] increased antioxidant availability, [113, 126] and scavenging of neurotoxic 
aldehydes. [71] One of the most promising and extensively studied mitochondrial 
targeted TBI therapies, however, is inhibition of mPTP by the FDA-approved 
immunosuppressant, cyclosporine A (CsA). In experimental TBI, CsA or its non-
immunosuppressant analog, NIM811, prevent mitochondrial swelling and axonal 
pathology, [223, 224] maintain mitochondrial membrane potential and decrease 
production of reactive oxygen species, [225] improve total (synaptic and non-synaptic) 
mitochondrial respiration, [226] prevent oxidative (synaptic and non-synaptic) 
mitochondrial damage, [123, 226] improve cortical tissue sparing, [122, 124, 227] 
decrease calpain-mediated cytoskeletal degradation and neurodegeneration, [110] and 
improve motor and cognitive function. [110, 123, 135, 136] 
Interestingly, despite the fact that CsA directly targets mitochondria, only a 
limited number of studies have evaluated the effects of CsA on mitochondria after 
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experimental TBI, [225, 226, 292] with no studies evaluating the effects of CsA on 
isolated synaptic and non-synaptic mitochondria. Mitochondria are heterogeneous, 
consisting of both synaptic and non-synaptic populations. Isolated synaptic mitochondria 
consist of pre-synaptic mitochondria located within the synaptosome, while isolated non-
synaptic mitochondria consist of neuronal (axonal, somal, dendritic) and non-neuronal 
(glial, vascular, etc.) mitochondria.  
To our knowledge, there is currently no method available to further separate the 
non-synaptic mitochondrial population into non-synaptic neuronal and non-synaptic non-
neuronal, (e.g., glial) populations. Therefore, whereas synaptic mitochondria consist of 
pure pre-synaptic neuronal mitochondria, non-synaptic mitochondria are isolated from 
numerous cell types. Synaptic mitochondria are considered essential for proper 
neurotransmission and synaptic plasticity, [44-46]  processes which are impaired after 
TBI. [47]  Their dysfunction has been implicated in neurodegeneration, as well as 
degeneration of synapses and neurons absent overt cell death, [37, 48, 49] and studies 
reveal synaptic mitochondria to be more susceptible to dysfunction. Importantly, these 
two mitochondrial populations show different characteristics both in-vitro [37, 38] and in-
vivo, [41, 50] including differential responses to pharmacotherapy. [50]   
The heterogeneity of the two populations, however, can be masked in total 
mitochondrial (synaptic and non-synaptic) preparations, especially because of the high 
glia to neuron ratio of the cerebral cortex. [293]  Therefore, it is essential that 
mitochondria targeted pharmacotherapies, such as CsA, be evaluated in both 
populations.  
This is the first study to examine the effects of CsA on isolated synaptic and non-
synaptic mitochondria after experimental TBI.  We hypothesized that synaptic 
mitochondria would sustain more damage than non-synaptic mitochondria 24h after 
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severe controlled cortical impact injury (CCI), and that intraperitoneal administration of 
CsA (20 mg/kg) 15 min after injury would differentially attenuate injury-induced synaptic 
and non-synaptic respiratory impairment.  
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Methods 
Animals 
Young adult male Sprague-Dawley rats (n=20, Harlan, Indianapolis, IN) weighing 
300 to 350 g were used for all studies. Animals were allowed food and water ad libitum 
and were housed in the Division of Laboratory Animal Resources of the University of 
Kentucky Medical Center. All animal and husbandry were conducted in accordance with 
the University of Kentucky Institutional Animal Care and Use Committee. Animals were 
randomly assigned to experimental groups: sham (n=6), CCI + vehicle (n=6), CCI + CsA 
(n=8).  
CCI TBI 
Animals were initially anesthetized with 4% isoflurane and placed in a stereotaxic 
frame (David Kopf, Tujunga, CA), where they were maintained at 3% isoflurane for the 
duration of the procedure. A midline incision was made to expose the skull, and a 6 mm 
craniotomy was made lateral to the sagittal suture midway between lambda and bregma. 
The exposed brain with intact dura was injured using a computer controlled pneumatic 
impactor (TBI 03010; Precision Systems and Instrumentation, Fairfax Station, VA) fitted 
with a 5 mm beveled tip set to impact at ~3.5 m/sec, 2.2 mm depth and 500 msec dwell 
time, as described previously. [71] After injury, Surgicel was placed onto the dura, and 
an 8 mm plastic disk was affixed with tissue adhesive to close the craniotomy site. Body 
temperature was monitored and maintained at 37°C with a thermo-regulating heating 
pad. Sham animals underwent all procedures but did not receive an impact injury.   
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Cyclosporine A Administration 
The CsA concentration chosen was based on previously optimized 
concentrations for CCI. [225, 294] The CCI + CsA group was administered CsA obtained 
from the University of Kentucky Medical Center Hospital Pharmacy (Perrigo, 
Minneapolis, MN; 50 mg/mL) 15 min after injury as a single intraperitoneal dose of 20 
mg/kg in saline/650 mg cremophor/33.2% (v/v) ethanol diluted in saline to a final 
concentration of 10 mg/mL. The injection volume was 0.2 mL/100g of body weight. CCI 
+ vehicle-treated animals received an equivalent dose of saline/cremophor/ethanol 15 
min after injury. 
Tissue Extraction 
Animals were euthanized at 24h using CO2 anesthetization followed by 
decapitation, and an 8 mm cortical punch centered over the injury site was collected for 
analysis of mitochondrial respiration. 
Mitochondrial Isolation 
Mitochondria were isolated as described previously [71, 163] with modifications 
to isolate synaptic and non-synaptic populations. [41, 50] Cortical tissue was 
homogenized in ice-cold isolation buffer (215 mmol/L mannitol, 75 mmol/L sucrose, 
0.1% bovine serum albumin, 20 mmol/L HEPES, 1 mmol/L EGTA, pH 7.2) using Potter-
Elvejhem homogenizers. Samples were then centrifuged twice at 1400 x g for 3 min at 
4°C. Supernatants were collected and spun at 13,000 x g for 10 min at 4°C.  
The crude mitochondrial pellet was resuspended and layered onto a 
discontinuous 7.5% and 10% Ficoll gradient and centrifuged at 100,000 x g for 30 min at 
4°C. The non-synaptic mitochondria pellet was resuspended in isolation buffer without 
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EGTA and centrifuged at 10,000 x g for 10 min at 4°C to remove Ficoll and then 
resuspended to a final concentration of approximately 10 mg/mL in isolation buffer 
without EGTA.  
The synaptosomal layer was removed from the 7.5%-10% Ficoll interface, 
resuspended in isolation buffer and spun at 13,000 x g for 10 min at 4°C to remove 
Ficoll. The synaptosome pellet was resuspended in isolation buffer, placed into a 
nitrogen bomb at 1200 psi for 10 min at 4°C to release synaptic mitochondria, [295, 296] 
layered onto a second discontinuous 7.5% and 10% Ficoll gradient, and centrifuged at 
100,000 x g for 30 min at 4°C. The synaptic mitochondria pellet was resuspended in 
isolation buffer without EGTA and centrifuged at 10,000 x g for 10 min at 4°C to remove 
Ficoll and resuspended in isolation buffer without EGTA. Protein concentrations were 
determined with a BCA protein assay kit and measured at absorbance 562 nm with a 
BioTek Synergy HT plate reader (Winooski, VT, USA). Mitochondria were immediately 
used for respiratory analysis.   
Measurement of Mitochondrial Respiratory Function 
Mitochondria respiratory rates were measured using a Clark-type electrode in a 
continuously stirred, sealed, thermostatically controlled chamber (Oxytherm System, 
Hansatech Instruments, Norfolk, UK) that was maintained at 37°C. Mitochondria (>30 
µg) were placed into a chamber containing 250 µl of KCl respiration buffer (125 mmol/L, 
2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 0.1% bovine serum albumin, 20 mmol/L HEPES, 
pH 7.2). Mitochondria equilibrated for 1 min prior to complex-I initiation.  
Complex-I respiration was initiated with 5 mmol/L pyruvate and 2.5 mmol/L 
malate and state II respiration was monitored. Two boluses of 150 μmol/L adenosine 
diphosphate (ADP) were added to initiate state III respiration.  State IV respiration was 
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monitored following 2 μmol/L addition of the ATP synthase inhibitor oligomycin. Maximal 
state V(I) respiration was initiated by addition of 2 μmol/L of the protonophore FCCP. 
Complex I was inhibited by addition of 100 nmol/L rotenone. Complex II driven 
respiration was initiated by addition of 10 mmol/L succinate and state V(II) was 
monitored. Respiratory control ratio (RCR) was calculated by dividing the state III 
respiration rate (second bolus ADP rate) by the state IV respiration rate. [163, 248]  
Statistical analysis 
Statistical analysis was conducted using Prism version 6.0 (Graph Pad, San 
Diego, CA). Results are reported as mean ± standard deviation. Initial statistical analysis 
was performed using a two-way analysis of variance (ANOVA), followed by a Tukey post 
hoc analysis when appropriate.  
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Results 
The following details the comparative effects of CCI TBI, with and without early 
CsA treatment, on the respiratory functional status of non-synaptic versus synaptic 
mitochondria as measured by changes in oxygen utilization during the various 
respiratory states. Overall, the results show that, in general, synaptic mitochondria are 
more susceptible to post-traumatic complex I and II-driven dysfunction within the 
electron transport chain than non-synaptic mitochondria.  Nevertheless, early CsA 
treatment is able to protect respiration that is linked to neuronal ATP production within 
the more damaged synaptic mitochondria. 
State II: Addition of Pyruvate + Malate to Activate Mitochondrial Complex I 
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20) = 23.75, p < 0.0001] and population [F (1, 20) = 17.22, p = 0.0005], but 
not interaction [F (1, 20) = 0.2018, p = 0.6581]. Post-hoc testing (Tukey’s) revealed that 
state II respiration for non-synaptic CCI + vehicle was significantly impaired compared 
with non-synaptic sham (p < 0.01), synaptic CCI + vehicle was significantly impaired 
compared with synaptic sham (p < 0.05), and that the state II respiration rate for synaptic 
sham was significantly decreased compared with non-synaptic sham (p < 0.05) (Fig. 
2.1A).  
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Figure 2.1 State II: Effect of CsA on synaptic and non-synaptic mitochondria. (A) 
Effect of injury on non-synaptic and synaptic mitochondria for state II respiration 
(pyruvate/malate) 24 h after severe controlled cortical impact (CCI). (B) Effect of early 
post-injury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg) on 
non-synaptic and synaptic mitochondria for state II respiration (pyruvate/malate) 24h 
after severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6), Sham 
Syn, sham synaptic (n = 6), CCI + Veh NS, CCI + vehicle non-synaptic (n = 6), CCI + 
Veh Syn, CCI + vehicle synaptic (n = 6), CCI + CsA NS, CCI + CsA non-synaptic (n = 8), 
CCI + CsA Syn, CCI + CsA synaptic (n = 8); values, mean ± standard deviation; two-way 
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, #p < 0.05 
compared with non-synaptic sham. 
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To assess drug effect, state II respiratory rates for CCI + vehicle and CCI + CsA 
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA 
(treatment x population) revealed a significant main effect for treatment [F (1, 24) = 
11.07, p = 0.0028], but not for population [F (1, 24 = 0.06332, p = 0.8035] or interaction 
[F (1, 24) = 3.182, p = 0.0871). While CsA improved state II respiration in both injured 
non-synaptic and injured synaptic mitochondria, post-hoc testing (Tukey) revealed this 
effect was only significant in the synaptic population (p <0.01) (Fig. 2.1B). 
State III: Addition of ADP to Activate Complex V ATP Production 
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20) = 31.10, p < 0.0001) and population [F (1, 20) = 12.39, p = .0022], but 
not interaction [F (1, 20 = .0075, p = 0.9318]. Post-hoc testing (Tukey’s) revealed that 
state III respiration for non-synaptic CCI + vehicle was significantly impaired compared 
with non-synaptic sham (p < 0.01), and synaptic CCI + vehicle was significantly impaired 
compared with synaptic sham (p < 0.01) (Fig. 2.2A).  
To assess drug effect, state III respiratory rates for CCI + vehicle and CCI + CsA 
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA 
revealed a significant main effect for treatment [F (1, 24) = 10.45, p = 0.0036], and 
population [F (1, 24) = 4.847, p = 0.0375], but not interaction [F (1, 24) = 0.5409, p = 
0.4692). While CsA improved state III respiration in both injured non-synaptic and injured 
synaptic mitochondria, post-hoc testing (Tukey) revealed this effect was only significant 
in the synaptic population (p < 0.05) (Fig. 2.2B).  
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Figure 2.2 State III: Effect of CsA on synaptic and non-synaptic mitochondria (A) 
Effect of injury on non-synaptic and synaptic mitochondria for state III respiration 
(pyruvate/malate/adenosine diphosphate [ADP]) 24h after severe controlled cortical 
impact (CCI). (B) Effect of early post-injury (15 min) intraperitoneal administration of 
cyclosporine A (CsA) (20 mg/kg) on non-synaptic and synaptic mitochondria for state III 
respiration (pyruvate/ malate/ADP) 24h after severe CCI, calculated as % sham. Sham 
NS, sham non-synaptic (n = 6), Sham Syn, sham synaptic (n = 6); CCI + Veh NS, CCI + 
vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI + vehicle synaptic (n = 6); CCI + CsA 
NS, CCI + CsA non-synaptic (n = 8); CCI + CsA Syn, CCI + CsA synaptic (n = 8); values 
= mean ± standard deviation; two-way analysis of variance followed by Tukey post hoc; 
*p < 0.05, **p < 0.01. 
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State IV: Addition of Oligomycin to Inhibit Complex V ATP Production 
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20) = 27.77, p < 0.0001) and population [F (1, 20) = 8.680, p = .0080], but 
not interaction [F (1, 20 = .0276, p = 0.8698]. Post-hoc testing (Tukey) revealed that 
state IV respiration for non-synaptic CCI + vehicle was significantly impaired compared 
with non-synaptic sham (p < 0.01), and synaptic CCI + vehicle was significantly impaired 
compared with synaptic sham (p < 0.01) (Fig. 2.3A).  
To assess drug effect, state IV respiratory rates for CCI + vehicle and CCI + CsA 
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA 
revealed a significant main effect for treatment [F (1, 24) = 11.91, p = 0.0021], but not 
population [F (1, 24) = 1.964, p = 0.1738] or interaction [F (1, 24) = 0.0046, p = 0.9465). 
While CsA improved state IV respiration in both injured non-synaptic and injured 
synaptic mitochondria, post-hoc testing (Tukey) revealed these effects were not 
significant (Fig. 2.3B).  
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Figure 2.3 State IV: Effect of CsA on synaptic and non-synaptic mitochondria (A) 
Effect of injury on non-synaptic and synaptic mitochondria for state IV respiration 
(oligomycin) 24h after severe controlled cortical impact (CCI). (B) Effect of early post-
injury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg), on non-
synaptic and synaptic mitochondria for state IV respiration (oligomycin) 24h after severe 
CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, sham 
synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI 
+ vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI + CsA 
Syn, CCI + CsA synaptic (n = 8); values mean ± standard deviation; two-way analysis of 
variance followed by Tukey post hoc; **p < 0.01. 
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RCR (State III / State IV): Difference in Oxygen Utilization Between Activation and 
Inhibition of ATP Production 
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20 = 26.02, p < 0.0001), population [F (1, 20) = 12.23, p = 0.0023], and 
interaction [F (1, 20) = 5.418, p = 0.0305]. Post-hoc testing (Tukey) revealed that RCR 
for synaptic CCI + vehicle was significantly impaired compared with synaptic sham (p < 
0.001) and that synaptic CCI + vehicle was significantly impaired compared with non-
synaptic CCI + vehicle (p < 0.01) (Fig. 2.4A).  
To assess drug effect, RCR for CCI + vehicle and CCI + CsA were calculated as 
a percentage of sham RCR. A two-way ANOVA revealed a significant main effect for 
treatment [F (1, 24) = 7.092, p = 0.0136) and population [F (1, 24) = 9.680, p = 0.0048], 
but not interaction [F (1, 24) = 3.437, p = 0.0761]. Post-hoc testing (Tukey) revealed that 
CsA treatment significantly improved RCR in the injured synaptic population (p < 0.05) 
and that the RCR for synaptic CCI + vehicle is significantly impaired compared to the 
RCR for non-synaptic CCI + vehicle (p < 0.05) (Fig. 2.4B). 
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Figure 2.4 RCR: Effect of CsA on synaptic and non-synaptic mitochondria (A) 
Effect of injury on non-synaptic and synaptic mitochondria for respiratory control ratio 
(RCR) (state III/state IV) 24h after severe controlled cortical impact (CCI). (B) Effect of 
early post-injury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20 
mg/kg), on non-synaptic and synaptic mitochondria for RCR (state III/state IV) 24h after 
severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, 
sham synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh 
Syn, CCI + vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI 
+ CsA Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way 
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.001, #p < 0.05 vs 
non-synaptic vehicle, ##p < 0.01 vs. non-synaptic vehicle. 
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State V(I): Maximal Complex I-Driven Respiration After Addition of the 
Protonophore FCCP  
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20) = 37.82, p < 0.0001) and population [F (1, 20) = 9.556, p = .0058], but 
not interaction [F (1, 20 = .2492, p = 0.6231]. Post-hoc testing (Tukey) revealed that 
state V(I) respiration for non-synaptic CCI + vehicle was significantly impaired compared 
with non-synaptic sham (p < 0.001), and synaptic CCI + vehicle was significantly 
impaired compared with synaptic sham (p < 0.01) (Fig. 2.5A).  
To assess drug effect, state V(I) respiratory rates for CCI + vehicle and CCI + 
CsA were calculated as a percentage of the sham respiratory rate. A two-way ANOVA 
revealed a significant main effect for treatment [F (1, 24) = 14.25, p = 0.0009], but not 
population [F (1, 24) = 3.580, p = 0.0706] or interaction [F (1, 24) = 0.0084, p = 0.9276). 
While CsA improved state V(I) respiration in both injured non-synaptic and injured 
synaptic mitochondria, post-hoc testing (Tukey) revealed neither effect was statistically 
significant (Fig. 2.5B).  
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Figure 2.5 State V(I): Effect of CsA on synaptic and non-synaptic mitochondria (A) 
Effect of injury on non-synaptic and synaptic mitochondria for state V(I) respiration 
(FCCP) 24h after severe controlled cortical impact (CCI). (B) Effect of early post-injury 
(15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg) on non-
synaptic and synaptic mitochondria for state V(I) respiration (FCCP) 24h after severe 
CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, sham 
synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI 
+ vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8);CCI + CsA 
Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way analysis 
of variance followed by Tukey post hoc; **p < 0.01, ***p < 0.001. 
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State V(II): Succinate-Activated Complex II-Driven Respiration after Inhibition of 
Complex I with Rotenone 
A two-way ANOVA (injury x population) revealed a significant main effect for 
injury [F (1, 20 = 23.97, p <0.0001] and population [F (1, 20) = 15.37 p = 0.0008], but not 
for interaction [F (1, 20 = 0.3787, p = 0.5452]. Post-hoc testing (Tukey) revealed that 
state V(II) respiration for non-synaptic CCI + vehicle was significantly impaired compared 
with synaptic sham (p < 0.05), and that the state V(II) respiration rate for synaptic sham 
was significantly decreased compared with non-synaptic sham (p < 0.05) (Fig. 2.6A).  
To assess drug effect, state V(II) respiratory rates for CCI + vehicle and CCI + 
CsA were calculated as a percentage of the sham respiratory rate. A two-way ANOVA 
revealed a significant main effect for treatment [F (1, 24) = 10.45, p = 0.0035], but not for 
population [F (1, 24) = 0.3533, p = 0.5578] or interaction [F (1, 24) = 1.272, p = 0.2706]. 
While CsA improved state V(II) respiration in both injured non-synaptic and injured 
synaptic mitochondria, post-hoc testing (Tukey) revealed this effect was only significant 
in the synaptic population (p < 0.05) (Fig. 2.6B). 
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Figure 2.6 State V(II): Effect of CsA on synaptic and non-synaptic mitochondria (A) 
Effect of injury on non-synaptic and synaptic mitochondria for state V(II) respiration 
(rotenone/succinate) 24h after severe controlled cortical impact (CCI). (B) Effect of early 
post-injury (15 min) intraperitoneal administration of CsA (20 mg/kg) on non-synaptic 
and synaptic mitochondria for state V(II) respiration (rotenone/succinate) 24h after 
severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, 
sham synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh 
Syn, CCI + vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI 
+ CsA Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way 
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, #p < 0.05 vs. non-
synaptic sham. 
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Discussion 
These results indicate that synaptic mitochondria sustain more damage than 
non-synaptic mitochondria 24h after severe CCI and that intraperitoneal administration 
of CsA (20 mg/kg) 15 min after injury improves synaptic and non-synaptic respiration 
(Fig. 2.7), with a significant improvement being seen in the more severely impaired 
synaptic population.  
CsA is an FDA-approved immunosuppressant, used clinically to prevent organ 
rejection after transplant through a mechanism that involves inhibition of calcineurin and 
T-cell activation. [217] CsA, however, also has the ability to bind the mitochondrial matrix 
protein cyclophilin D, [218, 219]  which inhibits its interaction with the adenine nucleotide 
transporter, an inner mitochondrial membrane protein, thus preventing formation of 
mPTP. [220]  It is through inhibition of mPTP that CsA exerts its neuroprotective effects 
after TBI.  
NIM811, a non-immunosuppressive analog of CsA unable to bind calcineurin, but 
capable of binding cyclophilin D and inhibiting mPTP, [297]  maintains the 
neuroprotective effects of CsA, improving mitochondrial respiration, decreasing oxidative 
damage, decreasing calpain-mediated cytoskeletal degradation and neurodegeneration, 
and improving motor and cognitive function after experimental TBI. [110, 123, 226]   
Under normal physiologic conditions CsA is minimally blood brain barrier 
penetrable. [221]  After TBI, however, CsA is able to enter the CNS because of blood-
brain-barrier breakdown, [222]  and although concerns have been raised regarding CsA 
and neurotoxicity,  [237-244]  two phase II clinical trials show CsA to be safe for use in 
patients with severe TBI. [234, 235] 
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Figure 2.7 Representative oxymetric traces. Rates of oxygen consumption of sham, 
vehicle, and cyclosporine A (CsA) (20 mg/kg, intraperitoneally, 15 min post-injury) for (A) 
non-synaptic and (B) synaptic mitochondria isolated from ipsilateral cortex 24h after 
severe controlled cortical impact (CCI). Purified mitochondrial protein (>30 µg) was 
suspended in respiration buffer (125 mmol/L KCl, 2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 
0.1% BSA, 20 mmol/L HEPES, pH 7.2) in a final volume of 250 µl, and oxygen 
consumption rates were measured using a Clark-type oxygen electrode in the presence 
of 5 mmol/L pyruvate and 2.5 mmol/L malate (state II), two boluses of 150 µmol/L ATP 
(state III), 2 µmol/L oligomycin (state IV), 2 µmol/L FCCP (state VI), and 100 nmol/L 
rotenone and 10 mmol/L succinate (state VII). Sham, sham; CsA, CCI + CsA; vehicle, 
CCI + vehicle; ADP, adenosine diphosphate. 
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Despite the fact that the neuroprotective effects of CsA rely on direct protection 
of mitochondria, [51, 110, 124, 226]  many experimental TBI studies using CsA have 
focused on outcome measures downstream of mitochondrial dysfunction, such as 
cortical lesion volume, [122, 124, 227, 294] axonal pathology, [110, 117, 223, 224, 298]  
behavior, [110, 135]  and synaptic plasticity. [119]  Although important work does confirm 
the ability of CsA to protect mitochondria after injury, those studies focused on acute 
injury, [225] microscopic structure analysis, [223] or more indirect measures of 
mitochondrial function such as brain oxygen consumption [135] and whole brain ATP 
levels. [299]  Only two studies have assessed mitochondrial bioenergetics via oxygen 
consumption rates, one of which did not extend beyond 12h and was conducted in mice, 
[226] and one of which utilized juvenile animals. [292]  Importantly, none of these 
mitochondria-focused studies evaluated isolated synaptic and non-synaptic populations.  
While it should be noted that Sullivan and coworkers [225] showed that CsA 
maintains mitochondrial membrane potential in isolated non-synaptic mitochondria and 
intact synaptosomes acutely (30-60 min) after CCI, this is the first study to examine the 
effects of CsA on isolated and purified synaptic and non-synaptic mitochondria after 
experimental TBI.  As such, CsA was administered 15 min post-injury. Early 
administration allows for the greatest chance of neuroprotection, and allows for 
contextualization of future therapeutic window studies. The 20mg/kg intraperitoneal 
dosage used is considered optimal and has been used extensively in previously 
experimental TBI studies. [110, 117, 119, 124, 225-227, 292, 294]   
The CsA used in this study is solubilized in a vehicle containing cremophor. 
Toxicity concerns have been raised in regard to cremophor, and reported side effects 
include hypersensitivity reactions, hyperlipidemia, erythrocyte aggregation, and 
peripheral neuropathy, but are usually associated with intravenous infusions or high 
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cremophor concentrations. [245] Several studies have shown that cremophor has the 
ability to impair mitochondrial function. These studies, however, were performed in 
mitochondria isolated from heart muscle, skeletal muscle, and kidney tissue, and 
cremophor was either administered chronically or in-vitro. [300-302] 
Interestingly, chronic administration of cremophor or CsA + cremophor impairs 
heart and skeletal muscle mitochondria similarly, suggesting that any cremophor toxicity 
is still observable when administered along with CsA. The safety of low doses of CsA + 
cremophor, such as the dose used in this study (20mg/kg, intraperitoneally), is well 
supported in the literature, however. For example, administration of CsA + cremophor to 
sham animals has no effect on long term potentiation, [119] motor or cognitive function, 
[136] or brain metabolism, [299] although chronic administration can result in weight 
loss. [136]  
Although it is feasible that administration of vehicle or CsA to sham animals could 
alter basal mitochondrial respiration, evaluating the protective effect of CsA after injury in 
comparison to sham animals not receiving vehicle or drug is the most clinically 
appropriate assessment. Therefore, neither vehicle nor CsA were administered to sham 
animals for this study.  
The respiratory function of isolated synaptic and non-synaptic mitochondria was 
assessed 24h after injury. Total (synaptic and non-synaptic) mitochondrial respiratory 
dysfunction peaks between 12h and 24h after severe rat CCI, [22] with several studies 
confirming mitochondrial respiratory dysfunction 24h after injury. [22, 248, 303] 
In sham animals, synaptic mitochondria showed decreased respiratory rates 
compared to non-synaptic mitochondria, decreases that were only significant in state II 
and state V(II). Previous studies have also shown that healthy synaptic mitochondria 
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have decreased respiration rates compared with healthy non-synaptic mitochondria, [41, 
42] as well as decreased pyruvate dehydrogenase activity, [304] the enzyme responsible 
for generating the nicotinamide adenine dinucleotide that feeds into complex I of the 
electron transport chain. Because non-synaptic mitochondria contain mitochondria from 
both neurons and glia, it is possible the higher respiration rates found in non-synaptic 
mitochondria are because of astrocytic mitochondria; mitochondria isolated from cultured 
astrocytes have higher respiration rates than mitochondria isolated from cultured 
neurons as well as higher levels of electron transport chain subunits. [296]  
 RCR (state III/state IV) is considered one of the best general measures of 
mitochondrial function and health and represents the ability of mitochondria to couple 
oxidation of substrates with generation of ATP via ADP phosphorylation under minimal 
proton leak. Therefore, healthy mitochondria will have a high RCR, while damaged 
mitochondria will have a low RCR [30]. In this study, the RCR for synaptic mitochondria 
was significantly reduced 24h after injury compared with sham, while the RCR for non-
synaptic mitochondria was not. The RCR for injured synaptic mitochondria was also 
significantly reduced compared to the RCR for injured non-synaptic mitochondria. 
Interestingly, statistical analysis revealed a significant interaction between injury and 
population for this measure, indicating that synaptic mitochondria are indeed more 
susceptible to injury.  
Importantly, the decrease in synaptic RCR was significantly attenuated by CsA 
administration. While RCR represents an overall measure of mitochondrial function, its 
value is affected by multiple aspects of oxidative phosphorylation. [30]  Therefore, in 
addition to RCR we assessed individual states of respiration to identify specific aspects 
of bioenergetic impairment.  
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State II respiration is measured after addition of the complex-I substrates 
pyruvate and malate, but before ADP addition, and represents a slow state of 
respiration. Severe CCI significantly reduced state II respiration for both synaptic and 
non-synaptic mitochondria 24h after injury. Decreases in state II respiration are 
consistent with the fact that pyruvate dehydrogenase, the enzyme linking glycolysis with 
the citric acid cycle, is known to have decreased activity after TBI. [305, 306]  While CsA 
was able to improve injury induced decreases in state II respiration in both populations, 
the improvements only reached statistical significance in the synaptic population. 
 State III respiration is measured following addition of ADP, allowing coupling of 
oxidative phosphorylation, and is considered one of the most important states of 
respiration to measure after injury, because decreases in State III respiration are 
indicative of defects in complex I-driven substrate oxidation and/or ATP turnover. [30]  
Severe CCI significantly reduced state III respiration for both synaptic and non-synaptic 
mitochondria 24h after injury. While CsA was able to improve injury-induced decreases 
in state III respiration in both populations, the improvements only reached statistical 
significance in the synaptic population. Importantly, the ability of CsA to significantly 
improve state III synaptic respiration is a major contributory factor to the ability of CsA to 
also significantly improve synaptic RCR (state III/IV) after injury.  
State IV is measured after addition of the ATP synthase inhibitor oligomycin, 
which returns the mitochondria to a basal state of respiration. Severe CCI significantly 
reduced state IV respiration for both synaptic and non-synaptic mitochondria 24h after 
injury. While CsA was able to improve injury induced decreases in state IV respiration in 
both populations, the improvements were not statistically significant.  
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State V(I) respiration is measured following addition of the protonophore FCCP, 
which uncouples substrate oxidation from ATP production, and is used to assess 
maximal respiration, with decreases in state V(I) respiration being indicative of defects in 
complex-I driven substrate oxidation. [30]  Severe CCI significantly reduced state V(I) 
respiration for both synaptic and non-synaptic mitochondria 24h after injury. While CsA 
was able to improve injury-induced decreases in state V(I) respiration in both 
populations, the improvements were not statistically significant. 
State V(II) respiration is assessed following addition of the complex-I inhibitor 
rotenone, and the complex-II substrate succinate. Therefore, decreases in state V(II) 
respiration are indicative of defects in complex-II driven respiration. Severe CCI 
significantly reduced state V(II) respiration for both synaptic and non-synaptic 
mitochondria 24h after injury. While, CsA improved injury-induced decreases in 
complex-II driven respiration in both populations, the improvements only reached 
statistical significance in the synaptic population.    
In summary, synaptic mitochondria sustain more damage 24h after severe CCI 
than non-synaptic mitochondria, as best evidenced by the changes in RCR. This is in 
agreement with previous work indicating that synaptic mitochondria are more susceptible 
to dysfunction. For example, synaptic mitochondria are more susceptible to damage 3h 
after moderate CCI compared with non-synaptic mitochondria, an effect that is 
compounded by aging. [41]  In addition, in-vitro, healthy synaptic mitochondria have a 
decreased ability to buffer calcium before undergoing permeability transition compared 
with non-synaptic mitochondria. [37]   
Several hypotheses have been offered to explain the increased vulnerability of 
synaptic mitochondria compared with non-synaptic mitochondria, including high 
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concentrations of cyclophilin D, leading to increased susceptibility toward calcium-
induced permeability transition, [38]  as well as increased exposure of synaptic 
mitochondria to oxidative damage. [37, 38] Because non-synaptic mitochondria contain 
both neuronal and non-neuronal cell types, however, and mitochondria isolated from 
neurons and glia have differing properties, [38, 296] part of the increased susceptibility 
of synaptic mitochondria to injury may be because synaptic mitochondria represent a 
more purely neuronal population, [37-39] rather than their specific subcellular localization 
to the pre-synaptic terminal. It is likely, however, that both cell type and subcellular 
localization contribute to synaptic mitochondria vulnerability.  
These results also indicate that intraperitoneal administration of CsA (20 mg/kg) 
15 min after injury attenuates respiratory dysfunction in both populations 24h after 
severe CCI, with a statistically significant improvement being seen in the synaptic 
population. Although there was a significant decrease in each respiration state following 
injury for the non-synaptic mitochondria, the non-synaptic RCR was unaffected by injury, 
indicating no overall bioenergetics dysfunction. [30]  It is therefore likely that the 
improvements CsA had on the non-synaptic respiration states were only non-significant 
due to a lack of robust injury effect in this population, and that CsA would offer significant 
improvements at time points later than 24h when non-synaptic mitochondria are more 
significantly impaired.   
The fact that CsA is able to significantly protect synaptic mitochondria following 
injury is impressive, because synaptic mitochondria do not always respond as favorably 
to pharmaceutical intervention as the non-synaptic population. For example, following 
spinal cord injury, the catalytic peroxynitrite inhibitor, tempol, is only effective in non-
synaptic mitochondria, while the mitochondrial uncoupler 2-4 DNP works in both 
populations, but has a shorter therapeutic window in the synaptic mitochondria. [50]   
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Future studies will investigate if there is, indeed, a difference in the therapeutic 
window for CsA between synaptic and non-synaptic mitochondria. If so, studies may 
explain the fact that while CsA is able to improve cortical tissue sparing when 
administration is delayed up to 8h, it is significantly more protective when administered 
within 3h of injury. [122]  Further, the ability of CsA to protect synaptic neuronal 
mitochondrial respiration is made more impressive by the knowledge that there are 
higher concentrations of the CsA target protein cyclophilin D in synaptic mitochondria, 
[37] gamma-aminobutyric acid-ergic interneurons, [39] and cultured neurons when 
compared to cultured astrocytes. [38]  
In fact, in-vitro healthy synaptic mitochondria require higher concentrations of 
CsA to prevent calcium-induced permeability transition. [38]  Future studies will therefore 
evaluate the ability of CsA to attenuate calcium-induced permeability transition in both 
populations after injury, as well as the ability of CsA to retain its synaptic neuroprotective 
effect at time points beyond 24h.  
Conclusion 
This study confirms that synaptic mitochondria are more vulnerable than non-
synaptic mitochondria after experimental TBI, and therefore emphasizes the need for 
further characterization of synaptic and non-synaptic mitochondria after experimental 
TBI, including the contribution each population makes to TBI pathology, as well as the 
response each population has to mitochondrial-directed pharmacotherapies.  
While the pathology of TBI is complex and factors other than mitochondrial 
dysfunction contribute to downstream processes such as cytoskeletal degradation, 
neurodegeneration, and neurologic impairment, it is likely that successful protection of 
the more vulnerable synaptic population greatly contributes to inhibition of these 
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downstream processes. Because this study confirms the ability of CsA to significantly 
improve synaptic respiration following injury, CsA remains a promising neuroprotective 
candidate for the treatment of TBI.  
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CHAPTER THREE: 
 
Continuous Infusion of Phenelzine, Cyclosporine A, or Their Combination: 
Evaluation of Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal 
Degradation Following Severe Controlled Cortical Impact Traumatic Brain Injury in 
Rats 
 
Preface: Chapter Three has been adapted from: Kulbe JR, Singh IN, Wang JA, Cebak 
JE, Hall ED. Continuous infusion of phenelzine, cyclosporine A, or their combination: 
evaluation of mitochondrial bioenergetics, oxidative damage, and cytoskeletal 
degradation following severe controlled cortical impact traumatic brain injury in rats. 
Journal of Neurotrauma 35(11):1280-1293 (2018). DOI: 10.1089/neu.2017.5353. (Mary 
Ann Leibert, Inc., New York, NY). Figures have been renumbered and formatted in 
accordance with University of Kentucky Graduate School requirements. The figures 3.7-
3.9 have been added and portions of the Discussion and Conclusion have been 
expanded upon. The data which appears in Figure 3.6 was generated by Dr. John E. 
Cebak, Ph.D. and was first presented in his University of Kentucky Doctoral Dissertation, 
“Mitochondrial and neuroprotective effects of phenelzine related to scavenging of 
neurotoxic lipid peroxidation products” (2015).  
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Introduction 
 In the United States, there are more than 2.5 million documented cases of 
traumatic brain injury (TBI) annually [2], which resulted in direct and indirect medical 
costs of over $75 billion dollars in 2010, with the most severe injuries (those resulting in 
hospitalization and death) accounting for 90% of these costs [10, 11]. Currently, there 
are over 5 million people in the U.S. living with a TBI-related disability [12]. Further, over 
50% of persons hospitalized due to TBI will continue to suffer from a TBI-associated 
disability more than a year following injury [13]. Such disabilities can include cognitive, 
physical, and emotional impairments [12]. To date, there are no FDA-approved 
pharmacotherapies for neuroprotection following clinical TBI [1]. 
 Although numerous reasons have been cited for the failure of neuroprotective 
compounds in clinical TBI studies, [9, 213], due to the complex secondary injury cascade 
which occurs following injury and encompasses a multitude of neurodegenerative 
processes, single agent therapies may be unlikely to succeed at completely preventing 
the devastating neurological consequences that occur following injury [213]. In fact, in 
2008, the National Institutes of Health (NIH), in conjunction with the Department of 
Veterans Affairs, convened a workshop focusing on development of combinatorial 
approaches for the treatment of traumatic brain injury over the first 72h following injury; 
[213] underscoring the importance of developing multi-mechanistic combinational 
neuroprotective approaches for acute TBI.  
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Following injury (Fig. 3.1), increases in intracellular calcium are taken up by 
mitochondria in an attempt to maintain calcium homeostasis [22, 23]. However, high 
levels of intra-mitochondrial calcium lead to opening of the mitochondrial permeability 
transition pore (mPTP), resulting in collapse of the mitochondrial membrane potential, 
cessation of adenosine triphosphate (ATP) production, and release of calcium back into 
the cytosol [51]. Further, increases in intra-mitochondrial calcium can lead to increased 
generation of mitochondrial-produced reactive oxygen and nitrogen species (ROS/RNS) 
[17, 163]. For example, as the levels of mitochondrial calcium increase and the 
mitochondrial membrane potential depolarizes, electron transport slows, allowing 
electrons to leak from complex-I to combine with O2 to form superoxide radical (O2•
-) 
[307], which can go on to react with nitric oxide radicals (NO•) generated by the calcium-
activated mitochondrial nitric oxide synthase (mtNOS), forming peroxynitrite anion 
(ONOO-) [17, 53]. Peroxynitrite is unique in the fact that it has quite a large diffusion 
radius, thus allowing it to cross membranes, expanding its area of devastation [308]. 
Peroxynitrite is either protonated to form peroxynitrous acid (ONOOH) or reacts with CO2 
to form nitrosoperoxycarbonate (ONOOCO2
-), followed by decomposition into the highly 
reactive radicals, hydroxyl (•OH), nitrogen dioxide (•NO2) or carbonate (CO3
•-) [17, 55, 
308]. 
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Figure 3.1 Simplified schematic of TBI pathophysiology and phenelzine and 
cyclosporine A mechanisms of action. The role of mitochondrial dysfunction and lipid 
peroxidation following traumatic brain injury (TBI) and the mechanisms of action of 
phenelzine (PZ) and cyclosporine A (CsA). Following injury, mitochondria uptake 
calcium (Ca2+) which leads to opening of the mitochondrial permeability transition pore 
(mPTP), generation of superoxide (O2
•-) and activation of mitochondrial nitric oxide 
synthase (mtNOS), which leads to formation of nitric oxide (•NO). O2•
- and •NO combine 
to form peroxynitrite anion (ONOO-), which can be protonated or react with CO2 to form 
peroxynitrous acid (ONOOH) or nitrosoperoxycarbonate (ONOOCO2
-), followed by 
degradation into hydroxyl (•OH), nitrogen dioxide (•NO2) or carbonate (CO3•
-), highly 
reactive radicals which initiate lipid peroxidation (LP). LP terminates with the formation of 
the LP-derived aldehydes 4-hydroxynonenal (4-HNE) and acrolein. 4-HNE and acrolein 
bind mitochondrial proteins causing mitochondrial dysfunction and can exacerbate 
opening of the mPTP. Mitochondrial dysfunction itself exacerbates the reactive oxygen 
species/nitrogen species-lipid peroxidation-aldehyde cascade. Ca2+ is released back into 
the cytosol upon mPTP opening, activating calpain, which degrades cytoskeletal α-
spectrin, resulting in neurodegeneration and neurologic impairment. CsA inhibits mPTP. 
PZ scavenges the LP-derived aldehydes 4-HNE and acrolein.  
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These highly reactive radicals initiate lipid peroxidation (LP) of polyunsaturated 
fatty acids, which are highly enriched in brain cells and cellular and organelle 
membranes [1, 55]. As lipid peroxyl radicals are formed, they are able to react with 
neighboring polyunsaturated acids, resulting in a self-propagating process [1, 55]. Lipid 
peroxidation terminates upon formation of LP-derived aldehydes, such as 4-
hydroxynonenal (4-HNE) and acrolein [1, 55]. These LP-derived aldehydes have multiple 
reactive sites, making it possible for them to covalent bind lysine, histidine, arginine and 
cysteine protein residues through both Schiff base and Michael addition reactions [1, 79-
81]. Once covalently bound to proteins, including mitochondrial proteins, LP-derived 
aldehydes induce protein dysfunction and enzyme inactivation, neurotoxicity and cellular 
death [77, 84-89]. In the case of mitochondria, binding of LP-derived aldehydes 
exacerbates impairment of bioenergetics and generation of the ROS/RNS-lipid 
peroxidation-aldehyde cascade, as well as opening of mPTP [29, 72, 93, 100-102]. Once 
permeability transition occurs and calcium has been released back into the cytosol, it 
can activate calcium-dependent proteases, such as calpain, which can cleave 
cytoskeletal proteins, such as α-spectrin, resulting in further downstream consequences, 
including neurodegeneration and neurologic impairment [1, 51, 55, 56, 70, 109, 110]. 
As central mediators of the TBI secondary injury cascade, both mitochondria and 
LP-derived aldehydes make promising neuroprotective targets. In fact, several pre-
clinical studies have demonstrated the neuroprotective ability of agents which aim to 
prevent mitochondrial dysfunction or attenuate lipid peroxidation [58, 69-72, 75, 109, 
110, 123, 125, 226, 249, 257, 309, 310]. One of the most extensively investigated 
mitochondrial protective agents, the FDA-approved immunosuppressant cyclosporine A 
(CsA), is capable of inhibiting the mPTP [110, 218, 219, 226] (Fig. 3.1), and has been 
shown to be safe for use clinically in severe TBI patients [234, 235]. Another drug, 
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phenelzine (PZ) (Fig. 3.1), which is an FDA-approved irreversible non-selective 
monoamine oxidase inhibitor, contains a hydrazine moiety (-NH-NH2), which is capable 
of scavenging LP-derived aldehydes [71, 72, 74, 76, 198, 258, 262, 311, 312]. 
Importantly, scavenging of LP-derived aldehydes is likely to offer a more clinically 
translational approach in regards to therapeutic window, compared to conventional 
antioxidants, as LP-derived aldehydes are longer lived than their highly reactive free 
radical predecessors [79, 81, 259]. 
Both CsA and PZ have individually been shown capable of attenuating 
pathophysiologic processes in pre-clinical models of neurotrauma [71, 72, 74, 76, 110, 
122-124, 136, 223-227, 292, 294, 298, 309, 313]. Therefore, it follows that the mPTP 
inhibitor CsA and the LP-derived aldehyde scavenger PZ may together enhance 
neuroprotection over either agent alone through the combining of distinct but 
complementary mechanisms. In fact, CsA was one of the agents identified as a 
candidate for combinational therapy during the NIH combinational therapy TBI workshop 
[213]. Additionally, as the first 72h represents a critical time period following injury [213], 
including the peak of mitochondrial dysfunction, lipid peroxidation, and neuronal 
cytoskeletal (α-spectrin) degradation [73], it follows that continuous drug infusion over 
the first 72h following injury may also lead to optimal neuroprotective effects [79].  
This is the first study to investigate the neuroprotective effects of the combination 
CsA and PZ 72h following severe controlled cortical impact injury (CCI), a model 
combining focal, contusive, hemorrhagic and diffuse injury pathologies [128, 314]. 
Additionally, this is the first study to investigate the effects of 72h continuous infusion of 
CsA, PZ, and the combination on mitochondrial dysfunction, aldehydic modification of 
mitochondrial proteins, and α-spectrin degradation 72h following severe CCI, using a 
CsA dosing paradigm that previously has been shown to improve cortical tissue sparing 
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following CCI [122], and a PZ dosing paradigm based upon a 12hr intermittent dosing 
protocol which has previously been shown to be neuroprotective following CCI [72].  
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Methods 
Animals 
 Three-month-old male Sprague-Dawley rats (Harlan, Indianapolis, IN) were 
housed in the Division of Laboratory Animal Resources of the University of Kentucky 
Medical Center. All animal and husbandry were conducted in accordance with the 
University of Kentucky Institutional Animal Care and Use Committee. Animals were 
housed in a 12hr light and dark cycle and allowed food and water ad libitum.  
Experimental Design  
 Two cohorts of animals were randomly assigned to the following subcutaneous 
continuous infusion dosing paradigm experimental groups: sham, vehicle, PZ, CsA, and 
phenelzine + cyclosporine A (PZ + CsA), with one cohort of animals being used for all 
mitochondria experiments and another cohort of animals being used for cortical α-
spectrin analysis. An additional cohort of animals was randomly assigned to the 
following 12hr intermittent PZ dosing paradigm experimental groups: sham, vehicle, or 
PZ. Following injury and closing of the craniotomy site, all animals in the subcutaneous 
continuous infusion dosing paradigm, other than sham, were immediately implanted with 
two subcutaneous osmotic pumps loaded with either drug or vehicle, and additionally 
received two bolus doses of either drug or vehicle 15 min following impact. Animals 
within the subcutaneous continuous infusion dosing paradigm received the following 
doses: i) sham (no impact injury, no drug administration); ii) vehicle (15 min post-injury 
bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: 
subcutaneous saline; subcutaneous osmotic pump: cremophor/ethanol/saline; 
subcutaneous osmotic pump: saline); iii) PZ (15 min post-injury bolus dose: 
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 
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10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d saline); iv) CsA (15 min post-injury bolus 
dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus 
dose: subcutaneous saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in 
cremophor/ethanol/saline; subcutaneous osmotic pump: saline) v) PZ + CsA (15 min 
post-injury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min 
post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic 
pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline, subcutaneous osmotic pump: 
10mg/kg/day/3d PZ in saline) (Table 3.1). Following euthanasia one group of the 
subcutaneous continuous infusion dosing paradigm animals were used for mitochondria 
experiments while the other group was utilized for analysis of α-spectrin degradation.  
The third cohort of animals was assigned to the 12hr intermittent PZ dosing 
paradigm. Animals in the 12hr intermittent PZ dosing paradigm received the following 
dosing schedule: sham (no impact injury, no drug administration); vehicle (15 min post-
injury bolus dose of subcutaneous saline, followed by subcutaneous bolus saline every 
12h up to and including 60h); PZ (15 min post-injury bolus dose of 10mg/kg PZ in saline, 
followed by subcutaneous bolus 5mg/kg PZ in saline every 12h up to and including 60h) 
(Table 3.2). 
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Table 3.1 Subcutaneous Continuous Infusion Dosing Paradigm 
Group 
Loading Dose  
(15min post-injury) 
Osmotic Pump 
(Immediate) 
Sham None None 
Vehicle 
Saline s.c. 
Cremophor i.p. 
Saline 
Cremophor 
Phenelzine 
10mg/kg s.c. PZ 
Cremophor i.p. 
10mg/kg/day/3d PZ 
Cremophor 
Cyclosporine A 
Saline s.c. 
20mg/kg i.p. CsA 
Saline 
10mg/kg/day/3d CsA 
Phenelzine + Cyclosporine 
A 
10mg/kg s.c. PZ 
20mg/kg i.p. CsA 
10mg/kg/day/3d PZ 
10mg/kg/day/3d CsA 
 
Demonstration of the subcutaneous continuous infusion dosing paradigm followed. 
Osmotic pumps were placed subcutaneously immediately following impact injury and 
closure of the craniotomy site. Pumps were removed 72h later at the time of euthanasia. 
Loading doses were administered 15 min following impact. Cremophor (saline/650mg 
cremophor/32.9% ethanol/ml) was prepared to deliver an equal amount cremophor as 
received by CsA animals. Saline was prepared to deliver an equal amount of saline as 
PZ animals. PZ, phenelzine (in saline); CsA, cyclosporine A (in saline/650mg 
cremophor/32.9% ethanol/ml); s.c, subcutaneous, i.p., intraperitoneal.  
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Table 3.2 Phenelzine 12hr Intermittent Dosing Paradigm 
Group 
Loading Dose  
(15min post-injury) 
Maintenance dosing: 
12h, 24h, 36h, 48h, 60h 
Sham None None 
Vehicle Saline s.c. Saline s.c.  
Phenelzine 10mg/kg s.c. PZ 5mg/kg s.c. PZ 
 
Demonstration of the PZ 12hr intermittent dosing paradigm followed. Loading doses 
were administered 15 min following impact. Maintenance doses were administered every 
12h up to and including 60h. Animals were euthanized 72h post-injury. Saline was 
prepared to deliver an equal amount of saline as PZ animals. PZ, phenelzine (in saline); 
s.c., subcutaneous.  
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Controlled Cortical Impact Traumatic Brain Injury  
 Animals were anesthetized using 4% isoflurane, shaved, and placed into a 
stereotaxic frame (David Kopf, Tujunga, CA), where isoflurane was maintained at 3% for 
the duration of the procedure. A midline incision was made to expose the skull, and a 6 
mm craniotomy was created lateral to the sagittal suture and midway between lambda 
and bregma using a Michele Trephine (Miltex, Bethpage, NY). The exposed brain with 
intact dura received a severe CCI using a computer-controlled pneumatic impact device 
(TBI 03010; Precision Systems and Instrumentation, Fairfax Station, VA) fitted with a 5 
mm beveled tip and set to impact at a depth of 2.2 mm with a 500 ms dwell time and an 
impact velocity of ~3.5 m/s, as described previously [71]. After injury, Surgicel (Johnson 
& Johnson, Arlingtin, TX) was placed onto the dura and an 8 mm plastic disk was affixed 
to the skull using tissue adhesive (Gesswein, Bridgeport, CT) to close the craniotomy 
site, and the incision was closed using wound clips. Sham animals underwent the same 
procedure but did not receive an impact injury. 
Loading Dose Drug Administration 
 Fifteen minutes following injury, animals assigned to the subcutaneous 
continuous infusion dosing paradigm, received a loading dose of the appropriate drug. 
CsA (Perrigo; Minneapolis, MN; 50mg/ml in saline/650mg cremophor/32.9% ethanol/ml) 
was administered intraperitoneal at 20mg/kg [122, 227]. Cremophor (CsA vehicle) was 
administered intraperitoneal to deliver an equivalent volume of 
saline/cremophor/ethanol. Phenelzine (MP Biochemicals, Solon, OH) was administered 
subcutaneously at 10mg/kg in saline [72]. Saline (PZ vehicle) was administered 
subcutaneously to deliver an equivalent volume of saline. Sham animals did not receive 
injections. 
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Osmotic Pump Preparation  
 The day prior to implantation, osmotic pumps (2ML1, Alzet osmotic pumps, 
Cupertino, CA) were loaded with appropriate drug concentrations and allowed to prime 
overnight at 37°C and then maintained at 37°C until the time of implantation. CsA  
pumps were loaded to deliver 10mg/kg/day/3d of CsA (Perrigo; Minneapolis, MN; 
50mg/ml in saline/650mg cremophor/32.9% ethanol/ml) based on a previously optimized 
CsA dosing protocol [122, 227]. Cremophor pumps (CsA vehicle) were loaded to deliver 
an equivalent volume of saline/cremophor/ethanol. PZ pumps were loaded to deliver 
10mg/kg/day/3d of PZ (MP Biochemicals, Solon, OH) in saline based on an approximate 
12h plasma half-life in humans and a previously optimized 12hr intermittent dosing 
protocol [72]. Saline pumps (PZ vehicle) were loaded to deliver an equivalent amount 
saline. 
Implantation of Osmotic Pumps 
 Immediately following impact injury and closure of the craniotomy site, a sagittal 
incision was made approximately half-way down the animal’s back. Hemostats were 
used to create a subcutaneous pocket anterior and posterior to the incision site. Pre-
loaded osmotic pumps (2ML1, Alzet osmotic pumps, Cupertino, CA) were inserted into 
the subcutaneous pockets with the flow moderator positioned away from the incision 
site. The incision was then closed with wound clips, and animals were allowed to recover 
while body temperature was maintained at 37°C using a warm water circulating heating 
pad. Vehicle animals received a saline pump (PZ’s vehicle) and a cremophor pump 
(CsA’s vehicle). PZ animals received a PZ pump and a cremophor pump. CsA animals 
received a CsA pump and a saline pump. PZ + CsA animals received a PZ pump and a 
CsA pump. Sham animals did not undergo pump implantation.  
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 Phenelzine 12hr Intermittent Dosing Protocol  
 Fifteen minutes following injury, PZ animals received 10mg/kg PZ (MP 
Biochemicals, Solon, OH) in saline subcutaneously, followed by 5mg/kg PZ 
subcutaneously every 12h up to including 60h [72]. Vehicle animals received an 
equivalent amount of saline at the appropriate time point.  Sham animals did not receive 
injections (Table 3.2).  
Tissue Extraction and Pump Removal  
Animals were euthanized 72h following injury, which represents the peak of 
mitochondrial dysfunction, LP and α-spectrin degradation [73], using CO2, followed by 
decapitation. An 8 mm cortical punch centered over the injury was collected in order to 
collect the epicenter of injury and the penumbral region. Cortical punches were either 
processed for isolation of mitochondria or cortical protein. Pumps were removed and 
residual volumes were measure to ensure proper drug delivery. Animals in which pumps 
did not run properly, as determined by the removed pumps still having most of their drug 
still in the pumps, were removed from the study.  
Isolation of Ficoll-Purified Cortical Mitochondria  
Mitochondria were isolated as described previously [71, 163]. Cortical punch 
tissue was immediately homogenized in ice-cold isolation buffer (215 mmol/L mannitol, 
75 mmol/L sucrose, 0.1% bovine serum albumin, 20mmol/L HEPES, 1mmol/L EGTA, pH 
7.2) using Potter-Elvejhem homogenizers. Samples were then centrifuged twice at 1300 
g for 3 min at 4°C. Supernatants were additionally centrifuged at 13,000 g for 10 min at 
4°C. The crude mitochondrial pellet was resuspended in isolation buffer, placed into a 
nitrogen bomb at 1200 psi for 10 min at 4°C to release synaptic mitochondria, and then 
layered onto a discontinuous 7.5% and 10% Ficoll gradient and centrifuged for 100,000 
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g for 30 min at 4°C. The mitochondrial pellet was resuspended in isolation buffer without 
EGTA, centrifuged at 10,000 g for 10 min at 4°C to remove Ficoll, and then resuspended 
in isolation buffer without EGTA to a final concentration of ~10mg/kg. Protein 
concentrations were determined with a BCA protein assay kit (ThermoFisher, Cleveland, 
OH) and measured at absorbance 562nm with a BioTek Synergy HT plate reader 
(Winooski, VT). 
Mitochondrial Bioenergetics Analysis  
 Mitochondrial respiratory function was measured using a Clark-type electrode in 
a continuously stirred, sealed, and thermostatically controlled chamber maintained at 
37°C (Oxytherm System; Hansatech Instruments, Norfolk, UK). Mitochondria (60 μg – 80 
μg) were placed into the chamber containing 250 μl of KCl respiration buffer (125 
mmol/L KCl, 2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 0.1% bovine serum albumin, 20 
mmol/L HEPES, pH 7.2). Following a 1 minute equilibration, complex-I respiration was 
initiated by addition of 5 mmol/L pyruvate and 2.5 mmol/L malate. Two boluses of 150 
μmol/L ADP were added and state III respiration was monitored. The ATP synthase 
inhibitor, oligomycin (2 μmol/L) was added and state IV respiration was monitored. The 
protonophore FCCP (2 μmol/L) was added and maximal state V(I) respiration was 
monitored. Complex-I was inhibited by addition of 100 nmol/L rotenone. Complex-II 
maximal respiration was initiated by the addition of succinate (10 mmol/L) and state V(II) 
was monitored. Respiratory rates for individual states were calculated as nmol O2 per 
mg of protein per min. Respiratory control ratio (RCR) was calculated by dividing state III 
respiration rate (second bolus of ADP) by state IV respiration rate [163, 248]. Following 
bioenergetics analysis, remaining mitochondrial protein was immediately frozen at -80°C 
for use in Western blot.  
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Western Blot Analysis: Cortical α-Spectrin Degradation & Lipid Peroxidation-
Induced Cortical Mitochondrial Oxidative Damage  
Cortical punch tissue collected from the cohorts of animals designated for 
analysis of α-spectrin degradation was immediately placed into ice-cold Triton-lysis 
buffer (1% Triton, 20 mmol/L Tris-HCl, 150 mmol/L NaCl, 5 mmol/L EGTA, 10 mmol/L 
EDTA, 20 mmol/L HEPES, pH 7.4) containing protease inhibitors (Complete Mini™ 
Protease Inhibitor Cocktail tablet, Roche).  Similarly, mitochondria protein being stored 
at -80°C following bioenergetics analysis was thawed and resuspended in lysis buffer. 
All samples were sonicated, vortexed, and then centrifuged at 14,000 rpm for 30 min at 
4°C. Protein concentrations were determined with a BCA protein assay kit 
(ThermoFisher, Cleveland, OH) and measured at absorbance 562nm with a BioTek 
Synergy HT plate reader (Winooski, VT). Due to the limited yield of mitochondrial protein 
following Ficoll-purified isolation, bioenergetics analysis and processing for Western blot, 
only samples containing greater than 100 μg of protein, allowing for analysis of both 4-
HNE and acrolein, were utilized for Western Blot. For analysis of α-spectrin, 10 μg of 
protein was run on a 3-8% Tris-Acetate Criterion™ XT polyacrylamide gel (Bio-Rad, 
Hercules, CA) with XT Tricine Running Buffer (Bio-Rad, Hercules, CA). For analysis of 
4-HNE or acrolein, 50 μg of protein was run on a 4-12% Tris-Acetate Criterion™ XT 
polyacrylamide gel (Bio-Rad, Hercules, CA) with MOPS buffer (Bio-Rad, Hercules, CA). 
Following separation of proteins by polyacrylamide gel, protein was transferred to a 
nitrocellulose membrane using a semi-dry electro-transferring unit for 15 min (α-spectrin) 
or 1hr (4-HNE, acrolein) at 15V. Following transfer, membranes were blocked at room 
temperature for 1hr in Tris-buffered saline (TBS) containing 5% milk. Membranes were 
incubated with the following primary antibodies in TBS with Tween (TBST) containing 
5% milk overnight at 4°C: mouse monoclonal anti-αII-spectrin (Enzo, Farmingdale, NY, 
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1:5,000), rabbit polyclonal anti-β-tubulin (Abcam, Cambridge, CA, 1:5,000-1:10,000),  
rabbit polyclonal anti-4HNE (Alpha Diagnostics, San Antonio, TX, 1:1,000), rabbit 
polyclonal anti-acrolein (Abcam, Cambridge, CA, 1:2,000), and rabbit polyclonal anti-
VDAC (EMD Millipore,  Billerica, MA, 1:30,000). Membranes were washed in TBST 
following incubation with primary antibody. 
 Membranes were incubated with the following secondary antibodies in TBST 
with 5% milk for one 1hr at room temperature: goat anti-rabbit IgG IRdye800CW 
(Rockland, Limerick, PA, 1:5,000), goat anti-rabbit IgG Alexa Fluor 680 (ThermoFisher, 
Waltham, MA1:10,000), and goat anti-mouse IgG IRDye800CW (Rockland, Limerick, 
PA, 1:5,000). Membranes were washed in TBST, and then imaged and quantified using 
the Li-Cor Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). For 
analysis of α-spectrin degradation, α-spectrin breakdown products were normalized to 
tubulin. For analysis of mitochondrial protein, 4-HNE and acrolein were normalized to 
VDAC. A protein loading control was loaded onto each gel to control for inter-gel 
variability. For α-spectrin, bands at 145kD and 150kD were analyzed. Due to broad 
binding of 4-HNE and acrolein to lysine, histidine, arginine, cysteine protein residues, as 
well as differential banding patterns between 4-HNE and acrolein [73], mitochondrial 4-
HNE was analyzed between 80kD-150kD and mitochondrial acrolein was analyzed 
between 60kD-100kD. 
Statistical Analysis 
 Statistical analysis was conducted using Prism version 7.0 (Graph Pad, San 
Diego, CA). Results are reported as mean ± standard deviation. Analysis was done by 
one-way analysis of variance (ANOVA), followed by Student-Newman-Keuls (SNK) post-
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hoc analysis when appropriate. A p-value <0.05 was considered significant. Grubb’s test 
was used to remove statistical outliers.  
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Results 
CCI-TBI Induced Mitochondrial Bioenergetics Dysfunction 
State III: ADP Activation of ATP Synthase and Coupling of Electron Transport with 
Oxidative Phosphorylation  
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,35] = 19.45, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham, 
state III respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001), CsA 
(p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly 
decreased state III respiration compared with sham, and that 72h subcutaneous 
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate 
CCI-induced decreases in state III respiration (Fig. 3.2A). 
State IV: Oligomycin Inhibition of ATP Synthase  
A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,35] = 11.44, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham, 
state IV respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001), 
CsA (p<0.001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly 
decreased state IV respiration compared with sham, and that 72h subcutaneous 
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate 
CCI-induced decreases in state IV respiration (Fig. 3.2B). 
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Figure 3.2 State III – State V(II): PZ, CsA, and PZ + CsA. Effect of the 15 min post-
injury loading dose + 72h subcutaneous continuous infusion dosing paradigm on 
mitochondrial oxygen consumption 72h following severe cortical impact injury for (A) 
state III (pyruvate/malate/ADP), (B) state IV (oligomycin), (C) state V(I) (FCCP), and (D) 
state V(II) (rotenone/succinate). Sham (no impact injury, no drug administration). Vehicle 
(15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-
injury bolus dose: subcutaneous saline; subcutaneous osmotic pump: 
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ = phenelzine (15 
min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury 
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 
cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). 
CsA = cyclosporine A (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in 
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; 
subcutaneous osmotic pump: saline). PZ + CsA + cyclosporine A (15 min post-injury 
bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury 
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 
10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump: 
10mg/kg/day/3d PZ in saline). One-way analysis of variance followed by Student-
Newman-Keuls post-hoc test. ***p<0.001, ****p<0.0001 compared with sham. Error bars 
represent mean ± standard deviation. n = 8 rats per group.  
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Respiratory Control Ratio (RCR): State III Respiration / State IV Respiration  
A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,35] = 5.961, p=0.0009). Post-hoc testing (SNK) revealed that compared with sham, 
RCR was significantly impaired for vehicle (p<0.05), CsA (p<0.01), and PZ + CsA 
(p<0.01), whereas PZ was not significantly different from either vehicle (p>0.05) or sham 
(p>0.05), thus indicating that severe CCI significantly decreased RCR compared with 
sham, and that 72h subcutaneous continuous infusion of neither CsA, nor PZ + CsA was 
able to significantly attenuate CCI-induced decreases in RCR.  However, PZ was able to 
maintain RCR, compared with sham (Fig 3.3). 
State V(I): FCCP Protonophore Addition and Initiation of Maximal Complex-I Respiration  
A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,35] = 33.55, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham, 
state V(I) respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001), 
CsA (p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly 
decreased state V(I) respiration compared with sham, and that 72h subcutaneous 
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate 
CCI-induced decreases in state V(I) respiration (Fig. 3.2C). 
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Figure 3.3 RCR: PZ, CsA, and PZ + CsA Effect of the 15 min post-injury loading dose + 
72h subcutaneous continuous infusion dosing paradigm on mitochondrial respiratory 
control ratio (state III respiration / state IV respiration) 72h following severe cortical 
impact injury. Sham (no impact injury, no drug administration). Vehicle (15 min post-
injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus 
dose: subcutaneous saline, subcutaneous osmotic pump: cremophor/ethanol/saline; 
subcutaneous osmotic pump: saline). PZ = phenelzine (15 min post-injury bolus dose: 
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 
10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). CsA = cyclosporine A (15 
min post-injury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 
min post-injury bolus dose: subcutaneous saline; subcutaneous osmotic pump: 
10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump: saline). 
PZ + CsA (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in 
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 10mg/kg PZ in 
saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). One-way analysis of 
variance followed by Student-Newman-Keuls post-hoc test. *p<0.05, **p<0.01 compared 
with sham. Error bars represent mean ± standard deviation. n = 8 rats per group.  
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State V(II): Rotenone Inhibition of Complex-I and Succinate Activation of Maximal 
Complex-II Respiration 
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,35] = 19.55, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham, 
state V(II) respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001), 
CsA (p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly 
decreased state V(II) respiration compared with sham, and that 72h subcutaneous 
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate 
CCI-induced decreases in state V(II) respiration (Fig. 3.2D). 
CCI-TBI Modification of Mitochondrial Proteins by 4-HNE and Acrolein 
4-HNE 
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,30] = 6.765, p=0.0005). Post-hoc testing (SNK) revealed that compared with sham, 
binding of 4-HNE to mitochondrial proteins was significantly increased for vehicle 
(p<0.001) and PZ + CsA (p<0.01), and that binding of 4-HNE to mitochondrial proteins 
was significantly decreased in the PZ group (p<0.05) and the CsA group (p<0.05) 
compared with vehicle, with neither the PZ group or the CsA group being significantly 
different from sham (p>0.05), thus indicating that severe CCI significantly increases 
formation of 4-HNE bound mitochondrial proteins compared with sham, and that 72h 
subcutaneous continuous infusion of either PZ or CsA, but nor PZ + CsA, significantly 
decreases CCI-induced formation of 4-HNE bound mitochondrial proteins (Fig. 3.4A).  
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Figure 3.4 4-HNE and Acrolein: Effect of PZ, CsA, and PZ + CsA. Effect of the 15 min 
post-injury loading dose + 72h subcutaneous continuous infusion dosing paradigm on 
binding of (A) 4-HNE (4-hydroxynonenal) or (C) acrolein to mitochondrial protein 72h 
following severe cortical impact injury as assessed by Western blot. Representative 
Western blot images demonstrating analysis of (B) 4-HNE between 150 kD and 80 kD 
and internal loading control VDAC (voltage-dependent anion channel) and analysis of 
(D) Acrolein between 100 kD and 60 kD and internal loading control VDAC. Sham (no 
impact injury, no drug administration). Vehicle (15 min post-injury bolus dose: 
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 
saline; subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic 
pump: saline). PZ = phenelzine (15 min post-injury bolus dose: intraperitoneal 
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 10mg/kg PZ in 
saline; subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic 
pump: 10mg/kg/day/3d PZ in saline). CsA = cyclosporine A (15 min post-injury bolus 
dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus 
dose: subcutaneous saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in 
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ + CsA (15 min post-
injury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min 
post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic 
pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump: 
10mg/kg/day/3d PZ in saline). One-way analysis of variance followed by Student-
Newman-Keuls post-hoc test. *p<0.05, **p<0.01, ***p<0.001 compared with sham; 
#p<0.05 compared with vehicle; ^p<0.05 compared with CsA. Error bars represent mean 
± standard deviation. n = 6-8 rats per group.   
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Acrolein  
A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,32] = 4.607, p=0.0047). Post-hoc testing (SNK) revealed that compared with sham, 
binding of acrolein to mitochondrial proteins was significantly increased for vehicle 
(p<0.05) and PZ + CsA (p<0.05). The PZ + CsA group was also significantly increased 
as compared with the CsA group (p<0.05). Although the PZ group and the CsA group 
were not significantly different from vehicle (p>0.05), there was a 42% and 51% 
decrease in mean acrolein binding of mitochondrial proteins compared with vehicle for 
the PZ and CsA group, respectively. Further, the PZ group and the CsA group were not 
significantly different from sham (p>0.05), thus indicating that severe CCI significantly 
increases formation of acrolein bound mitochondrial proteins compared with sham, and 
that 72h subcutaneous continuous infusion of either PZ or CsA, but nor PZ + CsA, 
decreases CCI-induced formation of acrolein bound mitochondrial proteins (Fig. 3.4C).  
CCI-TBI Induced α-Spectrin Degradation: Continuous Infusion Dosing Paradigm  
145 kD – Calpain-Dependent α-Spectrin Breakdown Product 
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,34] = 3.032, p=0.0306). Post-hoc testing (SNK) revealed that compared with sham, 
145 kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05) 
and CsA (p<0.05). Although the PZ group and the PZ + CsA group were not significantly 
different from vehicle (p>0.05), there was a 53% and a 53% decrease in mean 
absorbance compared with vehicle for the PZ and PZ + CsA groups, respectively. 
Further, the PZ group and the PZ + CsA group were not significantly different from sham 
(p>0.05) or from each other (p>0.05), thus indicating that severe CCI significantly 
increases formation of the 145 kD calpain dependent α-spectrin breakdown product, and 
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that 72h subcutaneous continuous infusion of either PZ or PZ + CsA maintain 
cytoskeletal α-spectrin integrity to a similar degree, as compared with sham (Fig. 3.5A).  
150 kD – Calpain/Caspase 3-Dependent α-Spectrin Breakdown Product 
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[4,34] = 4.49, p=0.0051). Post-hoc testing (SNK) revealed that compared with sham, 150 
kD α-spectrin breakdown products were significantly increased for vehicle (p<0.01) and 
CsA (p<0.01). Although the PZ group and the PZ + CsA group were not significantly 
different from vehicle (p>0.05), there was a 47% and 47% decrease in mean 
absorbance compared with vehicle for the PZ and PZ + CsA groups, respectively. 
Further, the PZ group and the PZ + CsA group were not significantly different from sham 
(p>0.05) or from each other (p>0.05), thus indicating that severe CCI significantly 
increases formation of the 150 kD calpain/caspase 3-dependent α-spectrin breakdown 
product, and that 72h subcutaneous continuous infusion of either PZ or PZ + CsA 
maintain cytoskeletal α-spectrin integrity to a similar degree, as compared with sham 
(Fig. 3.5B).  
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Figure 3.5 Spectrin: Effect of PZ, CsA, and PZ + CsA. Effect of the 15 min post-injury 
loading dose + 72h subcutaneous continuous infusion dosing paradigm on degradation 
of cytoskeletal protein α-spectrin into (A) 145 kD (calpain dependent) and (B) 150 kD 
(calpain and caspase 3-dependent) α-spectrin breakdown products 72h following severe 
cortical impact injury as assessed by Western blot. (C) Representative Western blot 
image demonstrating analysis of 145 kD and 150 kD α-spectrin bands and the internal 
loading control tubulin. Sham (no impact injury, no drug administration). Veh = Vehicle 
(15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-
injury bolus dose: subcutaneous saline; subcutaneous osmotic pump: 
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ = phenelzine (15 
min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury 
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 
cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). 
CsA = cyclosporine A (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in 
cremophor/ethanol/saline; 15min post-injury bolus dose: subcutaneous saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; 
subcutaneous osmotic pump: saline). PZ + CsA (15 min post-injury bolus dose: 
intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus dose: 
subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA 
in cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in 
saline). One-way analysis of variance followed by Student-Newman-Keuls post-hoc test. 
*p<0.05, **p<0.01 compared with sham. Error bars represent mean ± standard deviation. 
n  = 7-9 rats per group.   
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CCI-TBI Induced α-Spectrin Degradation: Phenelzine 12hr Intermittent Dosing 
Paradigm 
145 kD – Calpain-Dependent α-Spectrin Breakdown Products 
A one-way ANOVA revealed a statistically significant effect across all groups (F 
[2,21] = 6.128, p=0.008). Post-hoc testing (SNK) revealed that compared with sham, 145 
kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05) and 
PZ (p<0.01), thus indicating that severe CCI significantly increases formation of the 145 
kD calpain-dependent α-spectrin breakdown product, and that a subcutaneous bolus 
dose of PZ (10 mg/kg) 15 min post-injury followed by subcutaneous maintenance doses 
(5 mg/kg) every 12h up to and including 60h is unable to attenuate degradation (Fig. 
3.6A).   
150 kD – Calpain/Caspase 3-Dependent α-Spectrin Breakdown Product 
 A one-way ANOVA revealed a statistically significant effect across all groups (F 
[2,21] = 5.426, p=0.0126). Post-hoc testing (SNK) revealed that compared with sham, 
150 kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05) 
and PZ (p<0.05), thus indicating that severe CCI significantly increases formation of the 
150 kD calpain/caspase 3-dependent α-spectrin breakdown product, and that a 
subcutaneous bolus dose of PZ (10 mg/kg) 15 min post-injury followed by subcutaneous 
maintenance doses (5 mg/kg) every 12h up to and including 60h is unable to attenuate 
degradation (Fig. 3.6B).   
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Figure 3.6 Spectrin: Intermittent PZ dosing. Effect of the 15 min post-injury loading 
dose + 12h intermittent phenelzine (PZ) dosing paradigm on degradation of cytoskeletal 
protein α-spectrin into  (A) 145 kD (calpain dependent) and (B) 150 kD (calpain and 
caspase-3 dependent) α-spectrin breakdown products 72h following severe cortical 
impact injury as assessed by Western blot. (C) Representative Western blot image 
demonstrating analysis of 145 kD and 150 kD α-spectrin bands and the internal loading 
control tubulin. Sham (no impact injury, no drug administration). Vehicle (15 min post-
injury bolus dose subcutaneous saline, followed by subcutaneous bolus saline every 12h 
up to and including 60h). PZ = phenelzine (15 min post-injury bolus dose of 10mg/kg PZ 
in saline, followed by subcutaneous bolus 5mg/kg PZ in saline every 12h up to and 
including 60h). One-way analysis of variance followed by Student-Newman-Keuls post-
hoc test. *p<0.05, **p<0.01 compared to sham. Error bars represent mean ± standard 
deviation. n = 7-9 rats per group. 
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Discussion 
TBI Induction of Mitochondrial Dysfunction and Lipid Peroxidation-Derived 
Aldehyde Generation   
 It is has been firmly established that mitochondrial dysfunction, lipid peroxidation, 
and production of LP-derived aldehydes occurs following TBI, and that each contributes 
to TBI pathology [1, 17, 55, 57, 73, 163, 285]. For example, mitochondrial dysfunction 
can contribute to induction of the ROS/RNS-lipid peroxidation-aldehyde cascade, energy 
failure, and downstream consequences such as cytoskeletal and neuronal degeneration 
and neurologic impairment [1, 17, 51, 55, 56, 70, 110, 163], while lipid peroxidation can 
impair membrane fluidity and destabilize membrane integrity [256], and the LP-derived 
aldehydes, including 4-HNE and acrolein, can have directly toxic effects on cellular 
function [29, 72, 77, 85-89, 93, 101, 102, 257, 258], with a notably devastating effect on 
the mitochondria.   
Cyclosporine A and Inhibition of the Mitochondrial Permeability Transition Pore  
Several approaches have been utilized to improve mitochondrial function 
following TBI, including mild uncoupling [125, 248], ketogenic diet [249], induction of 
endogenous antioxidant pathways [97, 113], and scavenging of lipid peroxyl radicals, 
peroxynitrite, and LP-derived aldehydes [58, 69, 71, 72, 109, 257, 310, 315]. However, 
inhibition of the mitochondrial permeability transition pore utilizing the FDA-approved 
immunosuppressant CsA as a neuroprotective strategy following TBI has remained a 
focus among the neurotrauma community for the past 20 years.  Although the 
immunosuppressive effects of CsA are attributable to its ability to inhibit calcineurin and, 
therefore, T-cell activation [316], its neuroprotective effects are purported to be due to 
inhibition of the mPTP through direct binding of the mPTP component protein, cyclophilin 
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D [218-220, 317]. In fact, in experimental TBI, CsA or its non-immunosuppressive 
analog, the mPTP inhibitor NIM811, have been shown to prevent mitochondrial 
dysfunction, decrease oxidative damage, attenuate axonal pathology and 
neurodegeneration, and improve behavioral impairments [110, 123, 124, 135, 136, 223-
226, 292, 309].   
 The continuous CsA dosing paradigm utilized here, 20 mg/kg CsA delivered 
intraperitoneal 15 min post-injury combined with subcutaneous continuous infusion of 
10mg/kg/day/3 days CsA, is based on previously optimized dosing paradigms 
demonstrating that continuous infusion of CsA is more neuroprotective that bolus dosing 
[122, 227]. Additionally, a 72h continuous infusion CsA dosing protocol has proven safe 
for clinical use in severe TBI and was suggestive of improved outcomes [234].  However, 
previous to our study, the effects of continuous infusion of CsA following experimental 
TBI had not been assessed using outcome measures distinct from cortical tissue 
sparing. Our results indicate (Table 3.3) that while CsA was able to significantly 
decrease TBI-induced increases in aldehydic-modified mitochondrial proteins (Fig. 3.4), 
it was unable to prevent mitochondrial respiratory dysfunction (Fig 3.2 and 3.3) or 
cytoskeletal α-spectrin degradation (Fig. 3.5).  
  
 
 
132 
Table 3.3 Summary of Result: Subcutaneous Continuous Infusion Dosing 
Paradigm 
 Vehicle PZ CsA PZ + CsA 
Mitochondrial RCR ↓* ↔^ ↓* ↓* 
Mitochondrial Individual 
Respiratory States 
↓* ↓* ↓* ↓* 
Mitochondrial 4-HNE ↑* ↓# ↓# ↑* 
Mitochondrial Acrolein ↑* ↔^ ↔^ ↑* 
Spectrin Degradation ↑* ↔^ ↑* ↔^ 
 
Effect of the 15 min post-injury loading dose + 72h subcutaneous continuous infusion 
dosing paradigm on the above listed outcome measures 72h following severe cortical 
impact injury. Vehicle (15 min post-injury bolus dose: intraperitoneal 
cremophor/ethanol/saline’ 15 min post-injury bolus dose: subcutaneous saline; 
subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic pump: 
saline). PZ (15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 
min post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic 
pump: cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in 
saline). CsA (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in 
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; 
subcutaneous osmotic pump: saline). PZ + CsA (15 min post-injury bolus dose: 
intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus dose: 
subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA 
in cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in 
saline). PZ, phenelzine; CsA, cyclosporine A; RCR, respiratory control ratio (state 
III/state IV); 4-HNE, 4-hydroxynonenal; ↓* = significantly decreased from sham, ↑* = 
significantly increased from sham, ↓# = significantly decreased from vehicle, ↔^ = not 
significantly different from sham.  
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The fact that continuous infusion of CsA is able to decrease TBI-induced 
increases in mitochondrial bound 4-HNE and acrolein, is consistent with the fact that 
inhibition of the permeability transition pore in brain mitochondria is able to prevent 
calcium-induced increases in ROS [60], which would in turn decrease the ROS/RNS-
lipid peroxidation-aldehyde cascade.  However, this does not seem to be enough to 
maintain mitochondrial respiratory function or prevent downstream calpain-mediated 
cytoskeletal degradation, at least at the 72h post-injury time point examined (Fig. 3.7). It 
may be that CsA inhibition of the mPTP and sequestration of calcium has decreased 
mitochondrial membrane potential and led to a decrease in respiration. Additionally, 
there are known limitations to the ability of CsA to prevent permeability transition, 
particularly when mitochondria are in an extremely depolarized state [318], which is 
likely the case 72h following severe injury, the peak of mitochondrial dysfunction [73]. 
Similarly, there are types of mitochondrial permeability transition demonstrated to be 
insensitive to CsA [317, 319]. In fact, thiol-crosslinking agents have been implicated in 
induction of CsA-insensitive permeability through interaction with adenine nucleotide 
translocase (ANT), an additional component of the mPTP [320], a significant finding in 
light of the fact that LP-derived aldehydes are known to bind cysteine residues [1, 79-
81]. In fact, acrolein has been specifically shown capable of ANT inhibition [101].  
On the other hand, it is possible that continuous infusion of CsA did have a 
protective effect on mitochondrial respiration that was masked in our total mitochondrial 
preparations (synaptic and non-synaptic) due to the fact that CsA has a greater 
neuroprotective effect on synaptic mitochondria than non-synaptic mitochondria 
following CCI (Fig. 2.1-2.6) [309], but at 72h post-injury, synaptic mitochondria make up 
a minority of the mitochondrial population [121, 128, 321, 322]. However, we consider 
this explanation unlikely when taken in conjunction with the fact that continuous infusion 
of CsA was also unable to prevent cytoskeletal α-spectrin degradation (Fig. 3.5).   
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Figure 3.7 Schematic illustration of CsA monotherapy results. CsA decreases 
formation of mitochondrial bound 4-HNE and acrolein without attenuating respiratory 
dysfunction or cytoskeletal spectrin degradation. CsA inhibits mitochondrial permeability 
transition (mPTP) leading to attenuation of the mitochondrial dysfunction-ROS/RNS-lipid 
peroxidation-4-HNE/acrolein cascade (red arrows). Which leads to significant decreases 
in formation of 4-HNE/acrolein bound mitochondrial conjugates (green arrow). However, 
inhibition of mPTP and attenuation of 4-HNE and acrolein are not enough to improve 
overall respiratory dysfunction and downstream effects of mitochondrial calcium release, 
such as cytoskeletal spectrin degradation (red X’s). 
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 An additional caveat to consider is the fact that the CsA dosing paradigm utilized 
in this study was originally optimized using cortical tissue sparing [122, 227]. It is known 
that CsA preservation of cortical tissue following experimental TBI has a U-shaped dose-
response curve [227]. It is possible that that the dose-response for CsA in relation to 
cortical tissue sparing is not identical to the dose-response for CsA in relation to 
mitochondrial respiratory protection. This speculation is plausible in light of the fact that 
CsA has multiple mechanisms of action. For example, although it has been well-
established that CsA is able to improve mitochondrial function at early time points and 
ex-vivo through inhibition of mPTP [226, 313, 323], the neuroprotective effects of 
continuous CsA infusion on cortical tissue sparing at later time points may also be due to 
its immunosuppressive properties. For example, although FK506 (i.e. tacrolimus), a 
calcineurin-inhibiting immunosuppressant unable to inhibit mPTP, has been shown 
unable to attenuate cortical lesion volume following experimental TBI [124], several 
studies have demonstrated FK506 to be neuroprotective across several other injury 
paradigms [228-233], and calcineurin signaling is known to have an important role 
following brain injury [229, 324].  
 The fact that CsA is known to have a U-shaped dose response curve [227], 
combined with its multiple mechanisms of action [316, 317], may explain some of the 
disparities seen between CsA TBI studies, because although there have been a 
preponderance of studies supporting CsA’s neuroprotective capabilities, this is not the 
first study to demonstrate that CsA is not neuroprotective across all outcome measures 
[241].  
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Phenelzine Scavenging of Lipid Peroxidation-Derived Aldehydes 4-HNE and 
Acrolein  
Several approaches have been utilized to attenuate the lipid peroxidation 
cascade following neurotraumatic injury ranging from the use of antioxidants to the use 
of iron chelators [1, 55, 109, 325]. However, many of these approaches are limited by a 
variety of factors including, limited therapeutic window, blood-brain barrier penetrability 
and elimination rate [1, 55]. Fortunately, scavenging of LP-derived aldehydes, such as 4-
HNE and acrolein (the stable final breakdown products of lipid peroxidation) represents a 
practical therapeutic approach [1, 79].  
Phenelzine, a monoamine oxidase inhibitor clinically used for intractable 
depression contains a hydrazine moiety (-NH-NH2) making it capable of covalently 
binding both free LP-derived neurotoxic aldehydes, such as 4-HNE and acrolein, as well 
as binding aldehyde-protein conjugates, including mitochondrial protein conjugates, 
preventing further cross-linking [79, 198, 258, 260-262].  
Both in-vitro and in-vivo studies have shown hydrazine-containing compounds 
including PZ, to be neuroprotective in models of brain and spinal cord injury, decreasing 
generation of LP-derived aldehydes, improving mitochondrial bioenergetics, attenuating 
tissue damage, and improving behavioral outcomes [71, 72, 74-76, 257]. Importantly, ex-
vivo studies have confirmed that the ability of PZ to protect mitochondria against 
exogenously administered 4-HNE or acrolein is due to the presence of the hydrazine 
moiety [72].  
The continuous PZ dosing paradigm utilized here, 10 mg/kg PZ delivered 
subcutaneously 15 min post-injury combined with subcutaneous continuous infusion of 
10 mg/kg/day/3 days PZ,  was based on previous work showing that 12h intermittent 
 
 
137 
administration of PZ (10 mg/kg PZ delivered subcutaneously 15 min post-injury followed 
by 5 mg/kg PZ maintenance dosing every 12 hours) was neuroprotective following 
severe CCI [72], with the hypothesis being that continuous infusion of PZ should further 
enhance neuroprotection over the 12h maintenance dosing paradigm. 
Our results indicate (Table 3.3), that continuous infusion of PZ was able to 
maintain RCR (Fig. 3.3), decrease TBI-induced increases in aldehydic-modified 
mitochondrial proteins (Fig. 3.4), and maintain cytoskeletal α-spectrin integrity (Fig. 3.5), 
although it was unable to prevent decreases in individual states of mitochondrial 
respiration (Fig. 3.2). Encouragingly, this data parallels the results obtained in the 12h 
intermittent PZ dosing paradigm studies, in which PZ also demonstrated maintenance of 
RCR and decreases in 4-HNE and acrolein modification of mitochondrial proteins [72], 
without being able to attenuate decreases in individual mitochondrial respiratory states 
(unpublished data). However, one important improvement was seen with the continuous 
infusion PZ dosing paradigm (Table 3.4) because whereas continuous infusion of PZ 
was able to maintain cytoskeletal α-spectrin integrity (Fig. 3.5), 12h intermittent dosing of 
PZ was not (Fig 3.6). Although both of these dosing paradigms were designed based on 
an approximate 12h plasma half-life of PZ in humans, the fact that the continuous 
infusion dosing paradigm represented an improvement over intermittent dosing is 
unsurprising given recent findings that suggest the half-life of PZ in rats may be much 
shorter than 12h [74].  
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Table 3.4 α-Spectrin Degradation: Phenelzine Continuous Infusion Versus 
Phenelzine Intermittent Dosing 
 PZCI PZID 
Spectrin Degradation ↔^ 
↑* 
 
 
Comparison of the effect of the PZ continuous infusion dosing paradigm versus the PZ 
intermittent dosing paradigm on α-spectrin degradation 72h following severe cortical 
impact injury. PZCI = phenelzine continuous infusion (15 min post-injury bolus dose: 
intraperitoneal cremophor/ethanol/saline’ 15 min post-injury bolus dose: subcutaneous 
10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline; 
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). PZID = phenelzine 
intermittent dosing (15 min post-injury subcutaneous bolus dose of 10mg/kg PZ in saline 
followed by subcutaneous bolus dose of 5mg/kg PZ in saline every 12h up to and 
including 60h). ↑*= significantly increased from sham, ↔^ = not significantly different 
from sham. PZCI, phenelzine continuous infusion; PZID = phenelzine intermittent dosing.  
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On that note, it is also important to state that the animals receiving continuous PZ 
infusion were also receiving continuous cremophor infusion (CsA vehicle). Therefore, the 
fact that the continuous infusion dosing paradigm for PZ was able to perform equally [72] 
or better than (Table 3.3 and 3.4) the 12h intermittent PZ dosing paradigm indicates that 
continuous infusion of the CsA vehicle, cremophor, which is purportedly toxic [245, 301] 
is unlikely to be exerting detrimental effects under the current experimental conditions.  
Multiple possibilities may explain the ability of continuous infusion of PZ to 
decrease TBI-induced increases in mitochondrial bound 4-HNE and acrolein and 
maintain RCR and cytoskeletal α-spectrin integrity without being able to improve 
individual mitochondrial respiratory states. First, the ability of PZ to scavenge aldehydes 
[79, 262] would have a direct effect on decreasing aldehyde binding of mitochondrial 
proteins, as well as lead to attenuation of the mitochondrial dysfunction-ROS/RNS-lipid 
peroxidation-aldehyde cascade (Fig. 3.1), further decreasing binding of 4-HNE and 
acrolein to mitochondrial proteins. This decrease in mitochondrial bound 4-HNE and 
acrolein would then prevent mitochondrial permeability transition [326], decreasing the 
release of calcium back into the cytosol and attenuating calpain-dependent α-spectrin 
degradation. Further, the decrease in 4-HNE and acrolein mitochondrial binding also 
may result in a slight improvement in mitochondrial bioenergetics, resulting in 
maintenance of RCR, a general measure of mitochondrial health, but one which does 
not have a significant enough effect on mitochondrial bioenergetics to impact individual 
states of respiration (Fig. 3.8).  
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Figure 3.8 Schematic illustration of PZ monotherapy results. PZ attenuates 
mitochondrial bound 4-HNE and acrolein, maintains respiratory control ratio (RCR) and 
cytoskeletal spectrin integrity, without improving individual states of respiratory 
dysfunction. PZ scavenges 4-HNE and acrolein directly, decreasing mitochondrial bound 
4-HNE and acrolein (green arrow), leading to decreases in the 4-HNE/acrolein-
mitochondrial dysfunction-ROS/RNS-lipid peroxidation-4-HNE/acrolein cascade (blue 
arrows), further decreasing mitochondrial bound 4-HNE and acrolein, and improving 
respiratory control ratio (green arrows), effects which are able to improve downstream 
effects of mitochondrial calcium release, such as cytoskeletal spectrin maintenance 
(green arrow), but not enough to improve individual states of mitochondrial respiration 
(red X). Bottom left figure demonstrates a single mitochondrion bound to phenelzine and 
phenelzine-aldehyde conjugates. It is currently unknown what effect these bindings have 
on mitochondrial dynamics and mitophagy.  
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Second, it is possibly that we have again masked a significant mitochondrial 
protective effect. As stated previously, PZ can bind mitochondrial aldehyde-protein 
conjugates [79, 262]. Additionally, as an irreversible monoamine oxidase inhibitor [278], 
PZ also associates with the outer mitochondrial membrane enzyme monoamine oxidase 
[327]. Therefore, it is possible that each individual mitochondrion is bound to a significant 
amount of PZ, and it is unknown what effect this has on post-injury mitochondrial 
dynamics and mitophagy (Fig. 3.8). In fact, in general, the long-term consequences of 
drug-aldehyde adduct formation are unknown [258].  
It is possible that the binding of PZ to mitochondria which are beyond saving is 
preventing these mitochondria from being degraded by normal post-injury processes 
while also significantly improving the bioenergetics of less damaged mitochondria. The 
unusual presence of these considerably damaged mitochondria in our isolated 
mitochondria preps could mask improvements to individual states of mitochondrial 
respiration. Such an explanation would be consistent with an overall mitochondrial 
protective effect suggested by the α-spectrin data, as well as the improvement in tissue 
sparing seen in our previous 12h intermittent PZ dosing studies [72], despite no 
improvements to individual mitochondrial states of respiration (unpublished data). 
Last, although in-vitro experiments which have compared PZ to the non-
hydrazine, non-aldehyde scavenging monoamine oxidase inhibitor pargyline have 
confirmed that phenelzine’s aldehyde scavenging properties are due to the presence of 
the hydrazine moiety [72, 198], it is unknown what effect monoamine oxidase inhibition 
has on the bioenergetics of injured mitochondria or in the broader context of TBI 
pathophysiology.  The function of catecholamines and monoamine oxidase following 
brain injury remains controversial, with some studies suggesting monoamine oxidase 
inhibition and catecholamine agonists to be protective [154, 193, 278], with others 
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suggesting them to be pathologic [328]. In fact, for PZ to remain a clinically translatable 
pharmacotherapy, its role as a monoamine oxidase inhibitor in the context of brain injury 
must be elucidated. As such, we have planned future experiments aimed at determining 
the effect of monoamine oxidase inhibition following TBI.  
Phenelzine + Cyclosporine A: A multi-mechanistic Combinatory Pharmacotherapy 
Approach 
As pointed out earlier, all monotherapy clinical trials for TBI have failed, and 
although there have been numerous reasons cited for these failures, due to the 
heterogeneity of injury and the complexity of the secondary injury cascade, there has 
been a call for pre-clinical studies to focus on the development of combinational 
therapies for the acute (first 72h) treatment of TBI [213]. Several strategies have been 
proposed to aid in the selection of combinatorial agents, including but not limited to 
therapies that affect multiple targets and therapies that target convergent pathways 
[213]. This study was aimed at achieving both these goals by combining two drugs that 
have separate targets, the mPTP inhibitor CsA and the LP-derived aldehyde scavenger 
PZ both of which should also be capable of attenuating the convergent mitochondria 
dysfunction-ROS/RNS-lipid peroxidation-aldehyde cascade (Fig. 3.1). In fact, CsA was 
one of the drugs identified by the combinational therapy TBI working group as being a 
promising combinational candidate [213].   
Our results indicate (Table 3.3) that continuous infusion of PZ (10 mg/kg PZ 
subcutaneous 15 min post-injury + 10 mg/kg/day subcutaneous infusion of PZ for 3 
days) combined with continuous infusion of CsA (20 mg/kg CsA intraperitoneal 15 min 
post-injury + 10 mg/kg/day subcutaneous infusion of CsA for 3 days) is unable to 
improve mitochondrial bioenergetics (either RCR or individual respiratory states; (Fig. 
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3.2 and 3.3) or attenuate 4-HNE or acrolein bound to mitochondrial proteins (Fig. 3.4). 
Interestingly, it seems that the combining of PZ and CsA, negates the protective effects 
that individual administration of PZ or CsA had on formation of 4-HNE and acrolein 
bound mitochondrial proteins (Fig. 3.4). Although the combination of PZ and CsA was 
able to maintain cytoskeletal α-spectrin integrity (Fig. 3.5), it did so to a degree similar to 
PZ alone suggesting that this is most likely an effect mainly attributable to PZ.  
While these combinatorial results are disappointing, they are not entirely 
surprising given the fact that individually the continuous infusion CsA dosing paradigm 
utilized, which had been previously optimized based on cortical tissue sparing [122, 
227], did not have a protective effect on all of the neurochemical outcome measures 
studied.  
Moreover, this study combined two dosing paradigms that had been optimized 
for each drug individually [72, 122]. In fact, this is not the first study to find that utilization 
of doses optimized for monotherapy did not result in neuroprotection once combined 
[280].  Indeed, the complex pharmacokinetics and pharmacodynamics that results from 
the combining of multiple drugs has been identified as one of the most challenging 
hurdles in the development of combinational therapies for the treatment of TBI [213]. 
Although utilization of an alternate dosing paradigm following dose-response studies of 
the combined drugs together could lead to improved results, upon further consideration, 
the complex pharmacokinetics of each individual drug may make the clinical translation 
of the combination unfeasible. 
For example, CsA is known to be metabolized by cyp3A4 [246], and although PZ 
is not technically classified as a cyp3A4 inhibitor, there is data to suggest that PZ is 
capable of inhibiting cyp3A4 [266, 267]. Further, CsA has a U-shaped dose response 
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curve [294] and has limited blood-brain-barrier penetrability [236], which increases 
following injury due to blood-brain-barrier disruption [329] and decreases in 
mitochondrial production of ATP [23, 51] leading to failure of ATP-dependent p-
glycoprotein drug efflux pumps, of which CsA is a both a substrate and an inhibitor [236]. 
Taken together, these facts suggest that in a clinical setting maintaining appropriate CsA 
CSF levels following TBI will be quite challenging even as a monotherapy, while 
combining CsA with another drug, particularly a drug such as PZ which itself has a 
complicated pharmacology as it is both a monoamine oxidase inhibitor and a 
monoamine oxidase substrate which also has several active metabolites [330], would 
further complicate the matter.  
Along similar lines, although the choice of the combination PZ and CsA was 
aimed at targeting distinct mechanisms which converge on overlapping pathways (Fig. 
3.1), consistent with stated combinational TBI therapy design goals [213], both of these 
drugs are capable of physically binding the mitochondria, CsA through binding of the 
matrix protein cyclophilin D [218-220, 317], and PZ both through binding of 4-HNE and 
acrolein bound mitochondrial conjugates [79, 258] and through irreversible binding of the 
outer mitochondrial membrane protein monoamine oxidase [278, 327], which In 
hindsight may have resulted in too many non-physiologic interactions for the 
mitochondria to handle (Fig. 3.9).  
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Figure 3.9 Schematic demonstrating a mitochondrion extensively bound to CsA 
and PZ.  
 
CsA binds to the mitochondrial matrix protein cyclophilin D. PZ binds to the outer 
mitochondrial membrane protein monoamine oxidase. PZ-4-HNE and PZ-acrolein 
conjugates bind mitochondrial proteins throughout the mitochondrial membranes. 
  
 
 
146 
  
It is possible that assessment of additional outcome measures such as cortical 
tissue sparing or behavior could have yielded improved results. Indeed, achieving 
behavioral improvements is the utmost goal in TBI research. However, it must be noted 
that although a recent summary of NIH-funded pre-clinical combinatorial TBI drug 
studies reported improvements in non-behavioral outcomes, these positive effects were 
not maintained in long-term behavioral studies [280]. Therefore, it is unlikely that 
utilization of our current PZ + CsA combinational dosing paradigm would lead to 
improvements in more difficult-to-achieve behavioral outcomes.  
A better approach may have been to utilize drugs which are mechanistically 
complementary but are spatially distinct, such as combining either PZ or CsA with a drug 
such as tirilazad, whose primary effects are localized to the vasculature [1, 256]. In fact, 
the combination of tirilazad and CsA has been one of the combinations proposed to 
have beneficial effects [213].  
Conclusion 
In summary, we found that subcutaneous continuous infusion of PZ (10 mg/kg 
PZ subcutaneous 15 min post-injury + 10 mg/kg/day subcutaneous infusion of PZ for 3 
days) maintained mitochondrial RCR and neuronal cytoskeletal integrity, and decreased 
binding of 4-HNE and acrolein to mitochondrial proteins 72h following severe controlled 
cortical impact injury. In fact, continuous infusion of PZ was able to maintain cytoskeletal 
integrity, whereas 12hr intermittent dosing of PZ was not (10 mg/kg PZ subcutaneous 15 
min post-injury + 5 mg/kg PZ subcutaneous every 12h up to and including 60h). 
Additionally, continuous infusion of CsA (20 mg/kg CsA intraperitoneal 15 min post-injury 
+ 10 mg/kg/day subcutaneous infusion of CsA for 3 days) decreased binding of 4-HNE 
and acrolein to mitochondrial proteins. Although the combination of PZ + CsA was able 
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to maintain cytoskeletal integrity, it did so to a similar degree as PZ alone, suggestive of 
a purely PZ effect, and was unable to attenuate other outcome measures. In fact, once 
combined the protective effect PZ and CsA individually had on formation of 
mitochondrial bound 4-HNE and acrolein was lost. 
We concede that this study was limited to a single dosing paradigm and time 
point and a limited number of outcome measures, making it difficult to conclude that the 
combinational therapy PZ + CsA is unable to enhance neuroprotection under any 
circumstances. However, upon contemplation of the complicated pharmacokinetics and 
pharmacodynamics of each drug individually, coupled with the fact that both drugs can 
physically interact with the mitochondria, in hindsight we believe the combination of CsA 
and PZ may lack feasible clinical translation and that any further animal studies utilizing 
the combination may prove unethical. Therefore, for the time being we feel that our 
future directions are better spent further investigating the less well-characterized drug, 
PZ, including long-term behavioral studies as well as the effect the non-aldehyde 
scavenging PZ mechanism of action, monoamine oxidase inhibition, has on 
mitochondrial function and neuroprotection following TBI. Importantly, we also believe 
this study highlights some of the challenges in developing combinational therapies for 
traumatic brain injury including, optimization of combined dosing paradigms, 
consideration of altered pharmacokinetics and pharmacodynamics, choice of outcome 
measure and time point, as well as variations in neuroprotective efficacy across distinct 
outcome measures.  
On that note, one reason the combination PZ + CsA was chosen for this study 
was because both CsA and PZ are FDA-approved drugs, which would make their clinical 
translation for TBI easier, faster, and cheaper than that of experimental agents. 
However, combining drugs which are known to have multiple mechanisms of action, CsA 
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is both a calcineurin inhibitor/immunosuppressant and an inhibitor of mPTP [219, 220, 
316, 317], and PZ is both an aldehyde-scavenger and a monoamine oxidase inhibitor 
[71, 72, 74, 76, 198, 278, 311], may lead to a number of confounding factors. Therefore, 
although more difficult in regards to clinical translational, it may in fact represent a better 
approach to limit combinational approaches to compounds with less complicated 
mechanisms of action, such as the non-immunosuppressive mPTP inhibitor, NIM811, or 
a pure aldehyde-scavenger, at least in the early proof–of-principle stages of 
investigation. 
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CHAPTER FOUR: 
 
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and 
Memory and Cortical Tissue Sparing Following Experimental Traumatic Brain 
Injury 
 
Preface: Portions of Chapter Four to be submitted for publication as: Kulbe JR, 
Dunkerson JA, Huettl PF, Wang JA, Smith R, Gerhardt GA, and Hall ED. Comparative 
Effects of Phenelzine, Hydralazine, and Pargyline on Learning and Memory and Cortical 
Tissue Sparing Following Experimental Traumatic Brain Injury.  
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Introduction 
 Traumatic brain injury (TBI) represents a significant health crisis. Within the 
United States, 2.8 million TBIs are diagnosed annually [2]. Although the most severe 
injuries, those resulting in death or requiring hospitalization account for a minority of the 
TBI diagnoses, they account for 90% of TBI-associated costs [10, 11]. The most severe 
injuries also result in the highest rates of morbidity. In fact, over fifty percent of TBI 
patients requiring hospitalization will continue to suffer from TBI-related cognitive, 
physical or emotional disabilities more than a year following injury [13]. However, to 
date, no FDA-approved neuroprotective pharmacotherapies exist for acute TBI [1]. 
Therefore, it is imperative that more robust pharmacological neuroprotective agents be 
developed.  
Lipid peroxidation (LP) is a well-documented pathology that occurs following TBI 
[1, 17, 55] (Fig. 4.1). LP is initiated by reactive oxygen and nitrogen species (ROS/RNS), 
which extract electrons from the polyunsaturated fatty acids located within neuronal and 
organelle membranes, generating lipid and lipid peroxyl radicals [1, 55]. Although 
dysfunctional mitochondria and the electron transport chain serve as a primary source 
for generation of pathologic ROS/RNS [1, 17, 55], these reactive species are also 
produced by other sources. Such sources include the metabolism of monoamines by 
monoamine oxidase (MAO), autoxidation of biogenic amines, inflammatory cell oxidative 
bursts, and the metabolism of arachidonic acid [1].  LP is a self-propagating process 
which terminates upon formation of LP-derived neurotoxic aldehydes such as 4-
hydroxynonenal (4-HNE) and 2-propenal (i.e. acrolein) [1, 55]. These LP-derived 
neurotoxic aldehydes covalently bind to proteins, inducing protein dysfunction, cell death 
and neuronal degeneration [1, 17, 55, 77, 85, 88].  
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Figure 4.1 Simplified schematic of traumatic brain injury (TBI) pathophysiology 
and pargyline (PG), phenelzine (PZ) and hydralazine (HZ) mechanisms of action. 
TBI induces generation of reactive oxygen and nitrogen species, leading to lipid 
peroxidation of polyunsaturated fatty acids. Lipid peroxidation terminates upon formation 
of neurotoxic aldehydes, such as 4-hydroxynonenal (4-HNE) and 2-propenal (acrolein). 
4-HNE and acrolein covalently bind proteins, including mitochondrial proteins, causing 
dysfunction, neurodegeneration, and neurologic impairment. PZ and HZ are capable of 
scavenging 4-HNE and acrolein. Additionally, PZ, along with PG, can inhibit monoamine 
oxidase (MAO), an outer mitochondrial membrane protein responsible for metabolizing 
monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine.  
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Importantly, LP-derived neurotoxic aldehydes and their protein-aldehyde 
derivatives are longer lived than their free radical predecessors [77, 331]. Therefore, 
scavenging of LP-derived neurotoxic aldehydes offers a practical therapeutic approach 
[1, 79, 331, 332].  
Fortunately, a drug-class exists that is capable of scavenging LP-derived 
aldehydes. Compounds which contain a hydrazine moiety (-NH-NH2), including the FDA-
approved drugs phenelzine (PZ) and hydralazine (HZ) [198], can scavenge LP-derived 
neurotoxic aldehydes through formation of hydrazone derivatives [258, 261]. Clinically 
PZ, a non-selective irreversible monoamine oxidase inhibitor (MAOI), is used in the 
treatment of intractable depression and as an anxiolytic [169]. However, PZ has also 
been shown to be neuroprotective in experimental TBI, especially in regard to 
biochemical outcome measures such as attenuating TBI-induced mitochondrial 
respiratory dysfunction [71, 72, 333, 334]. Similar to TBI, PZ and HZ, clinically used as 
an anti-hypertensive, have been shown to be neuroprotective in models of spinal cord 
injury (SCI) [74, 75]. Although the neuroprotection PZ and HZ provide is well-established 
to rely on the presence of their aldehyde-scavenging hydrazine moieties (-NH-NH2) [72, 
198, 258], it is currently unclear what effect the MAOI properties of PZ may have on TBI 
pathophysiology.  
MAO is an outer mitochondrial membrane enzyme responsible for the 
metabolism of monoamine neurotransmitters such as norepinephrine (NE), serotonin (5-
HT), and dopamine (DA) [197]. Therefore, inhibition of MAO can lead to increases in 
these neurotransmitters [197]. The effect MAO inhibition and increases in monoamine 
neurotransmitters would have on TBI pathophysiology remains controversial. For 
instance, oxidative deamination of monoamine neurotransmitters by MAO generates 
ROS [193], suggesting that MAO inhibition could reduce ROS and provide an additional 
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antioxidant neuroprotective mechanism. However, inhibition of MAO also leads to 
increases in biogenic amines, such as DA, which is capable of directly inhibiting 
mitochondrial respiration [194], and undergoing non-enzymatic autoxidation formation of 
toxic H2O2 and quinones [194], suggesting that MAO inhibition could also lead to 
increases in neurotoxicity and oxidative stress. Additionally, while some studies have 
shown that acute administration of monoamine agonists can be neuroprotective 
following TBI; [154] others have shown a correlation between high levels of 
monoamines, such as NE, and poor outcome [181].  
Several pre-clinical studies have indicated that PZ shows promise for use as a 
neuroprotective agent in brain injury [71, 72, 76, 333, 334]. However, in order for PZ to 
be further developed for use in clinical TBI, the effect its MAOI properties have on TBI 
pathophysiology must first be explored. Therefore, the goal of this study was to further 
investigate PZ’s MAOI effects following TBI by comparing PZ, an aldehyde-scavenger 
and MAOI, to the non-MAOI aldehyde scavenge HZ, and the non-aldehyde-scavenger 
MAOI pargyline (PG) (Fig. 4.2). This is not only the first study to evaluate the effects of 
PG and HZ in experimental TBI, but also the first study to assess the behavioral effects 
of PZ in experimental TBI. We evaluate the ability of PZ, HZ, and PG to improve learning 
and memory and enhance cortical tissue sparing following a severe controlled cortical 
impact injury (CCI) in 3-month old male Sprague-Dawley rats. Additionally, HPLC is 
used to measure NE, 5-HT, DA, and their metabolites in uninjured cortical tissue in order 
to determine the effect of the PZ, HZ, and PG dosing paradigms on MAO inhibition.   
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Figure 4.2 Chemical structures of pargyline, phenelzine and hydralazine. Both 
phenelzine and hydralazine are capable of scavenging aldehydes via a hydrazine (-NH-
NH2) moiety. Pargyline does not contain a hydrazine moiety (-NH-NH2) and is unable to 
scavenge aldehydes. Pargyline and phenelzine are monoamine oxidase inhibitors 
(MAOI), whereas hydralazine is not.  
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Methods 
Animals 
 Three-month-old male Sprague-Dawley rats (Harlan, Indianapolis, IN) were 
housed in the Division of Laboratory Animal Resources of the University of Kentucky 
Medical Center. All animal and husbandry were conducted in accordance with the 
University of Kentucky Institutional Animal Care and Use Committee. Animals were 
housed in a 12hr light and dark cycle and allowed food and water ad libitum. Animals 
were housed in pairs of two in housing containing Enviro-dry enrichment. For behavioral 
experiments, animals were weighed and handled on a daily basis through the day of 
euthanasia beginning five days prior to surgery. 
Experimental Design: High Performance Liquid Chromatography (HPLC) 
Monoamine and Metabolite Analysis (Fig. 4.3) 
In order to assess MAO inhibition of our dosing paradigm we used HPLC to 
evaluate monoamine and metabolite tissue levels and turnover ratios in uninjured cortex. 
Uninjured animals (n = 6 animals per group) were administered an intraperitoneal (i.p.) 
dose of saline, PZ (Sigma, St. Louis, MO), HZ (Sigma, St. Louis, MO), or PG (Sigma, St. 
Louis, MO) at time 0h, 24h, and 48h for a total of three injections. Sample size was 
based upon the University of Kentucky Center for Microelectrode Technology (CenMeT) 
standard of practice. PZ was administered at 15mg/kg in saline [74], HZ was 
administered at 5mg/kg in saline [74], and PG was administered at 15mg/kg to parallel 
in-vitro experiments in which equal concentrations of PZ and PG were utilized [72]. 
Animals were euthanized by CO2 and decapitation 72h following the first drug 
administration (24h following third drug administration).  
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Figure 4.3 Monoamine and metabolite HPLC experimental design. Uninjured rats 
received intraperitoneal injections (Inj.) of vehicle (saline), pargyline (15mg/kg), 
phenelzine (15mg/kg), or hydralazine (5mg/kg) at 0h, 24h, and 48h for a total of 3 
injections, representative of the dosing paradigm utilized in CCI-MWM studies. Animals 
were euthanized and tissue was collected for HPLC analysis 72h following the first 
injection.   
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A sterile biopsy punch (Integra Miltex, Plainsboro, NJ) was used to collect cortical 
punches 3mm in diameter and 2mm in thickness from the parietal cortex in the same 
anatomic location to which injured animals would have received a CCI injury. Tissue was 
immediately placed on dry ice, weighed and stored at -80°C until time of analysis. Tissue 
was sent to CenMeT for HPLC evaluation of norepinephrine (NE), dopamine (DA), 5-
hydroxytryptamine (5-HT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
(HVA), and 5-hydroxyindoleacetic acid (5-HIAA).  
High Performance Liquid Chromatography with Electrical Detection (HPLC-EC) for 
Monoamine and Metabolite Tissue Levels 
 Cortical tissue samples (5mg – 25mg) for HPLC-EC were thawed and 
immediately processed by CenMeT as previously described [187]. A total of 50μl of 
filtrate (in mobile phase) was injected onto an HPLC column. Retention times for NE, 5-
HT, 5-HIAA, DA, DOPAC, and HVA standards and dihydroxybenzylamine (DHBA), 
which was used as an internal standard, were used to identity peaks and to determine 
tissue levels of each neurotransmitter or metabolite found in each brain sample 
represented as ng/g wet weight of tissue sample [187].  
Controlled Cortical Impact Traumatic Brain Injury (CCI) 
 Animals were anesthetized using 4% isoflurane, shaved, and placed into a 
stereotaxic frame (David Kopf, Tujunga, CA), where isoflurane was maintained at 3% for 
the duration of the procedure. Following ethanol and betadine sterilization, a midline 
incision was made to expose the skull, and a 6mm craniotomy was created lateral to the 
sagittal suture and midway between lambda and bregma using a Michele Trephine 
(Miltex, Bethpage, NY). The exposed brain with intact dura received a severe CCI using 
a computer controlled pneumatic impact device (TBI 03010; Precision Systems and 
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Instrumentation, Fairfax Station, VA) fitted with a 5mm beveled tip and set to impact at a 
depth of 2.0mm with a 500ms dwell time and an impact velocity of ~3.5m/s, as described 
previously [71]. After injury, Surgicel (Johnson & Johnson, Arlington, TX) was placed 
onto the dura and an 8mm plastic disk was affixed to the skull using tissue adhesive 
(Gesswein, Bridgeport, CT) to close the craniotomy site and the incision was closed 
using wound clips. Sham animals (n=13) underwent the same procedure, but did not 
receive an impact injury and did not receive drug administration. Our previously 
published PZ experiments which reported the results of biochemical measurements 
utilized sample sizes = 8 [71, 72, 333]. Therefore, to account for a potential increase in 
variability the sample size was increased by a factor of 1.5 for the behavioral 
experiments detailed here. A single experimenter completed all surgeries.  
CCI Dosing Paradigm (Fig. 4.4) 
 Animals exposed to CCI were randomly assigned to vehicle (n=13), PZ (n=13), 
HZ (n=13), or PG (n=13). As 48h-72h represents the peak of LP-derived aldehyde 
formation [73], it follows that drug should be administered throughout this acute time 
period [72, 333].  Therefore, drug or vehicle was administered 15min, 24h, and 48h post-
injury (three injections per animal). PZ was administered at 15mg/kg in saline. HZ was 
administered at 5mg/kg in saline. As this is the first study to directly compare PZ and HZ 
in experimental TBI, the dosing paradigms chosen were based on previously optimized 
doses in which PZ and HZ were compared in SCI [74], and are slightly higher than our 
previously published PZ dosing paradigms (10mg/kg/day subcutaneous)[72, 333]. 
Similar to PZ, PG was administered 15mg/kg in saline, to parallel ex-vivo mitochondrial 
studies in which equivalent concentrations of PZ and PG were used [72]. The vehicle 
group received an equal amount of saline as was administered to drug groups. Drug and 
vehicle were prepared and coded by a separate experimenter.  
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Figure 4.4 Controlled cortical impact and Morris water maze experimental design. 
Beginning on D0 rats were subjected to a severe controlled cortical impact injury (CCI). 
15min following injury animals received intraperitoneal injections (Inj.) of vehicle (saline), 
pargyline (15mg/kg), phenelzine (15mg/kg), or hydralazine (5mg/kg). Sham animals 
underwent surgical procedures but did not receive an impact or injections. Doses were 
repeated 24h (D1) and 48h (D2) following injury. On D3-D6 animals underwent Morris 
water maze (MWM) acquisition, which was followed by a probe trial for reference 
memory on post-CCI D7. Animals were euthanized, perfused, and whole brains were 
collected on post-CCI D8.  
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Morris Water Maze (Fig. 4.4) 
 Animals began Morris water maze (MWM) testing 72h following injury and 24h 
following the final drug administration. Animals began MWM testing at this early time 
point in order to parallel our previous in-vivo PZ studies which evaluated mitochondrial 
bioenergetics, aldehyde-protein modification, and cytoskeletal degradation 72h following 
injury [72, 333], the peak of mitochondrial dysfunction, lipid peroxidation, and αII-spectrin 
degradation [73]. The day prior to the start of MWM testing a circular pool (127 cm 
diameter x 56 cm height) was filled and water was allowed to acclimate to room 
temperature overnight. A submerged escape platform (13.5 cm diameter) was placed in 
the center of one quadrant approximately 2cm below the water’s surface. Visual cues 
were placed on curtains surrounding the pool. The pool was filled with black non-toxic 
paint to ensure opacity. All trials were recorded and analyzed with Noldus Ethovision XT 
version 12.0 (Cincinnati, OH).  MWM acquisition trials were conducted daily from post-
CCI D3 through D6 to assess working memory. On post-CCI D3 through D6, animals 
were given four trials (N, S, E, and W quadrant start) per day. At the beginning of each 
trial animals were placed into the pool facing the wall. The direction the first trial began 
from was varied each day. For each trial, animals were allowed 60 seconds to find the 
platform. Animals that did not find the platform were guided to the platform and manually 
placed there. Once on the platform, animals were allowed to remain for 20 seconds. A 
trial was considered successful when an animal reached the platform within 60 seconds 
and remained there for at least five seconds, which triggered the software to end the 
trial. Animals were allowed to rest 5min between trials. Software data was confirmed 
against manual time recordings.  To assess reference memory, a probe trial was 
conducted on post-CCI D7 in which the platform was removed and the animals were 
given 30 seconds to search the pool for the platform. To prevent hypothermia, all 
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animals were dried between trials and placed into dry cages sitting on heating pads near 
a ceramic heat source. At the beginning of the trials, all wound sites were inspected for 
signs of infection. No signs of infection were seen, but to insure asepsis, betadine was 
applied to the wound site at the conclusion of the day’s trials. Experimenters responsible 
for behavioral experiments were kept consistent throughout each day and block of 
testing.   
Tissue Processing for Histology (Fig. 4.4) 
 On post-CCI D8 (one day following completion of MWM testing) animals were 
euthanized with an overdose of sodium pentobarbital (150mg/kg). Animals were 
transcardially perfused with phosphate buffer solution (PBS) followed by 4% 
paraformaldehyde (PFA) in PBS. Following perfusion, brains were extracted and placed 
into 4% PFA at 4°C for 48h-72h. Brains were then transferred to a 30% sucrose solution 
in PBS at 4°C and allowed to sink before being flash frozen in isopentane and stored at -
80°C until further processing. Coronal slices 40μm thick were cut on a freezing 
microtome using a blade angle of 7.5° to the tissue surface. Sections were taken 
between the septal area and the posterior hippocampus. Every tenth section was 
collected per series. Sections were store at -20°C in cryoprotectant (30% ethylene 
glycol, 30% glycerol, Tris-buffered saline (TBS)). 
 Sections were mounted onto Superfrost Excell microscope slides (ThermoFisher 
Scientific, Waltham, MA) in TBS and dried. Mounted tissue was soaked in a CHCL3 
(100mL) + EtOH (400ml 95% EtOH) solution for 30min. Slides were then soaked in 
decreasing concentrations of EtOH (95%, 70%) for 3min each.. Slides were then soaked 
for 6-8min in a cresyl violet solution (5.64ml 1M acetic acid, 0.816g sodium acetate, 
500ml ddH2O, 0.2g cresyl violet powder). Slides were then dipped 8x each in the 
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following solutions: ddH2O, 50% EtOH, and 70% EtOH, 95% EtOH + acetic acid, 
followed by 2min in 95% EtOH, 100% EtOH, and Xylene. Slides were then cover slipped 
using permount.  
 Slides were imaged using Axio Scan.Z1 (Zeiss, Thornwood, NY) at 20x 
magnification and analyzed using HALO version 2.0 (Indica Labs, Corrales, NM). 
Cortical area was measured from the dorsal aspect of lamina I to the dorsal aspect of 
the corpus callosum, from the midline to the rhinal sulcus landmark laterally, from 
interaural level 8.20mm – 3.40mm (12 slices, 400μM apart). For the total percent cortical 
tissue sparing the area for each coronal section was multiplied by the distance between 
coronal sections (400μM) and then summed and the ipsilateral total was divided by the 
contralateral total to give total percent cortical tissue spared [∑(area x distance)ipsilateral] / 
[∑(area x distance)contralateral] x 100% [71, 72]. Sample size (n = 8-9) was based upon 
previously published histological data indicating that multiple PZ doses can improve 
cortical tissue sparing at 72h, an early point in tissue degeneration [72], and that single 
dose PZ can improve cortical tissue sparing at 14d [71]. For histologic analysis, animals 
were excluded if tissue showed evidence of damage sustained during tissue processing 
Statistical Analysis  
Statistical analysis was conducted using Prism version 7.0 (Graph Pad, San 
Diego. CA). All data are reported as mean ± standard deviation or median ± interquartile 
range as indicated. A p value <0.05 was considered significant. HPLC data were 
analyzed using a one-way ANOVA, followed by post-hoc Tukey’s. In cases in which 
homogeneity of variance was violated (Brown-Forsythe, p < 0.05), data was analyzed 
using Kruskal-Wallis, followed by post-hoc Dunn’s. Due to low levels of dopaminergic 
metabolites in the cortex, some samples showed non-detectable levels of homovanillic 
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acid (HVA) and were thus excluded as indicated in the results section. Additionally, for 
HPLC data Grubb’s test (α = 0.05) was used to remove statistical outliers as indicated in 
the results section. During the MWM acquisition trials (post-CCI D3 – D6) the four trials 
per day were averaged for each animal and statistical analysis of latency, distance, and 
swim speed was conducted using two-way repeated measures ANOVA, followed by 
post-hoc Tukey’s. Probe trial, weight, and total cortical tissue sparing were analyzed 
using a one-way ANOVA, followed by post-hoc Tukey’s. To determine if there was a 
difference in % cortical tissue sparing (ipsilateral/contralateral) between groups at the 
level of individual coronal sections (i.e. intraaural level) a two-way repeated measures 
ANOVA was utilized to analyze the CCI groups (vehicle, PG, PZ, and HZ).  
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Results 
PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels and Turnover 
Ratios in Uninjured Cortical Tissue (Fig. 4.5 – 4.7) 
PG and PZ are classified as monoamine oxidase inhibitors, whereas HZ is not. 
Saline, PG (15mg/kg), PZ (15mg/kg), or HZ (5mg/kg) were administered intraperitoneally 
at 0h, 24h, and 48h for a total of three doses and tissue was collected at 72h to parallel 
CCI-MWM experiments. However, uninjured animals were used in this set of 
experiments to determine the basal level of MAO inhibition induced by the dosing 
paradigms. The monoamine neurotransmitters NE, 5-HT, and DA, which are 
metabolized by MAO into metabolites, were measured along with the 5-HT metabolite 5-
HIAA, and the DA metabolites DOPAC and HVA. Monoamine turnover ratios 
(metabolite/monoamine) are used as a proxy measure of MAO inhibition. Although the 
metabolism of NE also involves MAO-A, as well as a variety of other enzymes, and 
results in the formation of metabolites such as VMA and MHPG, NE metabolites were 
not measured as part of this study due to their low cortical tissue levels. 5-HT is 
metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by MOA-A and ALDH [186], and is 
measured as part of this dissertation. 
For NE, a single saline sample was identified as an outlier (Grubb’s) and 
excluded (G = 1.915, Y = 6). For NE, a one-way ANOVA revealed a statistically 
significant effect across all groups (F[3,19] = 10.84, p = 0.0002). Post-hoc testing 
(Tukey’s) revealed that compared to saline, NE (ng/g) was significantly increased in PZ 
(p<0.001), and that compared to HZ, NE (ng/g) was significantly increased in PZ 
(p<0.001)(Fig. 4.5). Thus, PZ results in an increase in NE.  
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Figure 4.5 Tissue Level (ng/g) of norepinephrine (NE) in 72h uninjured cortex. NE 
measured via HPLC 72h following an initial intraperitoneal injection (0h) of saline, 
pargyline (PG), phenelzine (PZ), or hydralazine (HZ), with additional doses given at 24h 
and 48h. Values = mean ± standard deviation; one-way analysis of variance followed by 
Tukey post hoc; ***p < 0.001, compared to saline, ###p < 0.001 compared to HZ; n = 5-6 
per group.  
  
 
 
166 
 
Figure 4.6 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in 72h uninjured 
cortex. (A) 5-HT, (B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and 
the 5-HT turnover ratio (5-HIAA/5-HT) in uninjured cortex as measured via HPLC 72h 
following an initial intraperitoneal injection (0h) of saline, pargyline (PG), phenelzine 
(PZ), or hydralazine (HZ), with additional doses given at 24h and 48h. Values = (A) 
median ± interquartile range, Kruskal- Wallis followed by Dunn post-hoc (B,C) mean ± 
standard deviation, one-way analysis of variance followed by Tukey post hoc; *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 compared to saline; ###p < 0.001, ####p < 0.0001 
compared to HZ; n = 5-6 per group. 
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Figure 4.7 Tissue Level (ng/g) of dopamine (DA) and metabolites in 72h uninjured 
cortex. (A) DA, (B) the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), (C) the 
DA metabolite homovanilic acid (HVA), and the DA turnover ratios (D) (DOPAC + HVA) / 
DA, (E) DOPAC / DA, (F) and HVA / DA in uninjured cortex as measured via HPLC 72h 
following an initial intraperitoneal injection (0h) of saline, pargyline (PG), phenelzine 
(PZ), or hydralazine (HZ), with additional doses given at 24h and 48h. Values = (B) 
median ± interquartile range, Kruskal-Wallis followed by Dunn post-hoc (A,C-F) mean ± 
standard deviation, one-way analysis of variance followed by Tukey post hoc; *p<0.05, 
****p < 0.0001 compared to saline; ####p < 0.0001 compared to HZ; ^p < 0.05; n = 4-5 
per group.   
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For 5-HT, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,20] = 44.81, p < 0.0001). However, Brown-Forsythe revealed an inequality 
of variance (p = 0.0075). Therefore, Kruskal-Wallis was used in lieu of a one-way 
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 19.5, p = 
0.0002). Post-hoc testing (Dunn’s) revealed that compared to saline, 5-HT (ng/g) was 
significantly increased in PZ (p<0.01), and that compared to HZ, 5-HT (ng/g) was 
significantly increased in PZ (p<0.001)(Fig. 4.6A). Thus, PZ results in an increase in 5-
HT.  
 For the 5-HIAA, a one-way ANOVA revealed a statistically significant effect 
across all groups (F[3,20] = 23.64, p < 0.0001). Post-hoc testing (Tukey’s) revealed that 
compared to saline, 5-HIAA (ng/g) was significantly decreased in PZ (p<0.0001) and PG 
(p<0.001), and that compared to HZ, 5-HIAA (ng/g) was significantly decreased in PZ 
(p<0.0001) and PG (p<0.001)(Fig. 4.6B). Thus, both PZ and PG result in a decrease in 
5-HIAA, a 5-HT metabolite.  
 For the ratio 5-HIAA / 5-HT, a single HZ sample was identified as an outlier 
(Grubb’s) and excluded (G = 2.2024, Y = 6). For the ratio 5-HIAA / 5-HT, a one-way 
ANOVA revealed a statistically significant effect across all groups (F[3,19] = 54.29, p < 
0.0001). Post-hoc testing (Tukey’s) revealed that compared to saline, the ratio 5-HIAA / 
5-HT was significantly decreased in PZ (p<0.0001), PG (p<0.0001), and HZ (p<0.05) 
and that compared to HZ, the ratio 5-HIAA / 5-HT was significantly decreased in PZ 
(p<0.0001) and PG (p<0.001)(Fig. 4.6C). Thus, PZ, PG, and HZ result in a significant 
decrease in 5-HT turnover to 5-HIAA (i.e. increase in MAO inhibition). However, PZ and 
PG do so to a significantly greater degree than HZ.  
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Prior to statistical analysis, due to undetectable HVA levels, one animal was 
removed from each group (saline, PG, PZ, HZ) for all analysis of DA and DA 
metabolites. Additionally, during HVA statistical analysis, a single PZ sample was 
identified as an outlier (Grubb’s) and excluded (G = 2.2024, Y = 6). In order to maintain 
consistency and be able to calculate DA metabolite/DA turnover ratios, this PZ animal 
was further excluded from the entire DA data set.  
For DA, a one-way ANOVA did not reveal a statistically significant effect across 
all groups (F[3,15] = 0.06434, p = 0.9779 (Fig. 4.7A). Thus, PZ, PG, nor HZ affected DA 
levels.   
For DOPAC, a one-way ANOVA revealed a statistically significant effect across 
all groups (F[3,15] = 32.07, p < 0.0001). However, Brown-Forsythe revealed an 
inequality of variance (p = 0.0156). Therefore, Kruskal-Wallis was used in lieu of a one-
way ANOVA. KW revealed a significant effect across all groups (H[3, n = 19] = 14.1, p = 
0.0028). Post-hoc testing (Dunn’s) revealed that compared to saline, DOPAC (ng/g) was 
significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 4.7B). Thus, both PZ 
and PG result in a decrease in DOPAC, a DA metabolite. 
 For HVA, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,15] = 3.875, p = 0.0310. Post-hoc testing (Tukey’s) revealed a significant 
difference between PZ and PG (p<0.05)(Fig. 4.7C). Thus, PZ results in a decrease in 
HVA, a DA metabolite, but only when compared to PG.  
For the ratio (HVA + DOPAC) / DA, a one-way ANOVA revealed a statistically 
significant effect across all groups (F[3,15] = 56.69, p < 0.0001). Post-hoc testing 
(Tukey’s) revealed that compared to saline, the ratio (HVA + DOPAC) / DA is 
significantly decreased in PZ (p<0.0001) and PG (p<0.0001), and that compared to HZ, 
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the ratio (HVA + DOPAC) / DA is significantly decreased in PZ (p<0.0001) and PG 
(p<0.0001)(Fig. 4.7D). Thus, both PZ and PG result in a decrease in DA turnover to 
HVA+DOPAC (i.e. increase in MAO inhibition).  
 For the ratio DOPAC / DA, a one-way ANOVA revealed a statistically significant 
effect across all groups (F[3,15] = 63.42, p < 0.0001). Post-hoc testing (Tukey’s) 
revealed that compared to saline, the ratio DOPAC / DA was significantly decreased in 
PZ (p < 0.0001) and PG (p < 0.0001), and that compared to HZ, the ratio DOPAC / DA 
was significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 4.7E). Thus, both 
PZ and PG result in a decrease in DA turnover to DOPAC (i.e. increase in MAO 
inhibition). 
 For the ratio HVA / DA, a one-way ANOVA did not reveal a statistically significant 
effect across all groups (F[3,15] = 1.916, p = 0.1704)(Fig. 4.7F). Thus, PZ, PG, nor HZ 
affected the turnover of DA to HVA.  
 Overall these results indicate that for the specific dosing paradigms utilized, 
administration of PG or PZ, the two MAOIs, results in significant MAO inhibition as 
evidenced by the decrease in both 5-HT (Fig. 4.6C) and DA (Fig. 4.7D-F) turnover. 
Interestingly, HZ, which is not classified as an MAOI, also showed some possible MAOI 
inhibition as HZ administration resulted in a significant decrease to 5-HT turnover (Fig. 
4.6C). However, HZ did not have the same effect in regards to DA turnover (Fig. 4.7D-
F). Overall these results also indicate that for the specific dosing paradigms utilized, 
administration of PZ led to a significant increase in the monoamine neurotransmitters NE 
and 5-HT (Fig. 4.5 and 4.6A). 
  
 
 
171 
Morris Water Maze Latency to Platform (MWM D1-D4, Post CCI D3-D6) (Fig. 4.8A) 
 For latency to platform, a two-way repeated measures ANOVA revealed a 
statistically significant effect across time (F[3,180] = 31.26, p < 0.0001), and treatment 
(F[4,60] = 12.22, p < 0.0001). However, the interaction between time x treatment was 
not significant (F[12,180] = 1.681, p = 0.0743). Post-hoc testing (Tukey’s) revealed that 
all groups other than PZ learned to find the platform significantly faster on subsequent 
trial days. For the sham group, animals found the platform significantly faster on D2 (p < 
0.01), D3 (p < 0.0001), and D4 (p < 0.0001) compared to D1. For the vehicle group, 
animals found the platform significantly faster on D2 (p < 0.05), D3 (p < 0.01), and D4 (p 
< 0.01) compared to D1. For the PG group, animals found the platform significantly 
faster on D3 (p < 0.01) and D4 (p < 0.001) compared to D1. For the HZ group, animals 
found the platform significantly faster on D2 (p < 0.01) and D3 (p < 0.0001) compared to 
D1. However, HZ latency to platform was not significantly different on D4 compared to 
D1 (p > 0.05). Further, on D4 of MWM, vehicle (p < .05), PG (p < 0.05), PZ (p < 0.0001), 
and HZ (p < 0.0001) all took significantly longer to find the platform compared to sham 
(not annotated on figure). Thus, during the first four days of MWM all groups showed a 
decrease in the time it took to find the submerged platform. However, PZ was the only 
group in which none of these decreases reached statistical significance, suggesting that 
the PZ group had the most difficulty in learning to find the platform day to day during the 
first four days of MWM. Similarly, across the first four days of MWM, post-hoc testing 
(Tukey’s) revealed that the overall treatment effect showed a near significant difference 
between vehicle and PZ (p = 0.0706), but not between vehicle and PG (p = 0.9191) or 
vehicle and HZ (p = 0.6971) (not graphically shown). 
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Figure 4.8 Morris water maze latency and distance to platform. Rats began the 
Morris water maze (MWM D1) three days following controlled cortical impact injury 
(CCI). Animals and were given 4x60s trials to find the submerged platform per day for a 
total of four days (MWM D1 – D4).  (A) All groups other than PZ were able to find the 
platform significantly faster (seconds) on subsequent MWM days (D2, D3, D4) when 
compared to within group MWM D1. (B) All groups other than PZ traveled a significantly 
shorter distance (centimeters) to the platform on subsequent MWM days (D2, D3, D4) 
when compared to within group MWM D1. Values = mean ± standard deviation; 
repeated measures two-way analysis of variance followed by Tukey post hoc; *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 compared to within group MWM D1; Sham, Veh 
= vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine + CCI, HZ = hydralazine + CCI; 
n = 13 per group.  
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Morris Water Maze Distance to Platform (MWM D1-D4, Post CCI D3-D6) (Fig. 4.8B) 
For distance to platform, a two-way repeated measures ANOVA revealed a 
statistically significant effect across time (F[3,180) = 25.75, p < 0.0001), and treatment 
(F[4,60] = 9.364, p < 0.0001). However, the interaction between time x treatment was 
not significant (F[12,180] = 1.611, p = 0.0918). Post-hoc testing (Tukey’s) revealed that 
all groups other than PZ traveled significantly shorter distances to find the platform on 
subsequent trial days. For the sham group, animals traveled significantly less distance to 
the platform on D2 (p < 0.01), D3 (p < 0.0001) and D4 (p < 0.0001) compared to D1. For 
the vehicle group, animals traveled significantly less distance to the platform on D3 (p < 
0.05) and D4 (p < 0.05) compared to D1. For the PG group, animals traveled 
significantly less distance to the platform on D3 (p < 0.01) and D4 (p < 0.001) compared 
to D1. For the HZ group, animals traveled significantly less distance to the platform on 
D2 (p < 0.05) and D3 (p < 0.001) but not D4 (p > 0.05) compared to D1. Further, on D4 
of MWM, vehicle (p < .01), PG (p < 0.05), PZ (p < 0.0001), and HZ (p < 0.0001) all 
traveled significantly greater distance to the platform compared to sham (not annotated 
on figure). Thus, during the first four days of MWM all groups showed a decrease in the 
distance traveled to the submerged platform. However, PZ was the only group in which 
none of these decreases reached statistical significance, suggesting that the PZ group 
had the most difficulty in learning to find the platform day to day during the first four days 
of MWM. In regards to overall treatment effect, post-hoc testing (Tukey’s) revealed that 
across the first four days of MWM, there is not a significant difference between vehicle 
and PZ (p = 0.3412), vehicle and PG (p = 0.8911) or vehicle and HZ (p = 0.7387) (not 
graphically shown). 
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Morris Water Maze Swim Speed (MWM D1-D4, Post CCI D3-D6) (Fig. 4.9)  
For swim speed (i.e. velocity), a two-way repeated measures ANOVA revealed a 
statistically significant effect across time (F[3,180) = 12.52, p < 0.0001), and treatment 
(F[4,60] = 3.889, p = 0.007). However, the interaction between time x treatment was not 
significant (F[12,180] = 1.634, p = 0.0858). Post-hoc testing (Tukey’s) revealed that for 
the treatment main effect, PG (p < 0.05), PZ (p < 0.05) and HZ (p < 0.05), but not vehicle 
(p > 0.05) had a significantly increased swim speed compared to sham. Thus, during the 
first four days of MWM, the PZ, PG, and HZ groups had faster mean swim speeds than 
sham.  
Morris Water Maze Reference Memory (Fig. 4.10) 
Following removal of the platform (MWM D5, post-CCI D7), a one-way ANOVA 
revealed a statistically significant effect across all groups (F[4,60] = 8.22, p < 0.0001). 
Post-hoc testing (Tukey’s) revealed that the number of platform crossings was 
significantly decreased for vehicle (p < 0.01), PG (p < 0.01), PZ (p < 0.0001), and HZ (p 
< 0.001) compared to sham. Thus, PG, PZ, nor HZ significantly improved CCI-induced 
decreases in platform crossings, indicating the drugs were unable to improve CCI-
induced deficits to reference memory.  
Percentage Weight Loss Following CCI-MWM (Fig. 4.11)  
 For percentage weight loss between D0 (surgery day) and post-injury D7 (last 
MWM day), a one-way ANOVA revealed a statistically significant effect across all groups 
(F[4,60] = 6.646, p = 0.0002). Post-hoc testing (Tukey’s) revealed that the PZ group lost 
a significant amount of weight compared to sham (p < 0.001), vehicle (p < 0.05), PG (p < 
0.05), and HZ (p < 0.001). Thus, PZ animals lost a significant amount of weight 
compared to all other groups.   
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Figure 4.9 Overall Morris water maze swim speed. The mean swim speed (velocity, 
cm/sec) across the first four MWM days was significantly different between groups 
following controlled cortical impact injury (CCI). The swim speed of the PG, PZ, and HZ 
groups was significantly increased compared to sham. Values = mean ± standard 
deviation; repeated measures two-way analysis of variance followed by Tukey post hoc; 
*p < 0.05 compared to sham; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ = 
phenelzine + CCI, HZ = hydralazine + CCI; n = 13 per group. 
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Figure 4.10 Morris water maze reference memory. On MWM D5 (post-CCI D7) the 
platform was removed and the number of platform crossing was counted within the 30s 
timeframe. Following controlled cortical impact injury (CCI), Veh, PG, PZ, and HZ 
performed significantly worse than sham. Values = mean ± standard deviation; one-way 
analysis of variance followed by Tukey post hoc; **p < 0.01, ***p < 0.001, ****p < 0.0001 
compared to sham; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine 
+ CCI, HZ = hydralazine + CCI; n = 13 per group. 
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Figure 4.11 Percent weight loss between D0 (CCI) and D7 (MWM probe trial). All 
groups lost significantly less weight compared to PZ. Values = mean ± standard 
deviation; one-way analysis of variance followed by Tukey post hoc; *p < 0.05, ***p < 
0.001 compared to PZ; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ = 
phenelzine + CCI, HZ = hydralazine + CCI; n = 13 per group. 
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Total Percentage Cortical Tissue Sparing (Fig. 4.12 and 4.13) 
 For total cortical tissue sparing (ipsilateral / contralateral), a one-way ANOVA 
revealed a statistically significant effect across all groups (F(4,37) = 21.07, p<0.0001). 
Post-hoc testing (Tukey’s) revealed a significant decrease in cortical tissue sparing 
compared to sham for vehicle (p < 0.0001), PG (p < 0.0001), PZ (p < 0.0001), and HZ (p 
< 0.0001). The mean (± s.d.) cortical tissue sparing (ipsilateral / contralateral) for each 
group is as follows: sham = 97.1% ± 4.9%, vehicle = 70.0% ± 6.1%, PG = 74.0 % ± 
6.3%, PZ = 72.4% ± 6.4%, HZ = 76.9% ± 8.9%. Based upon mean values each drug 
increased cortical tissue sparing compared to vehicle as follows (% treatment / % 
vehicle): PG = 5.7%, PZ = 3.3%, and HZ = 9.8% (Table 4.1).  Thus, PG, PZ, nor HZ was 
able to significantly improve CCI-induced decreases in cortical tissue sparing. However, 
HZ performed the best with a near 10% improvement compared to vehicle. 
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Figure 4.12 Total percent cortical tissue sparing (ipsilateral/contralateral) D8 post-
CCI. For each individual animal the total percent cortical tissue sparing was calculated 
as the sum of ipsilateral cortical tissue spared across 12 coronal sections / sum of 
contralateral cortical tissue across 12 coronal sections. All groups show a significant 
decrease in cortical tissue sparing compared to sham eight days following controlled 
cortical impact injury (CCI). Values = mean ± standard deviation; one-way analysis of 
variance followed by Tukey post hoc; ****p < 0.0001 compared to sham; Sham, Veh = 
vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine + CCI, HZ = hydralazine + CCI; n 
= 8-9 per group.  
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Figure 4.13 Representative cortical tissue sparing on post-CCI day 8. Selected 
coronal sections (40uM) imaged at 20x and stained with cresyl violet for the groups 
vehicle, pargyline, phenelzine, and hydralazine. Percent cortical tissue sparing was 
calculated as ipsilateral / contralateral. The cortical area measure ranges from the dorsal 
aspect of lamina I to the dorsal aspect of the corpus callosum and the midline to rhinal 
sulcus, and is demonstrated by the black outline in the contralateral hemisphere of 
vehicle.   
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Table 4.1 Mean Percent Cortical Tissue Sparing for Vehicle, Pargyline, Phenelzine, 
and Hydralazine on Post-CCI D8 
  
Vehicle 
% Tissue Spared 
Treatment 
Drug 
Treatment 
% Tissue Spared 
% Improvement 
from vehicle 
70.0 Pargyline 74.0 5.7 
70.0 Phenelzine 72.4 3.3 
70.0 Hydralazine 76.9 9.8 
 
The percent improvement from vehicle calculated based upon the following equation: 
100% x [1- (% tissue spared treatment / % tissue spared vehicle)]. 
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Individual Coronal Section Percent Cortical Tissue Sparing (Fig. 4.14) 
 For the CCI groups (vehicle, pargyline, phenelzine, hydralazine) the percent 
cortical tissue sparing (ipsilateral/contralateral) of each individual coronal sections (12 
per animal) was compared. A two-way repeated measures ANOVA revealed a 
statistically significant effect across coronal section number (interaural level) (F[11,330] 
= 68.2, p < 0.0001), but not treatment (F[3,30]) = 1.386, p = 0.2661) or interaction 
(section x treatment) (F[33,330] = 1.204, p = 0.2099). Therefore, within each group there 
are significant differences in percent cortical tissue sparing between coronal section 
numbers (i.e. interaural levels), but within each corresponding coronal section number 
(i.e. interaural level) there are not significant differences between vehicle and drug 
groups (p > 0.05), indicating lack of a neuroprotective drug effect which is consistent with 
the total cortical tissue sparing results (Fig. 4.12). 
Qualitative Behavioral Observations of PZ group  
 Based upon our previous experience with PZ [71, 72, 333, 334] as well extensive 
literature findings [74, 76, 206-208, 335] we did not expect PZ administration at the 
dosing paradigm chosen to result in adverse effects. Therefore, the current study was 
not designed to include quantitative analysis of behaviors such as hyperactivity, anxiety, 
stereotypy, etc.  Although not measured directly, qualitative observations of the PZ 
group suggested an increase in locomotor activity (e.g. jumping off platform), stress (e.g. 
porphyrin secretion from eyes and nose), and stereotypy (e.g. rearing, head bobbing, 
etc. following PZ administration). In hindsight, inclusion of a more extensive battery of 
behavioral tests could have led to more thorough interpretation of the results.  
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Figure 4.14 Individual coronal section percent cortical tissue sparing post-CCI day 
8. Mean % cortical tissue sparing (ipsilateral/contralateral) for each coronal section (12 
per animal) by group. Coronal sections are 40μM thick, 400μM apart, and were collected 
between approximately interaural level 8.20mm and 3.40mm Values = ± standard 
deviation; (A) Overlay of all groups, (B) vehicle + CCI, (C) phenelzine + CCI, (D) sham, 
(E) pargyline + CCI, (F) hydralazine + CCI. n = 8-9 per group. Repeated measure two-
way analysis of variance revealed a non-significant (p > 0.05) treatment effect for CCI 
groups.  
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Discussion 
 Overall, these results indicate that for the dosing paradigms utilized PZ (aldehyde 
scavenger, MAOI), PG (non-aldehyde scavenger, MAOI), and HZ (aldehyde scavenger, 
non-MAOI) (Fig. 4.2) led to little improvement of the outcomes measured. None of the 
drugs were able to improve CCI-induced deficits to reference memory (Fig. 4.10), or to 
significantly improve cortical tissue sparing following injury (Fig. 4.12). However, HZ, the 
non-MAOI aldehyde scavenger, improved cortical tissue the most, increasing the 
amount of tissue spared compared to vehicle by nearly 10% (Table 4.1). Of concern, 
PZ, lost a significant amount of weight compared to all other groups (Fig. 4.11), and was 
the only group that did not show significant improvement in platform latency/distance 
performance over the first four days of MWM (Fig. 4.8). It is possible that the PZ results 
seen here are at least partially explained by an MAO inhibition effect as evidenced by 
the significant elevation to NE and 5-HT seen in uninjured cortical tissue following 
administration of the same PZ dosing paradigm utilized for CCI experiments (Fig. 4.5 
and 4.6A). However, at the dosage utilized other PZ non-aldehyde scavenging 
mechanisms of action or excessive aldehyde-scavenging could also be contributory 
factors.  
Lipid Peroxidation and TBI Secondary Injury 
Although the current study does not include direct measurements of 
mitochondrial function or LP-derived neurotoxic aldehyde formation (e.g. 4-HNE, 
acrolein), both are central mediators of the TBI secondary injury cascade [1, 25, 51, 55, 
332] and our previous work primarily focused on understanding the effects of PZ on 
mitochondria [71, 72, 333, 334]. Therefore, the synergistic role mitochondria and LP-
derived neurotoxic aldehydes play in exacerbating TBI pathophysiology and initiating 
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downstream consequences such as neurodegeneration and neurologic impairment is 
detailed here for context. However, it should be noted that ROS and neurotoxic 
aldehydes can be derived from a variety of non-mitochondrial sources such as the 
metabolism of arachidonic acid by prostaglandin synthase or 5-lipoxygenase, or the 
activities of several oxidases including xanthine, polyamine, and spermine [1, 336]. 
Following TBI increases in intracellular calcium are taken up by mitochondria in 
an attempt to maintain homeostasis [25, 51]. However, one consequence of elevations 
in intra-mitochondrial calcium is increased generation of ROS/RNS species [51], such as 
superoxide (O2
●-), nitric oxide (NO●), and peroxynitrite (PN) [17]. Highly reactive PN-
derived radicals are critical in initiating lipid peroxidation (LP). During LP, a hydrogen 
atom and its electron are extracted from membranous polyunsaturated fatty acids 
(PUFA) to form lipid (L●) and lipid peroxyl radicals (LOO●) [1, 55]. LP self-propagates 
throughout adjacent PUFA, but is also catalyzed by factors such as the presence of iron 
or low pH which occur following TBI [1, 55]. LP terminates upon a scission reaction 
which produces carbonyl end products such as the neurotoxic aldehydes 4-
hydroxynonenal (4-HNE) and 2-propenal (acrolein) [1, 55]. 
These neurotoxic aldehydes have multiple reactive sites, making it possible for 
them to covalently bind lysine, histidine, arginine and cysteine protein residues through 
both Schiff base and Michael addition reactions [1, 79, 81]. As a major site of PN 
formation, mitochondria are particularly susceptible to attack by LP-derived neurotoxic 
aldehydes. Following TBI, binding of LP-derived neurotoxic aldehydes to mitochondrial 
proteins further exacerbates TBI-induced impairment of mitochondrial bioenergetics and 
the ROS/RNS-LP-aldehyde cascade, which combined with high levels of intra-
mitochondrial calcium leads to opening of the mitochondrial permeability transition pore 
(mPTP) [17, 51], causing  cessation of ATP generation, release of cytochrome c and 
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other apoptotic proteins [51], and extrusion of mitochondrial-sequestered calcium back 
into the cytosol where it activates calcium-dependent proteases, such as calpain [51], 
leading to degradation of cytoskeletal proteins (e.g. αII-spectrin) [106], 
neurodegeneration, neuronal cell death, and neurologic impairment [1, 55, 116, 332].   
Overall, several studies have confirmed that mitochondrial dysfunction and LP 
peroxidation/formation of LP-derived aldehydes occur upstream of neurodegeneration 
and neurologic impairment [55, 56, 73] and that targeting mitochondrial dysfunction or 
lipid peroxidation can attenuate neurodegeneration and improve cognitive deficits [1, 25, 
51, 55, 110, 122, 125, 303].   
Aldehyde Scavengers and Neuroprotection 
 LP-derived aldehydes such as the α,β-unsaturated fatty acids, 4-HNE and 
acrolein, are strong electrophiles [260], and therefore can be scavenged by strong 
nucleophiles [260], including drugs that contain a hydrazine moiety (-NH-NH2). In fact, 
hydrazine (-NH-NH2) compounds have been demonstrated to be some of the most 
potent aldehyde scavengers available and are capable of scavenging both free 
aldehydes and binding aldehyde-protein conjugates, the latter of which prevents the 
formation of damaging cross-linking reactions [79, 258, 261]. 
 Of the FDA-approved hydrazine (-NH-NH2) drugs, PZ and HZ have been the 
most studied in the context of brain and spinal cord injury. In-vitro, PZ has been found to 
improve mitochondrial function and decrease formation of mitochondria-aldehyde protein 
conjugates following exogenous administration of the neurotoxic aldehydes 4-HNE and 
acrolein [72]. Similarly, PZ attenuates retinal ganglion cell death following administration 
of the neurotoxic aldehyde 3-aminopropanal (3-MP) [76], and protects both neurons and 
glia from exogenous formaldehyde administration [311]. In experimental TBI, PZ has 
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been shown to improve mitochondrial function, decrease aldehyde load, attenuate 
cytoskeletal degradation, and improve cortical tissue sparing [71, 72, 333, 334]. 
Additionally, PZ improves survival of CA1 hippocampal neurons in ischemic-reperfusion 
injury [76]. Further, PZ has also been demonstrated to be neuroprotective in models of 
SCI, decreasing aldehyde load and pain hypersensitivity, attenuating motor dysfunction, 
and improving tissue and neuronal survival [74, 337].  
Likewise, although the neuroprotective effects of HZ have not previously been 
evaluated in experimental TBI, in-vitro and in-vivo models of SCI and of exogenous 
acrolein administration demonstrate that HZ decreases aldehyde-load, attenuates 
mitochondrial dysfunction and free radical generation, restores antioxidant activity, 
improves tissue sparing and axonal function, and attenuates pain hypersensitivity and 
motor dysfunction [75, 88, 257, 270, 338].  
Monoamines and Monoamine Oxidase (MAO) 
 The neurotransmitters measured in the current study (Fig. 4.5 – 4.7), DA, NE, 
and 5-HT, are classified as monoamine neurotransmitters. DA and NE are 
catecholamines, sequentially synthesized from the amino acid tyrosine, whereas the 
non-catecholamine 5-HT is derived from tryptophan [151, 169].  The complexity, 
nuances, and interplay of the DA, NE, and 5-HT monoaminergic systems are beyond the 
scope of this study however; their general roles will be briefly reviewed here for context.   
Dopamine 
Within the nervous system DA is involved with a wide range of processes 
including movement, motivation, reward, addiction, memory, stress and mood [154]. 
Although the majority of DA is found within the striatum, DA is found throughout the brain 
[154]. For example, within the mesocorticolimbic system, DA neurons from the ventral 
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tegmental area project directly to the hippocampus and prefrontal cortex [153, 170]. 
Further, although the nigrostriatal pathway, predominately involved in movement 
regulation, consists of dopaminergic neurons projecting directly from the substantia nigra 
to the striatum, it is part of complex circuitry that includes input and output to the motor 
cortex, along tracts that pass through the thalamus [153]. As a catecholamine, in 
addition to binding DA receptors, DA can bind adrenergic receptors [154]. Clinically, DA 
can be used as a vasopressor to elevate cerebral perfusion pressure and mean arterial 
blood pressure following severe TBI [154].  
Norepinephrine 
Within the brain NE neurons are concentrated in the locus coeruleus with 
widespread connections to areas including the cortex, limbic system, and thalamus, and 
it is involved in modulation of arousal, attention, mood, cognition and memory [150, 151]. 
As a catecholamine, NE, also known as the “flight or fight” neurotransmitter can bind 
adrenergic receptors and induce sympathetic responses such as vasoconstriction [154, 
171]. As such, similar to DA, NE can be used as vasopressor in clinical TBI [154].  
Serotonin  
 Within the CNS, 5-HT neurons arise from the raphe nuclei and project 
extensively throughout most of the brain including the cortex, limbic system, and 
thalamus [151], modulating arousal, mood, cognition and memory [155]. Interestingly, 
the majority of 5-HT is found outside the CNS, within the gastrointestinal tract [155]. 
Additionally, 5-HT plays a role in platelet activation, vasodilation, and vasoconstriction 
[172].    
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Monoamine Oxidase (MAO) 
The enzyme monoamine oxidase (MAO) exists as two subtypes, MAO-A and 
MAO-B, both of which are located in the outer mitochondrial membrane. MAO contains a 
flavin group allowing it to participate in oxidative deamination reactions [186]. MAO is 
responsible for the metabolism of the monoamine neurotransmitters NE, 5-HT, and DA, 
measured within the current study, but additionally participates in the metabolism of 
epinephrine (EPI), several amino acids, and phenethylamine (PEA), a trace amine under 
physiologic conditions, but which is also an active metabolite of PZ [186, 189]. MAO-A 
and MAO-B have differing substrate affinities. For example, MAO-A is selective for NE 
and 5-HT, and the neurotransmitter EPI, whereas MAO-B is selective for PEA [186]. DA, 
on the other hand, is metabolized by both MAO-A and MAO-B [186]. However, the 
metabolism of DA by MAO differs between rodents and humans, with DA being 
predominately metabolized by MAO-A in rats and MAO-B in humans [186]. In the brain, 
monoamines are removed from the synaptic cleft by reuptake into pre-synaptic nerve 
terminals and glial cells [151]. In fact, the majority of MAO in the brain is located within 
the glial [190], with the MAO-B isoform predominating in glia as well as in serotonergic 
neurons and platelets [190].   
Several additional enzymes are involved in monoamine metabolism such as the 
mitochondrial matrix protein aldehyde dehydrogenase (ALDH) and the cytosolic enzyme 
catechol-O-methyl transferase (COMT) [186]. Of note to this study is the involvement of 
COMT in the metabolism of DA to HVA which can take two paths. In one DA is first 
metabolized by MAO to the intermediate DOPAC, and then DOPAC is metabolized by 
COMT to HVA (DA → MAO → DOPAC → COMT → HVA). In the other DA is first 
metabolized by COMT to the intermediate 3-methoxytyramine (3-MT), and then 3-MT is 
metabolized by MAO to HVA (DA → COMT → 3-MT → MAO → HVA). These dual 
 
 
190 
pathways likely explain why the MAO inhibitory effects of PZ and PG are more apparent 
in regards to DOPAC tissue levels than HVA tissue levels (Fig. 4.7). 
Choice of Experimental Design: Dosing Paradigms 
As lipid peroxidation and associated pathologies such as mitochondrial 
dysfunction and formation of LP-derived aldehydes peak 48h-72h following CCI [73], it 
follows that drug administration over the first 48h-72h may offer the best chance of 
neuroprotective success. Therefore, based on this assumption and previous studies 
demonstrating neuroprotective success with daily administration of PZ or HZ [72, 74, 75, 
333], drugs were administered 15min, 24h, and 48h following injury. 
 Prior to this study neither PG nor HZ had been utilized in an experimental TBI 
study. Therefore, the HZ dosage chosen (5mg/kg/day, intraperitoneal) was based upon 
a dosage optimized for SCI by Shi and colleagues [74, 75]. Similarly, although our 
previous PZ studies showed protection with 10mg/kg/day subcutaneous PZ 
administration [72, 333], here we chose to administer PZ intraperitoneal at 15mg/kg/day 
[75], a dosage which was shown to be neuroprotective in SCI in a study which directly 
compared PZ to HZ [74]. In fact, subcutaneous PZ administration at 15mg/kg/day has 
also shown to be neuroprotective in a gerbil model of ischemic-reperfusion injury [76]. 
PG (15mg/kg/day, intraperitoneal) was administered at an equal concentration to 
PZ to parallel ex-vivo experiments in which the ability of PZ to protect isolated 
mitochondria from exogenous administration of 4-HNE and acrolein was compared to 
that of PG [72]. Similarly, equal concentrations of PG and PZ have been utilized in-vivo 
to study the effects of aldehyde scavenging on preventing vascular carbonyl stress and 
atherosclerosis [198]. PG is similarly structured to PZ. However, unlike PZ, PG does not 
contain the aldehyde-scavenging hydrazine moiety (-NH-NH2) (Fig. 4.2). Our previous 
 
 
191 
ex-vivo results indicated that while PZ protected isolated cortical mitochondria against 
exogenously administered aldehydes, an equivalent concentration of PG did not, 
confirming that the presence of the hydrazine moiety (-NH-NH2) and not steric hindrance 
is responsible for PZ’s aldehyde scavenging properties [72]. Although the study did not 
likely allow for rigorous assessment of MAOI affects, as MAO substrates are largely 
absent from isolated mitochondria preparations [72], similar results were seen in an in-
vivo study which demonstrated PZ, but not PG prevented formation of carbonyls and 
atherosclerotic plaques [198].   
Although PZ and PG are both considered non-selective irreversible MAOIs, it 
must be noted that PZ is more selective toward MAO-A, whereas PG is more selective 
toward MAO- B [197], and both drugs have differing pharmacokinetics [189, 197, 208]. 
Therefore, although the choice was made to administer the two MAOIs, PG and PZ, in 
equivalent concentrations for the current study as an extension to previous work [72], 
results must be interpreted with caution as equal in-vivo concentrations of the two 
cannot be necessarily treated as equivalent in regards to their MAOI properties. In fact, 
this likely explains the HPLC data in which PZ administration leads to significant 
increases in NE and 5-HT, whereas PG administration at the same concentration does 
not (Fig. 4.5 and 4.6A).  
Choice of Experimental Design: Morris Water Maze  
Our previous PZ studies have focused on evaluating biochemical outcome 
measures 72h post-CCI, the peak of lipid peroxidation and mitochondrial dysfunction 
[72, 73, 333, 334]. Therefore, in order to correlate the current study with previous in-vivo 
PZ biochemical TBI studies, the current study began MWM testing at the early time point 
of 72h (3 days) post-CCI (Fig. 4.4). In theory, drugs capable of attenuating mitochondrial 
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dysfunction and preventing formation of LP-derived aldehydes such as PZ over the first 
72h following injury [71, 72, 109, 333, 334] should also be able to attenuate downstream 
consequences such as neurodegeneration and neurologic impairment  [1, 25, 51, 55, 
110, 122, 125, 303]. Although based upon the literature, 72h (3 days) does appear to be 
an early point in which to begin cognitive behavioral testing, interventional improvements 
to TBI-induced cognitive deficits have been previously seen at this acute time period 
[141, 273]. Additionally, although the results of this study indicate that none of the drugs 
were able to improve CCI-induced deficits to reference memory (Fig. 4.10), all CCI 
groups, PZ excluded, were able to find the platform significantly faster as MWM 
acquisition trial days progressed (Fig. 4.8), indicating that following severe CCI the rats 
do have intact working memory at the acute 72h (3 days) post-CCI time point. However, 
it should be noted that sham animals took an average of 20s to find the platform on 
MWM day 4, which is longer than times reported in MWM studies that where conducted 
at later time points [125, 387] and may be the result of a residual anesthesia effect [388]. 
Similarly, although direct assessments of motor function were not conducted as part of 
this study (in order to avoid overloading the rats with too many behavioral tasks during 
the acute post-CCI period), the ability of rats to decrease their latency to platform (Fig. 
4.8) and the lack of swim speed deficits in vehicle (Fig. 4.9) over the first four MWM 
days should indicate that if any CCI-induced motor or sensory deficits are present they 
are not interfering with MWM performance to a substantial degree.  
In additional consideration to MWM performance, is the fact that monoamine 
neurotransmitters, such as NE, 5-HT, and DA, have important roles in cognitive and 
motor function [150, 151, 153-155]. Therefore, it is possible that MAO inhibition and the 
resulting increase in monoamine neurotransmitter levels, as was seen with PZ 
administration in the uninjured cortical tissue HPLC experiment (Fig. 4.5 and 4.6A), 
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could have had an effect on MWM performance absent injury or neuroprotective effects. 
For example, low-dose amphetamines are known to improve learning and memory, 
whereas high-dose amphetamines can be detrimental [339].  This is an interesting 
question which could have potentially been answered by adding additional cohorts of 
uninjured + drug or sham + drug groups to the study. However, several anti-depressants 
which modulate monoaminergic systems, including MAOIs, have been shown to have no 
ill effects on MWM performance in control animals [156-158]. Therefore, in the interest of 
reducing animal numbers and focusing specifically on protective effects (i.e. CCI + drug 
vs. CCI + vehicle), these extra cohorts were not included in the current study.  However, 
it should be noted that upon further review of the literature the effect of acute PZ 
administration (15min – 2h prior to behavioral testing) on learning and memory seems to 
be mixed with some studies indicating impairment [159, 339] and some indicating 
improvement [340], with impairment seeming to be more likely to occur at higher PZ 
doses [159, 339] (for further discussion see “The Effects of Phenelzine on Behavior” 
section)  
Although delaying the start of MWM testing beyond the acute time point chosen 
(3 days post-CCI, 24h following final drug administration) (Fig. 4.4) may have decreased 
the potential for MAOI-induced elevated monoamine levels to directly impact MWM 
performance, it is unlikely to have completely remitted theoretical effects because of the 
long lasting nature of irreversible MAOIs (e.g. PZ and PG). Whereas the plasma half-life 
of PZ is estimated to be anywhere from 30 minutes in rats to 11.5 hours in humans [74, 
341], due to the fact that PZ and PG are irreversible MAOIs, their MAOI effects are much 
longer than their plasma-half lives would suggest and rely on MAO turnover rates. In 
rats, the half-life of MAO in healthy brain is 10-13 days [195]. In fact, both MAO isoforms 
remain significantly inhibited for at least a week following single PZ administration [342]. 
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However, the effective recovery time for rat brain MAO may be lower, due to the fact that 
65-80% of MAO inhibition is likely necessary to modulate monoamine neurotransmitter 
levels [186, 342]. Therefore, based upon previous studies of neurotransmitter levels in 
uninjured brain following PZ  administration, the “wash out” period following single 
administration may range anywhere from 48h to greater than one week [205, 342]. 
Therefore, we concede that delaying the start of MWM beyond this timeframe may have 
resulted in a less confounding experimental design.  However, considering that MAO is a 
mitochondrial enzyme [186], mitochondrial trafficking is impaired following TBI [19], and 
that mitochondrial dysfunction has been documented for weeks following TBI [22], MAO 
turnover may be much longer in injured brain, particularly in critical pre-synaptic nerve 
terminals, as regeneration of MAO within presynaptic nerve terminals requires trafficking 
of MAO and mitochondrion to the synapse [191]. Therefore, it is unknown the length of 
time MWM would have had to been delayed for direct MAOI/monoamine effects to 
completely “wash out” in order to conduct a cognitive assessment more isolative of 
neuroprotective effects.  Further, as our research has focused on investigating PZ as a 
neuroprotectant for acute use in TBI [71, 72, 333, 334], and early and intensive 
neurorehabilitation following severe TBI is encouraged [343], the effects of PZ on 
behavior acutely following TBI are still important to discern.   
Finally, in regard to the MWM protocol utilized here, on MWM day 5 during 
reference memory testing, following removal of the platform, platform crossings were 
only counted for 30s. Upon analysis of the latency to platform times during the MWM 
acquisition phase, only the sham group was on average able to find the platform in fewer 
than 30s on MWM day 4 (Fig. 4.8). Therefore, it unsurprising that during reference 
memory testing that there were no differences found between the vehicle and drug 
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groups (Fig. 4.10). In hindsight, allowing animals 60s to complete the reference memory 
task on day 5 of MWM would have represented a better experimental approach.  
Phenelzine: A Comparison to Previous Neuroprotective CCI Studies 
 The results of the current study indicate that 15mg/kg PZ administered 
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly 
improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10) or to 
improve cortical tissue sparing on post-CCI D8 (Fig. 4.12). These results differ from 
previous findings in which PZ was found to be protective in CCI [71, 72, 333, 334]. 
However, many of these prior PZ studies reported PZ improvement to more biochemical-
type outcome measures such as mitochondrial function and protein-aldehyde conjugate 
formation at early time points ranging from 3h-72h [71, 72, 333, 334]. Although there is 
robust evidence in the literature that acute pharmacologic attenuation of mitochondrial 
dysfunction and lipid peroxidation can in turn lead to downstream behavioral and 
histologic improvements at later time points [1, 25, 51, 55, 110, 122, 125, 303], it is 
possible that while PZ can acutely (3h-72h) improve mitochondrial respiration and 
calcium-buffering capacity, and decrease formation of mitochondrial-aldehyde 
conjugates [71, 72, 333, 334], that such early biochemical protections do not translate to 
improvements in learning and memory or cortical tissue sparing. There is some evidence 
within the previous PZ studies to support this idea. For example, the ability of PZ to 
prevent cytoskeletal spectrin degradation or attenuate cellular wide protein-aldehyde 
formation, outcome measures that can also correlate with behavioral and histologic 
outcomes [56, 109, 110], but which are affected to a greater degree by mitochondrial-
independent secondary injury mechanisms [1, 16, 59, 161], is more variable and less 
robust than it’s mitochondrial specific effects [333, 334].  
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Additionally, it could also be the case that the protection provided by PZ acutely 
[71, 72, 333, 334] is not sustained out to more subacute time points. For example, in the 
current study, administration of PZ (15mg/kg, i.p., 15min, 24h, 48h post-CCI) was unable 
to improve cortical tissue sparing 8 days post-CCI (Fig. 4.12), whereas we had 
previously shown that subcutaneous (s.c.) administration of PZ (10mg/kg) 15min post-
CCI followed by maintenance dosing (5mg/kg) every 12hr up to and including 60h, could 
significantly improve cortical tissue sparing 72h post-CCI [72]. Admittedly, 72h was an 
early time point for previous studies to conduct histologic analysis, as cortical contusions 
have been documented to continue to increase in volume for at least 28 days following 
experimental TBI [164]. However, because the primary targets of PZ (i.e. LP-derived 
neurotoxic aldehydes and aldehyde-damaged mitochondria) peak 48h-72h following 
injury before recovering 5-7 days post injury [73], it would be expected that a robust PZ 
protection of cortical tissue at 72h post-CCI [72] would maintain some effect at 8 days 
post-CCI.  
Therefore, the inability of PZ to improve cortical tissue sparing here (Fig. 4.12) 
whereas it has been previously reported to do so at 72h [72], may be more likely due to 
methodological differences. For one, the current study included an early behavioral task, 
whereas the study by Cebak et al. did not [72]. Although other research groups have 
implemented water maze testing in rodents acutely following experimental TBI with no ill 
effects [141, 273], it is possible that the early use of MWM in this study could have led to 
an increase in neurodegeneration which expanded cortical lesion volumes. Although this 
study did not include any non-behavioral cohorts in which this question could have been 
analyzed directly, this is unlikely the case as the cortical lesion volumes observed here 
do not vary widely from those reported in similar studies in which MWM was not 
performed [122, 124, 227, 294].  Further, although clinical guidelines regarding the 
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optimal timing and structure of rehabilitation following severe TBI are still being 
developed [344], current evidence suggests that early and intensive neurorehabilitation 
following TBI promotes the best functional recovery [343].  
The second major methodological difference between the current study and the 
72h PZ histology study conducted by Cebak et al. [72] is the dosing paradigm. The 
current study represents an increase in total amount of PZ received over the first 48h, as 
well an increase in the amount of PZ received per bolus dose. Although our reasoning 
behind administering PZ over the first 48h-72h [72, 333] has been based on the idea that 
drug should be administered throughout the peak lipid peroxidation and mitochondrial 
dysfunctional periods [73], recent data from our lab indicates that lower dose PZ may 
actually offer better protection [334] than prolonged dosing [72, 333]. For example, PZ 
(10mg/kg, s.c.) administered 15min post-CCI with a second dose (5mg/kg, s.c.) given 
12h post-injury is able to improve individual states of mitochondrial respiration [334], 
whereas 10mg/kg/day/3d subcutaneous continuous infusion of PZ or equivalent bolus 
dosing cannot [72, 333]. Similarly, an early PZ study showed that a single dose of PZ 
(10mg/kg) administered 15min following CCI can improve cortical tissue sparing 14 days 
post-injury [71].  
Further, the current study was the first time in which PZ was administered 
intraperitoneal following experimental TBI, a route that results in more rapid drug 
absorption than subcutaneous administration [345]. Although intraperitoneal 
administration of PZ up to 60mg/kg has been reported safe under different conditions 
[74], it is unknown if this remains true in TBI. In fact, the majority of the MAO substrate, 
5-HT, is found outside the CNS, within the gastrointestinal tract [155], as are naturally 
occurring trace amounts of tyramine, an amino acid known capable of inducing 
hypertensive crisis at extra-physiologic levels through both conversion to and 
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displacement of NE [346]. Therefore, it is possible that intraperitoneal administration of 
PZ following TBI had a greater effect on monoamines outside the CNS than 
subcutaneous administration, and the elevation of such monoamines had adverse 
effects.  
Phenelzine as a Monoamine Oxidase Inhibitor  
As PZ is an irreversible non-selective MAOI, as well as an MAO substrate, it is 
possible that the decrease in protective effects seen here and with the higher PZ dosing 
paradigms [71, 72, 333, 334] is related to its MAOI effects. In fact, the PZ dosing 
paradigm utilized here, when evaluated in uninjured cortical tissue, shows significant 
MAO inhibition as measured by the decrease in 5-HT turnover to 5-HIAA (Fig. 4.6C) and 
DA turnover to DOPAC and/or HVA (Fig. 4.7D-F). In fact, not only does PZ result in 
MAO inhibition, but the MAO inhibition leads to a significant increase in NE (Fig. 4.5) 
and 5-HT (Fig. 4.l6A). This is unsurprising given the fact that although classified as a 
non-selective MAO inhibitor, PZ is more selective toward MAO-A than MAO-B with a 
reported MAO-A: MAO-B selectivity ratio of 2:1 [197], and that both NE and 5-HT are 
selectively metabolized by MAO-A [186]. Interestingly, PZ did not affect overall DA tissue 
levels (Fig. 4.7A), possibly due to the lower affinity of PZ for MAO-B [197], the lower 
affinity of MAO-B for DA in rat [347], overall low tissue levels of DA in the cortex [348], or 
a compensatory-type effect as in addition to metabolism, monoamine turnover levels are 
affected by monoamine synthesis, release and re-uptake [349]. One consideration in 
regards to HPLC analysis is that it was conducted on cortical tissue samples which had 
not undergone saline perfusion. Therefore, neurotransmitters measurements, particularly 
that of 5-HT, a neurotransmitter which can be transported in platelets [172], are not 
necessarily specific to neuronal or glial compartments, however; in general the HPLC 
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data should be representative of an overall measure of drug-induced changes to 
monoamine turnover and monoamine and metabolite tissue levels.  
The Effects of Phenelzine on Weight 
As the PZ dosing paradigm utilized for the current experiment was unable to 
attenuate CCI-induced memory impairment of enhance cortical tissue sparing (Fig. 4.8, 
4.10, 4.12) and led to significant weight loss (Fig. 4.11), the decision was made to 
forego HPLC analysis of PZ effects on MAO inhibition and monoamine tissue levels 
following CCI. However, extrapolating from the effect the PZ dosing paradigm had on 
cortical tissue levels of NE (Fig. 4.5) and 5-HT (Fig. 4.6A) in uninjured tissue, it is 
possible similar elevations could explain the significant weight loss seen in PZ animals 
following CCI (Fig. 4.11). For example, catecholamines and 5-HT can induce weight loss 
through a variety of mechanisms ranging from increasing locomotor activity to 
decreasing appetite [350]. In fact, multiple PZ doses also led to weight loss in uninjured 
animals, albeit to a lesser degree (see “Chapter Five”). Similarly, non-PZ MAOIs have 
been shown to decrease weight gain and induce anorexia in a dose-dependent manner 
[158, 351]. Further, one of PZ’s metabolites, phenethylamine (PEA) [189], itself an MAO 
substrate with amphetamine-like stimulatory effects [207], could have also contributed to 
the observed weight loss.  
Additionally, it is possible that the weight loss experienced by the PZ group, as 
well as any associated anorexia or muscle wasting, could have been a factor in the poor 
performance of the PZ group during the first four days of MWM (4.8). However, if so, 
such factors did not seem to impair swim speed as compared to other CCI groups (4.9). 
Further, weight loss is unlikely to be a contributing factor in previous PZ studies which 
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found that acute administration of PZ can impair cognitive performance, particularly as 
dosage increases [159, 339].  
The Effects of Phenelzine on Behavior  
Although PZ animals performed the worst during assessment of reference 
memory, it was not significantly different from other CCI groups. (Fig. 4.10) However, 
over the first for days of MWM (MWM D1-D4, post-CCI D3-76), the PZ group was the 
only group which showed no significant improvement in finding the platform between 
MWM D1 and subsequent MWM days (Fig. 4.8). Additionally, in regards to latency to 
platform, for the overall treatment effect across the first four days of MWM there was a 
trend toward PZ being significantly impaired as compared with vehicle (p = 0.07). This 
suggests that PZ animals may have been struggling more with working memory than 
other groups, including vehicle. This is in contrast to several previous studies which have 
shown that use of anti-depressants either chronically or during MWM do not negatively 
affect working memory in naive rodents [156, 157], including such MAOI’s as PG, 
deprenyl (MAO-B), and clorgyline (MAO-A) [158].  
On the other hand, previous reports regarding the effects of acute PZ 
administration on cognition are variable. Low dose PZ (20mg/kg) administered 2h prior 
to training has been shown to improve Y-maze performance in rats [340]. However, 
20mg/kg PZ administered 15min prior to training has also been shown to non-
significantly impair T-maze performance in mice [339]. Similarly, administering PZ (15-
30mg/kg) 2h prior to beginning MWM acquisition has been shown to impair reference 
memory [159], whereas delaying PZ administration until the start of reference memory 
(i.e. probe trial) tests does not, suggesting PZ may interfere with storage processing 
rather than retrieval [159]. Interestingly, the higher PZ dose used for those trials 
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(30mg/kg) also impaired the rate of MWM acquisition, while not abolishing learning 
completely, whereas the lower PZ dose (15mg/kg) did not [159]. Those findings are in 
line with the ones of the current study in which PZ was the only CCI group which did not 
show significant improvement throughout the MWM acquisition phase, although non-
significant decreases in latency and distance were achieved (Fig. 4.8). Therefore, as 
previous studies have shown dose-dependent increases in cognitive impairment with PZ 
[339] it is possible that the MWM performance of the PZ+CCI group observed in the 
current study was due to the amount of PZ administered. However, an additional CCI-
induced exacerbation of PZ effects due to injury-induced increases in monoamines or 
MAO inhibition cannot be ruled out (see “Monoamines and TBI” section for further 
discussion). 
If PZ itself did contribute to cognitive impairment, there are several mechanisms 
of action in which it could have done so.  For example, it is possible that PZ induced 
elevations to catecholamine levels (Fig. 4.5) and such elevated catecholamine levels 
induced cognitive impairment, as occurs with high dose amphetamines [339, 352].  
Additionally, the PZ metabolite and MAO-substrate, PEA, [189] also has amphetamine-
like properties [207]. Similarly, high levels of 5-HT (Fig. 4.6A), such as those that occur 
in serotonin syndrome, are capable of inducing cognitive dysfunction [346]. Further, the 
PZ metabolite, phenylethyldenehydrazine (PEH), can inhibit GABA-transaminase 
(GABA-T), leading to increased levels of GABA, a neurotransmitter that has also been 
implicated in cognitive impairment [159, 335, 342].  
On the other hand, poor MWM performance is not always a reflection of cognitive 
impairment per se, but can instead be representative of sensorimotor dysfunction [147, 
353]. On cursory inspection PZ animals do not appear to have motor deficits as their 
swim speed is not impaired (Fig. 4.9). In fact their swim speed is significantly increased 
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compared to sham (Fig. 4.9), an effect which has been previously demonstrated to 
occur following amphetamine or MAOI administration [158], and is usually contributed to 
an increase in monoamine levels. In fact, high catecholamine levels can induce motor 
dysfunction, including hyperactivity and “amphetamine-stereotyping” behaviors [352-
355]. Similarly, high levels of 5-HT, as occur in serotonin syndrome, can induce motor 
dysfunctions characterized by restlessness, agitation, myoclonus, hyperreflexia, tremor, 
and ataxia [346, 354, 355]. Interestingly, previous studies have indicated that high 
(50mg/kg) – very high (80mg/kg) PZ doses can induce tremor and ataxia, respectively 
[207, 339]. Although sensorimotor function, locomotor activity, and “amphetamine-
stereotypy” behaviors were not quantitatively assessed as part of this study, qualitative 
observations of the PZ group as a whole suggest increased “amphetamine-stereotypy” 
behavior (directly following PZ administration) as well as an increase in hyperactivity. In 
fact, PZ animals tended to have more difficulty remaining on (i.e. increases tendency to 
jump off) the MWM platform, which can confound the ability to interpret MWM results as 
memory deficits [147]. Therefore, it is possible PZ-induced sensorimotor effects, rather 
than PZ-induced cognitive impairment, contributed to the inability of the PZ group, in 
contrast to all other groups, to significantly improve their performance over the first four 
days of MWM.  
 In hindsight, inclusion of tests to quantitatively assess sensorimotor function, 
locomotor activity, or an alternative memory test would have further clarified the effects 
of PZ on behavior following CCI. In fact, PZ has been shown to have task-dependent 
effects on memory. For example, whereas high dose PZ impairs spatial memory in the 
MWM task, the same PZ dose enhances memory during the continuous multiple trial 
inhibitory avoidance (CMIA) task [159].  
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Phenelzine: A Comparison to Previous Neuroprotective SCI and Ischemic-
Reperfusion Injury Studies 
Still, when taken in comparison to previous SCI and ischemic-reperfusion 
studies, which saw neuroprotection with 15mg/kg daily intraperitoneal PZ dosing 
paradigms and which extended out 7-14 days [74, 76], it is surprising that the PZ dosing 
paradigm (15mg/kg, i.p., 15min, 24h, 48h post-CCI) utilized in the current study was not 
only unable to enhance cortical tissue sparing (Fig. 4.12), but also had a negative effect 
on weight and behavior (Fig. 4.8, 4.11, qualitative observation). Contrarily, in SCI, 
intraperitoneal administration of PZ (15mg/kg/day/14d) beginning immediately following 
injury attenuates motor dysfunction and improves tissue sparing [74]. Similarly, 
subcutaneous administration of PZ (15mg/kg/day/7d) improves CA1 neuron survival in a 
gerbil modal of global ischemic-reperfusion injury [76].  
It is possible this finding is due to differences in temporal assessments, species, 
or injury models. For example, although TBI and SCI share similar secondary injury 
characteristics [51, 55, 356], they are not equivalent models. Beyond structural 
differences, LP-derived aldehydes remain elevated longer in SCI than TBI [73, 338], 
brain and spinal cord mitochondria have different sensitives to lipid peroxidation [29, 33] 
and inflammatory responses differ between TBI and SCI [356]. Further, 
pharmacotherapies do not always translate from one injury paradigm to the other. For 
instance, while acute methylprednisolone is a treatment option for SCI [55], its use is 
contraindicated in TBI [209].  
Additionally, acrolein has been demonstrated to be extremely toxic to myelin due 
to its high protein and lipid content [357]. Given the anatomical differences between 
brain and spinal cord, attenuation of acrolein-induced myelin damage utilizing aldehyde-
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scavengers, such as PZ, may lead to a more quantitatively observable behavioral effect 
in spinal cord than in brain. Moreover, in SCI, aldehyde-scavengers, including PZ, have 
a well demonstrated role in reducing pain hypersensitivity, which may help in attenuating 
other outcomes which have been assessed in SCI such as motor dysfunction, but which 
were not directly measured in the current study [74, 337, 338, 358, 359].  
Further, PZ was recently identified as an agonist of the neuronal cell adhesion 
molecule L1 (L1CAM) [360], a compound which has been shown to promote axonal 
growth and re-myelination in the injured spinal cord [361]. In fact, in models of SCI PZ 
can decrease astrogliosis, enhance axonal growth and sprouting, and improve motor 
function in an L1CAM-dependent manner [361, 362]. Yet, the role L1CAM may have in 
recovery and regeneration following TBI is less well understood.   
 However, it is also possible that the PZ dosing paradigm utilized in the current 
study did have subtle neuroprotective effects which were not apparent upon cortical 
tissue sparing analysis (Fig. 4.12), but which may have been revealed by use of 
histological methods more sensitive to neurodegeneration, such as silver stain, or 
through analysis or specific regions, such as the hippocampus, as was done in the gerbil 
ischemic-reperfusion injury study [76]. However, given the overall PZ results for the 
current study, this is unlikely to be true and even less likely to be clinically relevant. 
 Yet, given the success of a similar dosing paradigm in other models of CNS 
injury, combined with the knowledge that intraperitoneal administration of PZ up to 
60mg/kg has been reported to be safe in rodents following SCI [74], the PZ results 
obtained in the current study beg the following question: Is there something about TBI 
that causes a PZ dosing paradigm which is neuroprotective (or at the very least safe) in 
other models (e.g. SCI, ischemic-reperfusion, naïve), to become ineffective or even 
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detrimental following severe CCI? Is it possible that TBI itself leads to either an inhibition 
of monoamine oxidase or an increase in monoamine levels, effects which are then 
exacerbated by repetitive use of an irreversible MAO, such as PZ? Unfortunately, in 
general there is a paucity of information regarding acute monoamine dysfunction 
following TBI.  
Monoamines and TBI  
Neurobehavioral sequelae following TBI are common and include dysregulation 
of cognition (e.g. attention, memory), mood (e.g. depression, anxiety), and emotion (e.g. 
aggression) [127]. Given the role the monoamines DA, NE, and 5-HT have in modulating 
these domains, sustained neurobehavioral impairments following TBI points to chronic 
dysregulation of monoamine neurotransmitter systems. In fact, pharmacologic agents, 
such as anti-depressants and stimulants, which modulate monoamine neurotransmitter 
systems, are often used to treat chronic TBI-induced neurobehavioral sequelae [127].  
However, less is understood about acute effects to monoamine systems 
following TBI, with the majority of work being focused on DA systems [154, 170]. 
Although, we did not detect cortical elevations of DA, NE, or 5-HT in the pericontusional 
site over the first 24h following CCI (see “Chapter Five”), there is evidence that levels of 
DA, NE, and 5-HT become acutely elevated throughout various brain regions and 
systemically following TBI [154, 173, 174, 178, 182, 363-365].  
Although acute administration of DA agonists (e.g. bromocriptine, amantadine, 
etc.) and 5-HT agonists (e.g. 8-OH-DPAT, buspirone, etc.) have shown great promise as 
neuroprotective agents in TBI, the administration of DA agonists is often delayed until 
24h post-TBI [154, 170, 271], and therapeutic agonists are often receptor subtype 
specific. For example, bromocriptine is specific to the DA receptor subtype D2 [154], 
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amantadine doubles as an NMDA glutamate receptor antagonist [154], and 8-OH-DPAT 
and buspirone are specific to 5-HT1A, which is an inhibitory receptor [271]. Therefore, 
use of such agents, which target specific receptor subtypes, is not equivalent to 
increasing overall monoamine levels, as would be the case with the use of an MAOI, 
such as PZ.  
Interestingly, following TBI, high catecholamine levels are associated with 
increased  peripheral inflammation [366], cerebral edema [367], and poor outcome [181], 
However, because catecholamine levels increase with activation of the sympathetic 
nervous system, as would occur following trauma, it is difficult to determine whether high 
catecholamine levels following TBI are an actual cause or rather an effect of injury 
severity [181]. Yet, early administration of NE in experimental TBI has been shown to 
increase pericontusional extracellular glutamate levels [368], and high dose NE leads to 
increases in systolic arterial blood pressure and intraparenchymal hemorrhage [369]. 
Further, acute administration of DA antagonists following experimental TBI has anti-
excitotoxicity and neuroprotective effects [154].  
Therefore, it is possible that in the current experiment, PZ-induced elevations to 
monoamines or PZ-enhancement of TBI-induced monoamine elevations [154, 173, 174, 
178, 182, 363-365], led to exacerbation of dysfunction or even negated PZ aldehyde-
scavenging protective effects, further impairing MWM performance (Fig. 4.8) and 
increasing weight loss (Fig. 4.11) compared to the CCI + vehicle group. 
Extra-physiologic monoamines levels could have caused detrimental effects 
through a variety of mechanisms including direct catecholamine toxicity [170], 
vasoconstriction or thrombotic-induced ischemia [154, 171, 172, 182], or autoxidation 
generation of ROS/RNS [170, 194]. However, the latter scenario is unlikely, as even high 
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dose PZ has been shown to decrease markers of oxidative stress [72, 333]. Given the 
complexity, pervasiveness, and interconnectedness of the monoaminergic system, and 
the dearth of what is known regarding acute monoaminergic dysfunction in TBI, the 
complete answer of how PZ’s MAOI mechanism of action effects TBI pathophysiology 
and outcome is  likely complex. Further, as the current experiment did not directly 
measure MAO inhibition or monoamine tissue levels in PZ + CCI animals, the effects 
can only be hypothesized.  As such, additional PZ mechanisms of action must also be 
considered. 
Phenelzine: Other Possible Confounding Mechanisms of Action 
In general PZ has complicated pharmacokinetics. PZ is itself a MAO substrate 
with several active metabolites such as PEA and PEH [189]. As mentioned previously, 
PEA, also metabolized by MAO is an amphetamine-like metabolite that can produce 
stimulatory effects [207], and it is therefore possible that PEA, rather than more 
prevalent monoamine neurotransmitters such as DA, NE, and 5-HT, is responsible for 
PZ-induced weight loss (Fig. 4.11), working memory impairment (Fig. 4.8), and 
qualitative behavioral observations [352]. Additionally, the PZ metabolite, PEH, inhibits 
several important transaminases, including GABA transaminase (GABA-T), alanine 
transaminase (ALA-T), and ornithine transaminase (ORN-T) [169]. Although, GABA, 
ALA, and ORN levels were not measured as part of the current study, previous studies 
have shown a dose dependent increase in all three following PZ administration [342] 
[169, 335], and it is possible that inhibition of these transaminases following TBI could 
have negatives consequences. For example, GABA-T is responsible for the conversion 
of the inhibitory neurotransmitter GABA, to succinic semi-aldehyde, which can be further 
oxidized to succinate [169], a substrate of the Krebs cycle and complex II of the ETC. 
Therefore, inhibition of GABA-T could lead to increases in GABA, which can 
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paradoxically cause excitotoxicity following neuronal injury through reversal of chloride 
channels [264], as well as decreases in ETC substrates during a time in which there is 
ongoing mitochondrial dysfunction and ATP depletion [22, 25, 51, 73]. Similarly, 
inhibiting ALA-T, the enzyme which catalyzes the reaction of alanine + α-ketoglutarate to 
form glutamate + pyruvate, could also lead to decreased formation of Kreb cycle 
substrates. Further, ORN-T catalyzes the formation of glutamate, from the urea cycle 
product, ORN. However, inhibition of ORN-T could alternately lead to decarboxylation of 
ORN by ornithine decarboxylase (OCD), the result of which is formation of neurotoxic 
polyamines [169].  
On the other hand, because PEA and PEH are metabolites of PZ metabolism by 
MAO, the effects of PZ metabolites, such as PEH, can be inhibited through pre-inhibition 
of MAO [169]. Therefore, the effect multiple PZ doses would have on GABA, ALA, and 
ORN levels, particularly in the context of TBI is unknown. However, PZ itself is also 
capable of inhibiting transaminases, as well as enzymes involved in the biosynthesis of 
neurotransmitters such as DA, 5-HT, and glutamate, as it can scavenge physiologically 
important carbonyls, such as the B6-derived cofactor, pyridoxal phosphate [78]. 
Furthermore, it is currently unknown how drug-aldehyde-protein ternary complexes are 
metabolized or what the longer-term consequences of ternary complex formation are 
[78]. In fact, evidence suggests that such complexes can be immunogenic [258].  
Therefore, it is possible that in-vivo several PZ mechanisms of action could be interfering 
with its neuroprotective aldehyde-scavenging effects, particularly at higher doses.  
Pargyline 
The results of the current study indicate that 15mg/kg PG administered 
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly 
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improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10) or to 
improve cortical tissue sparing on post-CCI D8 (Fig. 4.12). However, PG animals were 
able to significantly improve the time/distance it took to find the platform over the first 
four MWM days (Fig. 4.8), and did not lose a significant amount of weight following 
injury (Fig. 4.11).  
In the literature PG is interchangeably referred to as a non-selective irreversible 
MAOI [191], and an MAO-B specific irreversible inhibitor [197], as the IC50 values of PG 
for MAO-A and MAO-B are 0.011522 μmol/L and 0.00820 μmol/L, respectively [202]. In 
fact, the ED50 for oral administration of PG gives a 6.6:1 selectivity ratio for MAO-B to 
MAO-A (1.4mg/kg for MAO-B, 9.3mg/kg for MAO-A) [197], whereas the ED50 for oral 
administration of PZ gives a 2:1 selectivity ratio of MAO-A to MAO-B (6mg/kg for MAO-A 
and 12mg/kg) [197]. The fact that PG is less selective for MAO-A, in conjunction with 
other pharmacokinetic differences between PG and PZ [189], likely explains why that for 
the dosing paradigms utilized in the current study, although both PG and PZ significantly 
inhibited MAO as measured by 5-HT and DA turnover (Fig. 4.6C and 4.7D-F), PG, 
unlike PZ, did not significantly raise tissue levels of the MAO-A substrates, NE (Fig. 4.5) 
or 5-HT (Fig. 4.6A).  
These findings are in line with previous studies which directly compared the 
effects of PG and PZ on drug (e.g. nicotine, cocaine, ethanol) substitution and 
discrimination [205-208], processes thought to require both MAO-A and MAO-B 
inhibition [205-207]. Those studies found that PZ, administered at lower doses than PG, 
was able to enhance the discriminatory effects of nicotine [205] and nicotine-induced 
locomotor activity [206], whereas PG was not [205]. Further, although PZ and PG were 
both able to decrease cocaine and ethanol self-administration, PZ did so at lower doses 
and with prolonged effects [207, 208]. This data suggests that PG, at least when used at 
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a similar dosing concentration to PZ, has less of an effect than PZ on behavioral 
processes mediated by MAO inhibition. This knowledge, combined with the current 
study’s HPLC data (Fig. 4.5 – 4.7), likely explains why the qualitative behavioral 
observations and negative effects such as weight loss (Fig. 4.11) and poor MWM 
acquisition performance (Fig. 4.6) that occurred in the PZ animals, was not seen in the 
PG group following CCI, despite both compounds being irreversible MAOIs. However, as 
with PZ, PG did significantly increase swim speed following CCI (Fig 4.9), suggesting 
that PG still possibly had some effect on elevating catecholamine levels following CCI 
[158]. Therefore, the absence of other confounding PZ mechanisms of action, such as 
formation of active metabolites or ternary drug-aldehyde-protein complexes (see 
“Phenelzine: Other Possible Confounding Mechanisms of Action” for further discussion) 
as factors in the behavioral differences between PG and PZ following CCI also cannot 
be ruled out.  
As stated previously, PG was chosen as a comparison to PZ because it is 
similarly structured but lacks the aldehyde-scavenging hydrazine moiety (-NH-NH2) (Fig. 
4.2), and that the dosing paradigms for the two were kept equivalent to parallel previous 
ex-vivo experiments [72]. However, we concede that choosing a non-hydrazine MAOI 
with more similar MAO-A to MAO-B affinity ratios, such as tranylcypromine [189, 197, 
208], or altering PG concentrations to better reflect PZ MOAI affinities or other 
pharmacokinetics may have offered more clear insight into the effects of MAOI following 
TBI. 
Due to PG’s lack of an aldehyde-scavenging hydrazine (-NH-NH2) moiety it was 
not surprising that PG was unable to improve behavioral deficits or cortical tissue 
sparing following CCI (Fig 4.8, 4.10, 4.12). However, it should be noted that some 
studies have demonstrated MAOIs to have neuroprotective effects. For example, MAO 
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substrates such as DA and tyramine (an MAO substrate incapable of undergoing 
autoxidation) have been shown to induce mitochondrial dysfunction, an effect which can 
be attenuated by administration of a variety of irreversible MAOIs, including PG [193]. 
Similarly, in-vitro, MAOIs can prevent mitochondrial-dependent apoptosis following 
serum withdrawal [275]. Although these results may seem to contradict our previous 
findings that PG is unable to protect mitochondria from exogenous administration of the 
toxic aldehydes 4-HNE and acrolein ex-vivo [72], the differences are likely explained by 
the isolative nature of the mitochondrial preparation technique in which monoamine 
substrates or other molecules such as those involved in apoptotic signaling are likely 
absent. As such, although not included as part of this study, evaluating the effects of in-
vivo administration of PG following CCI on mitochondrial function, as we have previously 
done with PZ [71, 72, 333, 334] could have yielded interesting results.     
Further, several irreversible MAOIs have demonstrated in-vivo neuroprotection in 
models of stroke [272], TBI [273], and aging [279]. However, many of these studies 
suggest that the neuroprotective effects of MAOIs are independent of MAO inhibition 
[274, 275], and are instead possibly due to the presence of an N-propargyl moiety, a 
structure shared by several demonstratively neuroprotective MAOIs, including deprenyl 
(selegiline), clorgyline, rasagiline, and importantly, PG [192, 201, 276-278]. Hypotheses 
regarding the mechanisms of action in which N-propargyl compounds may exert their 
neuroprotective effects are vast and include modulation of apoptotic proteins and protein 
kinase C (PKC), upregulation of antioxidants and growth factors, or direct targeting of 
the mPTP [192, 274-276, 278, 279]. 
Therefore, even though PG did not demonstrate protective effects following CCI 
in the current experiment, and other studies have demonstrated that PG can actually 
exacerbate DA neurotoxicity [194], it is possible that under different experimental 
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parameters, such as an alternative dosing paradigm, that PG could demonstrate acute 
neuroprotective effects following CCI, possibly due to the presence of an N-propargyl 
moiety. On the other hand, it should be noted that in addition to possible MAOI effects 
(see “Monoamines and TBI” section for further discussion), PG has several properties 
which could instead either negate protective effects or exacerbate dysfunction. Although 
the latter is unlikely the case as out of all three drugs, PG performed most similarly to 
vehicle (Fig. 4.8 – 4.12). 
First, PG is metabolized by the liver enzyme CYP2E1 to the toxic aldehyde, 
propioaldehyde, which has similar effects to acrolein and can induce hepatocyte toxicity, 
lipid peroxidation, and glutathione (GSH) depletion [370]. Interestingly, CYP2E1, itself a 
producer of ROS during substrate metabolism, is found in rat brain at 25% the levels of 
that in the liver and is highly expressed within rat brain mitochondria [371]. Although PG 
appears to be non-toxic to rat brain mitochondria when exogenously applied ex-vivo [72], 
it is unknown what role CYP2E1 and its potential products have in the metabolism of 
PG, particularly multiple doses of PG, following CCI.  
Second, although developed and classified as an MAOI, PG was more frequently 
used clinically as an anti-hypertensive [203]. Although this sounds counterintuitive given 
the known risk of hypertensive crisis that can be induced by combining MAOIs with 
ingestion of tyramine-rich foods [191], its anti-hypertensive properties are thought to be 
due to MAOI-induced increases in NE and its action on inhibitory α2-adrenergic 
receptors of the brainstem and periphery [204]. Although only slight and non-significant 
changes in NE tissue level were seen following multiple PG administration in uninjured 
animals (Fig. 4.5), and previous studies have not detected blood pressure changes in 
Sprague-Dawley rats over a 24h period following intravenous PG (10mg/kg) 
administration [204], as blood pressure was not measured during the current study, it is 
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unknown what effect PG has on blood pressure following CCI, an experimental model of 
TBI which can induce hypotension acutely following impact [372]. In fact, it is known that 
hypotension can exacerbate dysfunction following experimental TBI [373, 374]. 
Interestingly, given the proposed mechanism of action regarding PG’s anti-hypertensive 
effects, it is possible that as a drug class all MAOIs, and therefore PZ, could have anti-
hypertensive effects. In fact low blood pressure is an uncommon side effect of PZ [198, 
341]. Further, the third drug used in this study, HZ, also has potential anti-hypertensive 
effects [268] (see “Hydralazine” section for further discussion). On the other hand, blood 
pressure monitoring following drug administration could have revealed the opposite 
effect, as MAOI-induced catecholamine elevations can elicit increases in blood pressure 
[346]. Admittedly, including blood pressure measurements as part of the current study 
may have revealed important physiologic changes subsequent to CCI + drug 
administration.  
Hydralazine 
The results of the current study indicate that 5mg/kg HZ administered 
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly 
improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10). 
However, HZ animals were able to significantly improve the time/distance it took to find 
the platform over the first four MWM days (Fig. 4.8), and did not lose a significant 
amount of weight following injury (Fig. 4.11). Although HZ was unable to significantly 
decrease cortical degeneration on post-CCI D8 (Fig. 4.12), of the three drugs tested, HZ 
did lead to the greatest amount of cortical tissue spared, improving the amount of 
cortical tissue sparing seen in the vehicle group by nearly 10% (Table 4.1).  As this was 
the first time HZ was investigated in the context of TBI, it is possible that choosing an 
alternative HZ dosing paradigm could have enhanced protective effects. 
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For example, the plasma half-life of HZ is only 60 minutes [74, 78]. Therefore, 
theoretically more frequent doses of HZ could have led to enhanced protection. 
However, that is not the case in SCI, where intraperitoneal dosing of 5mg/kg HZ every 
24h has been shown to be neuroprotective, improving motor function, increasing tissue 
sparing, and decreasing pain hypersensitivity [74, 75, 338, 358]. In fact, as HZ can exert 
its effects as an aldehyde-scavenger by binding protein-bound aldehydes and preventing 
damaging cross-linking reactions [79, 262], its neuroprotective aldhehyde-scavenging 
effects are likely prolonged beyond its short plasma half-life. However, additional 
neuroprotective mechanisms of action for HZ have also been recently proposed. For 
example, HZ has been shown capable of activing Nrf2 (nuclear factor erythroid 2-related 
factor), a transcription factor which activates antioxidant genes following neuronal injury 
[375], which would also act in prolonging its neuroprotective effects.  
Unfortunately, the HZ dosing paradigm utilized in the current study did not 
translate well from SCI to TBI.  As discussed previously, this is not entirely surprising as 
the SCI and CCI injury models are not necessarily equivalent. In fact, it is possible that 
additional, non-aldehyde-scavenging HZ mechanisms of actions are more confounding 
in TBI than they are in SCI. 
First, like PZ and PG, HZ has MAOI properties [258, 269], likely due to the 
presence of its hydrazine moiety (-NH-NH2), which is known to participate in one 
mechanism of MAO inhibition [199].  Specifically, HZ has been demonstrated to 
reversibly inhibit MAO-A and MAO-B, with a slight preference for MAO-A [269]. Such a 
property likely explains the results shown in Fig. 4.6C in which HZ causes a slight but 
significant decrease in 5-HT turnover in uninjured cortex, as well as the slight but 
significant increase in swim speed (Fig. 4.9) seen in HZ animals following CCI, which 
was similar to that seen with the MAOIs PG and PZ. And although inhibiting MAO along 
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with scavenging acrolein may synergistically attenuate pain hypersensitivity in SCI [74, 
338], as discussed previously, modulation of MAO following TBI may have unintended 
negative consequences (see “Monoamines and TBI” section for further discussion).  
More concerning, however, is the fact that HZ is an anti-hypertensive, clinically 
used to treat emergent and essential hypertension [268]. The anti-hypertensive 
properties of HZ are due to its ability to act as an arteriolar vasodilator. Although the 
exact mechanism of action remains unclear, it has been hypothesized to be due to 
activation of guanylate cyclase, inhibition of sarcoplasmic reticulum calcium release, or 
increased conductance of calcium-dependent K+ channels [258]. Although 
intraperitoneal doses of HZ ranging from 5mg/kg - 25mg/kg have been reported not to 
induce changes to systolic blood pressure in rats [270], because CCI can acutely induce 
hypotension [372], and as mentioned previously blood pressures were not measured as 
part of the current study, it is currently unknown whether HZ induced hypotension under 
the current experimental conditions. However, if under the current experimental 
conditions HZ did induce hypotension and as a consequence cerebral hypoperfusion 
occurred, it could explain the differences between the results seen here and those seen 
in previous SCI studies [74, 75, 338, 358], as any protective aldehyde-scavenging 
effects could have been partially negated by the consequences of cerebral 
hypoperfusion. In fact decreases in cerebral perfusion pressure have been shown to 
exacerbate functional deficits and cortical lesion volumes [373, 374]. Admittedly, 
including blood pressure measurements, as well as measures of aldehyde load, either 
by tissue staining or evaluation of urine metabolites such as 3-HPMA (N-acetyl-S-3-
hydroxypropylcysteine) [270], could have potentially helped to interpret the current 
study’s results in regards to HZ’s aldehyde-scavenging properties versus its anti-
hypertensive effects.  
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Clinical Translation of PZ, HZ, and Other Aldehyde Scavengers  
The ultimate goal in evaluating neuroprotective agents in experimental TBI is to 
translate their use into the human TBI population. Therefore, selecting study compounds 
which are FDA-approved for other indications and which could be potentially repurposed 
for use in TBI often offers a faster and more cost-effective approach than development 
of novel agents. Of the hydrazine (-NH-NH2) aldehyde scavenging drugs available, three 
are currently FDA-approved and in clinical use, including PZ, HZ, and the anti-
tuberculosis agent isoniazid, which itself has some MAOI properties [198, 376].  
As MAOIs were designed to target the CNS, along with concerns that an anti-
hypertensive like HZ would be dangerous for use clinically in TBI, our lab originally 
selected PZ for its studies into the protective effects of aldehyde scavengers following 
TBI [71, 72, 333, 334]. Despite previous studies by our lab and other groups 
demonstrating PZ to be neuroprotective in experimental models of CNS injury [71, 72, 
74-76, 333, 334, 361, 362], unfortunately the PZ dosing paradigm utilized in the current 
study (15mg/kg, i.p., 15min, 24h, 48h post-CCI) was unable to provide protective effects 
in regards to reference memory (Fig. 4.10) or cortical degeneration (Fig. 4.12), while 
also inducing significant weight loss (Fig. 4.11) and impairing MWM acquisition 
performance (Fig. 4.8).  As discussed previously, it is becoming clearer that lower doses 
of PZ may offer better protection [71, 334], possibly due to several PZ mechanisms of 
action which may confound neuroprotective effects as dosage increases, including its 
MAOI properties (Fig. 4.5 – 4.7). As such, it may be possible to optimize PZ for 
neuroprotection in experimental TBI using low or single dosing paradigms. However, as 
an MAOI, even conservative dosing paradigm may still prove impractical for clinical 
translation. 
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For example, in rats a single dose of PZ has been shown capable of inhibiting 
MAO and increasing monoamine levels for at least a week following administration [205, 
342]. However, the half-life of MAO in healthy human brain is reported to be as much as 
30 days [196], three times that in the rat [195]. Further, it is currently unknown what 
effect TBI has on the turnover of MAO in human brain, suggesting that even a single 
dose of PZ could have either prolonged effects or unintended negative consequences in 
TBI patients. For example, although in general there is little known about the 
monoaminergic system acutely following TBI, high catecholamine levels have been 
shown to correlate with poor outcome [181], and  therefore, administration of PZ acutely 
in clinical TBI, even at low doses, may represent a risk in regards to modulating the 
monoaminergic system in a way that leads to direct catecholamine toxicity [170], or 
catecholamine-induced vasoconstrictive or ischemic events [154, 171, 172, 182]. 
 Additionally, clinical administration of PZ would likely be restricted to patients not 
receiving vasopressors (e.g. NE or DA) as part of their clinical treatment, and 
contraindicated for use in patients taking serotonin modulating drug such as SSRIs 
(serotonin-reuptake inhibitors) or SNRIs (serotonin-norepinephrine-reuptake inhibitors) 
[346], a medical history unlikely to be known at the time of acute clinical treatment given 
the severe nature TBI. Of additional concern in  regards to clinical translation of PZ is 
that anti-depressants can lower seizure threshold [265], a complication for which TBI 
patients are already at increased risk [209], although of all the anti-depressant drug 
classes, MAOIs are at the least risk to do so [265]. Therefore, use of PZ could increase 
the risk of post-traumatic seizure in TBI patients. 
 Similarly, although HZ was unable to provide significant protection in the current 
study (Fig. 4.8, 4.10, 4.12), it has shown extensive promise as a neuroprotective agent 
in experimental SCI [74, 75]. Yet, even if a HZ dosing paradigm for protection in 
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experimental TBI could be optimized, its anti-hypertensive properties also likely make it 
impractical for clinical translation. In fact, anti-hypertensives would be contraindicated for 
use in clinical TBI, as maintaining systolic blood pressure is important for decreasing 
mortality and improving outcome [209], particularly in patients in which autoregulation is 
impaired [377].  
However, despite the likely difficulty in clinical translation that PZ and HZ would 
face in order to be used in TBI, and despite the poor performance of the chosen PZ and 
HZ dosing paradigms in the current study in regards to the outcome measures 
evaluated, there is a preponderance of evidence that hydrazine (-NH-NH2) compounds 
such as PZ and HZ can provide protection in-vitro and in-vivo under a variety of injury 
paradigms [71, 72, 74-76, 88, 257, 270, 311, 333, 334, 337, 338]. Therefore, in our 
opinion it is still too early to abandon pursuit of aldehyde scavengers as therapeutic 
agents in TBI. 
However, there is a need for new hydrazine compounds (-NH-NH2) to be 
developed, such as ones with less complicated pharmacokinetics that do not result in 
potentially confounding off target effects such as MAO inhibition or hypotension. 
Although it should be noted that the hydrazine moiety (-NH-NH2) is purported to interact 
with MAO to cause inhibition [199], a variety of hydrazine (-NH-NH2) containing 
compounds have been shown to have differing levels of inhibitor activity [199, 378], 
therefore, development of an aldehyde-scavenging hydrazine (-NH-NH2) compound with 
no MAOI effects should theoretically be possible. Alternatively, although not as potent as 
the hydrazine (-NH-NH2) compounds, additional aldehyde-scavenging moieties exist 
including cysteines, histidines, and pyridines, and could also serve as the basis for 
further development [79].  
 
 
219 
Conclusion 
In conclusion, utilizing a severe CCI model of TBI in 3mo male Sprague-Dawley 
rats, intraperitoneal administration (15min, 24h, 48h post-CCI) of the drugs PG 
(15mg/kg, MAOI, non-aldehyde scavenger), PZ (15mg/kg, MAOI, aldehyde scavenger), 
and HZ (5mg/kg, non-MAOI, aldehyde scavenger) were unable to attenuate reference 
memory deficits (D7 post-CCI) (Fig. 4.10) or improve cortical tissue sparing (D8 post-
CCI) (Fig. 4.12) following injury. However, although non-significant, HZ led to the most 
improvement to cortical tissue sparing (Table 4.1). Of concern, following CCI PZ animals 
lost a significant amount of weight (Fig. 4.11), and their MWM acquisition performance 
did not significantly improve across time (D3-6 post-CCI) (Fig. 4.8), possibly due to PZ-
induced high monoamine levels as was seen in uninjured cortical tissue utilizing the 
same PZ dosing paradigm (Fig. 4.5 – 4.7). Similarly, qualitative behaviors observed in 
the PZ group following CCI may have also been suggestive of elevated monoamine 
levels. However, the effects of other PZ mechanism of actions, such as inhibition of 
GABA-T or formation of PEA, cannot be ruled out as factors effecting outcome. 
Admittedly, this study had several limitations that make precise data interpretation 
difficult. Namely, MAO inhibition and monoamine levels were not evaluated following 
CCI + drug administration, MWM testing began very early following CCI and final drug 
administration, blood pressure was not monitored, and quantitative behavioral testing 
was limited to one task. Although the precise reasons the aldehyde-scavengers PZ and 
HZ were unable to provide significant protection in the current study cannot be identified 
with certainty, the dosing paradigm and experimental parameters utilized are likely 
contributory factors, as a number of previous studies have shown that the aldehyde-
scavengers PZ and HZ are indeed protective under different conditions (e.g. lower 
doses, SCI, mitochondrial bioenergetics, etc.). However, given the fact that PZ is a non-
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selective irreversible MAOI with complicated pharmacokinetics and active metabolites 
and HZ is an anti-hypertensive, clinical translation of either drug for use in TBI patients 
may prove challenging. Therefore, we urge the development of aldehyde-scavenging 
drugs that do not contain confounding mechanisms of action such as irreversible MAO 
inhibition or hypotension, and for such compounds to be used in future investigations of 
aldehyde-scavenging as a means of neuroprotection in experimental TBI.  
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CHAPTER FIVE: 
 
Supplementary Data: Comparative Effects of Phenelzine, Hydralazine, and 
Pargyline on Learning and Memory and Cortical Tissue Sparing Following 
Experimental Traumatic Brain Injury 
 
Introduction 
 The data presented here is an extension of the work presented in “Chapter 4: 
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and Memory 
and Cortical Tissue Sparing Following Experimental Traumatic Brain Injury”. High 
Performance Liquid Chromatography (HPLC) is utilized to analyze the tissue levels of 
monoamines, metabolites, and turnover ratios in order to assess monoamine oxidase 
(MAO) inhibition in uninjured cortical tissue following a single dose of phenelzine (PZ), 
pargyline (PG), or hydralazine (HZ). Additionally, HPLC is utilized to analyze the tissue 
levels of monoamines, metabolites, and turnover ratios in the penumbra of cortical tissue 
in order to assess MAO inhibition and metabolite tissue levels 3h, 12h, and 24h following 
a severe controlled cortical impact injury (CCI). Further, percent weight loss for uninjured 
animals following two doses of PZ, PG, or HZ is presented. 
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Methods 
Please see “Chapter Four: Comparative Effects of Phenelzine, Hydralazine, and 
Pargyline on Learning and Memory and Cortical Tissue Sparing Following Experimental 
Traumatic Brain Injury” for detailed methods regarding animals, HPLC tissue collection, 
HPLC, CCI, choice of drug concentration, statistical analysis, etc.  
Experimental Design: 24h HPLC Monoamine and Metabolite Analysis (Fig. 5.1) 
In order to assess MAO inhibition 24h following single drug administration HPLC 
was used to evaluate monoamine and metabolite tissue levels and turnover ratios in 
uninjured cortex. Uninjured animals (n = 6 animals per group) were administered an 
intraperitoneal (i.p.) dose of saline, PZ (15 mg/kg), HZ (5 mg/kg) or PG (15 mg/kg) [72, 
74]. Animals were euthanized 24h following drug administration and cortical tissue 
punches were collected for HPLC analysis.    
 
 
223 
 
Figure 5.1 Monoamine and metabolite 24h HPLC experimental design. Uninjured 
rats received intraperitoneal injections of vehicle (saline), pargyline (15mg/kg), 
phenelzine (15mg/kg), or hydralazine (5mg/kg) at 0h. Animals were euthanized and 
cortical tissue was collected for HPLC analysis 24h following injection. 
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Experimental Design: CCI Time Course HPLC Monoamine and Metabolite Analysis 
(Fig. 5.2) 
HPLC was utilized to assess MAO inhibition and monoamine neurotransmitter 
tissue levels following severe CCI. Animals received a severe CCI (n = 6 per time point) 
or sham surgery (n = 6). At 3h, 12h, and 24h post-CCI 3mm cortical tissue punches were 
collected from the penumbra region lateral to the epicenter of injury and sent for HPLC 
analysis. Sham tissue was collected 12h post-surgery.  
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration  
 Animals were weighed daily prior to each drug administration for the uninjured 
72h HPLC experiments (Fig. 4.3). However, a final weight was not measured at the 72h 
time point prior to euthanasia. Therefore, percent weight loss is calculated between day 
zero (prior to drug administration) and day two following intraperitoneal administration of 
saline, PG (15mg/kg), PZ (15mg/kg), or HZ (5mg/kg) on day zero and day one.  
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Figure 5.2 Monoamine and metabolite CCI time course experimental design. Rats 
received severe a CCI (TBI). Cortical punches were collected from penumbral tissue 
lateral to the injury epicenter at 3h, 12h, and 24h following injury. Sham tissue was 
collected 12h following sham surgery. Tissue was sent for HPLC analysis.  
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Results 
24h Single Dose PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels 
and Turnover Ratios in Uninjured Cortical Tissue (Fig. 5.3 – 5.5) 
For norepinephrine (NE), a single saline sample was identified as an outlier 
(Grubb’s) and excluded (G = 2.009, Y = 6). For NE, a one-way ANOVA revealed a 
statistically significant effect across all groups (F[3,19] = 15.74, p < 0.0001). However, 
Brown-Forsythe revealed an inequality of variance (p = 0.0002). Therefore, Kruskal-
Wallis was used in lieu of a one-way ANOVA. KW revealed a significant effect across all 
groups (H[3, n = 23] = 15.33, p = 0.0016). Post-hoc testing (Dunn’s) revealed that 
compared with saline, NE (ng/g) was significantly increased in PZ (p<0.05) and PG 
(p<0.05), and that compared with HZ, NE (ng/g) was significantly increased in PZ 
(p<0.05) (Fig. 5.3). Thus, PZ and PG result in an increase in NE.  
For the analysis of 5-HT and 5-HT metabolites, during 5-HIAA analysis, a single 
PZ sample was identified as an outlier (Grubb’s) and excluded (G = 1.903, Y = 6). In 
order to maintain consistency and be able to calculate the 5-HIAA/5-HT ratio, this PZ 
animal was excluded from the entire 5-HT data set.  
For serotonin (5-HT), a one-way ANOVA revealed a statistically significant effect 
across all groups (F[3,19] = 28.13, p < 0.0001). Post-hoc testing (Tukey’s) revealed that 
compared with saline, 5-HT (ng/g) was significantly increased in PZ (p<0.0001) and PG 
(p<0.01), and that compared with HZ, 5-HT (ng/g) was significantly increased in PZ 
(p<0.0001) and PG (p<0.05), and that PZ and PG were significantly different from each 
other (p<0.01) (Fig. 5.4A).Thus, PZ and PG result in an increase in 5-HT. However, the 
increase in 5-HT is greater with PZ.  
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Figure 5.3 Tissue Level (ng/g) of norepinephrine (NE) in 24h uninjured cortex. NE 
measured via HPLC 24h following single intraperitoneal injection of saline, pargyline 
(PG), phenelzine (PG) or hydralazine (HZ). Values= median ± interquartile range; 
Kruskal-Wallis followed by Dunn post hoc; *p < 0.05 compared with saline; #p < 0.05 
compared with HZ; n = 5-6 per group.  
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Figure 5.4 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in 24h uninjured 
cortex. (A) 5-HT, (B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and 
the turnover ratio (5-HIAA / 5-HT) in uninjured cortex as measured via HPLC 24h 
following single intraperitoneal injection of saline, pargyline (PG), phenelzine (PG) or 
hydralazine (HZ). Values = mean ± standard deviation; one-way analysis of variance 
followed by Tukey post hoc; **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with 
saline; #p < 0.05, ###p < 0.001, ####p < 0.0001 compared with HZ; ^^p < 0.01, n = 5-6 per 
group.   
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Figure 5.5 Tissue Level (ng/g) of dopamine (DA) and metabolites in 24h uninjured 
cortex. (A) DA, (B) the DA metabolite 3,4 5-dihydroxyphenylacetic acid (DOPAC), (C) 
the DA metabolite homovanillic acid (HVA), and the DA turnover ratios (D) (DOPAC + 
HVA / DA, (E) DOPAC / DA, and (F) HVA / DA in uninjured cortex as measured via 
HPLC 24h following single intraperitoneal injection of saline, pargyline (PG), phenelzine 
(PG) or hydralazine (HZ). Values = mean ± standard deviation; one-way analysis of 
variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
compared to saline; #p < 0.05, ##p < 0.01, ####p < 0.0001 compared to HZ; n = 4-6 per 
group.  
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For 5-hydroxyindoleacetic acid (5-HIAA), a one-way ANOVA revealed a 
statistically significant effect across all groups (F[3,19] = 17.74, p < 0.0001). Post-hoc 
testing (Tukey’s) revealed that compared with saline, 5-HIAA (ng/g) was significantly 
decreased in PZ (p<0.001) and PG (p<0.001), and that compared with HZ, 5-HIAA 
(ng/g) was significantly decreased in PZ (p<0.001) and PG (p<0.001)(Fig. 5.4B). Thus, 
both PZ and PG result in a decrease in the 5-HT metabolite, 5-HIAA. 
For the ratio 5-HIAA / 5-HT, a one-way ANOVA revealed a statistically significant 
effect across all groups (F[3,18] = 46.37, p <0.0001). Post-hoc testing (Tukey’s) revealed 
that compared with saline, the ratio 5-HIAA / 5-HT was significantly decreased in PZ 
(p<0.0001) and PG (p<0.0001), and that compared with HZ, the ratio 5-HIAA / 5-HT was 
significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 5.4C). Thus, PZ and 
PG result in a decrease in 5-HT turnover to 5-HIAA (i.e. increase in monoamine oxidase 
inhibition).  
Prior to statistical analysis, due to undetectable HVA levels, two animals were 
removed from the PZ group for all analysis of DA and DA metabolites. Additionally, 
during HVA statistical analysis, a saline sample (G = 1.995, Y = 6) and PG sample (G = 
2.2027, Y =6) were identified as an outliers (Grubb’s) and excluded. In order to maintain 
consistency and be able to calculate DA metabolite/DA turnover ratios, these animals 
were further excluded from the entire DA data set.  
For dopamine (DA), a one-way ANOVA revealed a statistically significant effect 
across all groups (F[3,16] = 9.424), p = 0.0008). Post-hoc testing (Tukey’s) revealed that 
compared with saline, dopamine (ng/g) was significantly increased in PZ (p<0.05) and 
PG (p<0.01), and that compared with HZ, dopamine (ng/g) was significantly increased in 
PZ (p<0.05) and PG (p<0.01)(Fig. 5.5A). Thus, PZ and PG result in an increase in DA.  
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For 3,4-dihydroxyphenylacetic acid (DOPAC), a one-way ANOVA revealed a 
statistically significant effect across all groups (F[3,16]) = 12.17, p = 0.0002). Post-hoc 
testing (Tukey’s) revealed that compared with saline, DOPAC (ng/g) was significantly 
decreased in PZ (p<0.001) and PG (p<0.01), and that compared with HZ, DOPAC (ng/g) 
was significantly decreased in PZ (p<0.01) and PG (p<0.05)(Fig. 5.5B). Thus, PZ and 
PG result in a decrease in the DA metabolite, DOPAC.  
For homovanillic acid (HVA), a one-way ANOVA did not reveal a statistically 
significant effect across all groups (F[3,16] = 0.1774, p = 0.9101)(Fig. 5.5C). Thus, PZ, 
PG, nor HZ affected HVA levels.  
For the ratio (HVA + DOPAC) / DA, a one-way ANOVA revealed a statistically 
significant effect across all groups (F[3,16] = 80.58, p < 0.0001). Post-hoc testing 
(Tukey’s) revealed that compared with saline, the ratio (HVA + DOPAC) / DA was 
significantly decreased in PZ (p<0.0001), HZ (p<0.05) and PG (p<0.0001), and that 
compared with HZ, the ratio (HVA + DOPAC) / DA was significantly decreased in PZ 
(p<0.0001) and PG (p<0.0001) (Fig. 5.5D). Thus, PZ, PG, and HZ result in a decrease 
in DA turnover to HVA+DOPAC (i.e. increase in monoamine oxidase inhibition). 
However, PZ and PG do so to a greater degree.  
For the ratio DOPAC / DA, a one-way ANOVA revealed a statistically significant 
effect across all groups (F[3,16] = 83.17, p < 0.0001). Post-hoc testing (Tukey’s) 
revealed that compared with saline, DOPAC / DA was significantly decreased in PZ 
(p<0.0001), HZ (p<0.05), and PG (p<0.0001), and that compared with HZ, DOPAC / DA 
was significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 5.5E). Thus, PZ, 
PG, and HZ result in a decrease in DA turnover to DOPAC (i.e. increase in monoamine 
oxidase inhibition). However, PZ and PG do so to a greater degree.  
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For the ratio HVA / DA, a one-way ANOVA did not reveal a statistically significant 
effect across all groups (F[3,16] = 0.8669, p = 0.4785)(Fig. 5.5F). Thus, PZ, PG, nor HZ 
affected DA turnover to HVA.  
CCI Time Course HPLC Monoamine and Metabolite Tissue Levels and Turnover 
Ratios in Penumbral Cortical Tissue (Fig. 5.6 – 5.8) 
For NE, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,20] = 31.91, p < 0.0001). However, Brown-Forsythe revealed an inequality 
of variance (p = 0.0152). Therefore, Kruskal-Wallis was used in lieu of a one-way 
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 18.63, p = 
0.0003). Post-hoc testing (Dunn’s) revealed that compared with sham NE (ng/g) was 
significantly decreased at 3h (p < 0.05) and 24h (p < 0.001) post-injury (Fig. 5.6). Thus, 
following CCI NE is decreased at 3h and 24h.  
For 5-HT, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,20] = 21.29, p < 0.0001). However, Brown-Forsythe revealed an inequality 
of variance (p = 0.0324). Therefore, Kruskal-Wallis was used in lieu of a one-way 
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 15.65, p = 
0.0013)  Post-hoc testing (Dunn’s) revealed that compared with sham 5-HT (ng/g) was 
significantly decreased at 3h (p < 0.05) and 24h (p < 0.01) post-injury (Fig. 5.7A). Thus, 
following CCI 5-HT is decreased at 3h and 24h.  
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Figure 5.6 Tissue Level (ng/g) of norepinephrine (NE) in penumbral cortical tissue 
measured via HPLC 3h, 12h, and 24h following severe CCI. Values= median ± 
interquartile range; Kruskal-Wallis followed by Dunn post hoc; *p < 0.05 ***p < 0.00 
compared with sham; n = 6 per group.  
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Figure 5.7 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in penumbral 
cortical tissue measured via HPLC 3h, 12h, and 24h following severe CCI (A) 5-HT, 
(B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and the turnover ratio 
(5-HIAA / 5-HT). Values= median ± interquartile range; Kruskal-Wallis followed by Dunn 
post hoc; *p < 0.05, **p < 0.01 compared with sham; n = 5-6 per group.  
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Figure 5.8 Tissue Level (ng/g) of dopamine (DA) and metabolites in penumbral 
cortical tissue measured via HPLC 3h, 12h, and 24h following severe CCI (A) DA, (B) 
the DA metabolite 3,4 5-dihydroxyphenylacetic acid (DOPAC), (C) the DA metabolite 
homovanillic acid (HVA), and the DA turnover ratios (D) (DOPAC + HVA) / DA, (E) 
DOPAC / DA, and (F) HVA / DA. Values = mean ± standard deviation; one-way analysis 
of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, ***p < 0.001 compared 
with sham; #p < 0.05 compared with 12h; n = 3-5 per group.  
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For 5-HIAA, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,20] = 8.059, p = 0.001). However, Brown-Forsythe revealed an inequality of 
variance (p = 0.0001). Therefore, Kruskal-Wallis was used in lieu of a one-way ANOVA. 
KW revealed a significant effect across all groups (H[3, n = 24] = 13.98, p = 0.0029).  
Post-hoc testing (Dunn’s) revealed that compared with sham 5-HIAA (ng/g) was 
significantly decreased 3h (p < 0.01) (Fig. 5.7B) post-injury. Thus, following CCI the 5-
HT metabolite 5-HIAA is decreased at 3h.  
For the ratio 5-HIAA / 5-HT, a single 3h sample was identified as an outlier 
(Grubb’s) and excluded (G = 1.922, Y = 6). For the ratio 5-HIAA / 5-HT, a one-way 
ANOVA revealed a statistically significant effect across all groups (F[3,19) = 6.91, p = 
0.0025). However, Brown-Forsythe revealed an inequality of variance (p = 0.0365). 
Therefore, Kruskal-Wallis was used in lieu of a one-way ANOVA. KW revealed a 
significant effect across all groups (H[3, n = 23] = 11.76, p = 0.0082). Post-hoc testing 
(Dunn’s) revealed that the 5-HIAA / 5-HT at 24h was significantly increased compared 
with sham (p < 0.01)(Fig. 5.7C). Thus, following CCI there is an increase in the 5-HT 
turnover to 5-HIAA at 24h.  
Prior to statistical analysis, due to undetectable HVA levels, one animal was 
removed from the 3h group and two animals were removed from the 12h group for all 
analysis of DA and DA metabolites. Additionally, during DA statistical analysis, a sham 
sample (G = 1.908, Y = 6) and 24h sample (G = 2.009 Y =6) were identified as outliers 
(Grubb’s) and excluded. In order to maintain consistency and be able to calculate DA 
metabolite/DA turnover ratios, these animals were further excluded from the entire DA 
data set. During HVA statistical analysis, a sham sample (G = 1.759, Y = 5) and a 12h 
sample (G 1.653, Y = 4) were identified as outliers (Grubb’s) and excluded. In order to 
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maintain consistency and be able to calculate DA metabolite/DA turnover ratios, these 
animals were further excluded from the entire DA data set. 
 For DA, a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3,13] = 12.01, p = 0.0005). Post-hoc testing (Tukey’s) revealed that compared 
with sham DA (ng/g) was significantly decreased at 3h (p < 0.01) and 24h (p < 0.001) 
post-injury. Additionally, DA (ng/g) was significantly decreased at 24h (p < 0.05) 
compared with 12h post-injury (Fig. 5.8A). Thus, following CCI DA is decreased at 3h 
and 24h.  
 For DOPAC, a one-way ANOVA revealed a statistically significant effect across 
all groups (F[3,13] = 11.5, p = 0.0006). Post-hoc testing (Tukey’s) revealed that 
compared to sham DOPAC (ng/g) was significantly decreased at 3h (p < 0.01), 12h (p < 
0.05), and 24h (p < 0.001) post-injury (Fig. 5.8B). Thus, following CCI the DA metabolite 
DOPAC is decreased at 3h, 12h, and 24h.  
 For HVA, a one-way ANOVA did not reveal a statistically significant effect across 
all groups (F[3,13] = 1.633, p =0.2300) (Fig. 5.8C). Thus, the DA metabolite HVA 
remains unchanged following CCI.  
For the ratio (HVA + DOPAC) / DA, a single 24h sample was identified as an 
outlier (Grubb’s) and excluded (G = 1.771, Y = 5). For the ratio (HVA + DOPAC) / DA, a 
one-way ANOVA did not reveal a statistically significant effect across all groups (F[3,12]) 
= 0.6453, p = 0.6006) (Fig 5.8D).  Thus, the turnover of DA to HVA+DOPAC remains 
unchanged following CCI.  
For the ratio DOPAC / DA, a single 24h sample was identified as an outlier 
(Grubb’s) and excluded (G = 1.754, Y = 5). For the ratio DOPAC / DA, a one-way 
ANOVA did not reveal a statistically significant effect across all groups (F[3,12]) = 
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0.5785, p = 0.6402) (Fig. 5.8E). Thus, the turnover of DA to DOPAC remains unchanged 
following CCI.  
For the ratio HVA / DA, a single 24h sample was identified as an outlier (Grubb’s) 
and excluded (G = 1.768, Y = 5). For the ratio HVA / DA, a one-way ANOVA did not 
reveal a statistically significant effect across all groups. (F[3,12] = 1.1782, p = 0.2040 
(Fig. 5.8F). Thus, the turnover of DA to HVA remains unchanged following CCI.  
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration 
(HPLC Experiments) (Fig. 5.9) 
For the 72h triple dose HPLC monoamine and metabolite uninjured cortical 
tissue experiment a final weight for animals was taken at time 48h following 
intraperitoneal administration of saline, PG, PZ, or PG at time 0h and 24h for a total to 
two injections (Fig. 4.3). Animals were not weighed at the time of euthanasia (72h) and 
therefore had not received the third/final injection (48h) at the time of final weigh-in. For 
percent weight loss in uninjured rats between D0 (before first injection) and D2 (after 
second injection), a one-way ANOVA revealed a statistically significant effect across all 
groups (F[3, 20] = 5.157, p = 0.0084).  Post-hoc testing (Tukey’s) revealed that 
compared to the saline group (p < 0.01) and the PG group (p < 0.05), PZ lost a 
significant amount of weight.  
Thus indicating that intraperitoneal administration of PZ (15mg/kg) at 0h and 24h 
leads to significant weight loss at 48h in uninjured animals.  
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Figure 5.9 Percent weight loss in uninjured animals for 72h HPLC experiment. 
Percent weight loss in uninjured rats between D0 (before first injection) and D2 (after 
second injection). Animals were not weighed following third/final injection prior to 
euthanasia.  Values mean ± standard deviation; one-way analysis of variance followed 
by Tukey post hoc; *p < 0.05, ** p < 0.01 compared with PZ; Saline, PG = pargyline, PZ 
= phenelzine, HZ = hydralazine; n = 6 per group.  
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Discussion and Conclusion 
24h Single Dose PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels 
and Turnover Ratios in Uninjured Cortical Tissue 
 Overall these results indicate that 24h following a single intraperitoneal injection 
of the MAOIs PG (15mg/kg) and PZ (15mg/kg) there is significant MAO inhibition in 
uninjured cortical tissue as evidenced by the significant decrease in both 5-HT turnover 
(Fig 5.4C) and DA turnover (Fig 5.5D-F), as well as the significant increase in the tissue 
level of the MAO substrate NE (Fig 5.3). Additionally, the non-MAO HZ (5 mg/kg) also 
led to a significant decrease in DA turnover (Fig. 5.5D-F), likely due to a MAO effect as 
the significant decrease in DA turnover is seen in the ratios that contain the MAO 
product DOPAC (Fig. 5.5D-E). Interestingly, this is different than what was seen 
following the triple dosing HPLC experiments (Fig. 4.3), in which HZ led to a significant 
decrease in 5-HT turnover (Fig. 4.6C). However, it is likely still explained by the fact that 
HZ has previously been demonstrated to have reversible MAO inhibitory effects with a 
preference toward MAO-A [269]. As stated previously, NE and 5-HT are selectively 
metabolized by MAO, and although DA can be metabolized by either MAO isoform, the 
majority of DA in rats is metabolized by MAO-A [186].  
 There are several other important differences found between the single and triple 
dosing paradigms in regard to monoamine and metabolite tissue levels. First, continuing 
with DA, the 24h single injection dosing paradigm (Fig 5.1) led to a significant increase 
in DA tissue level (Fig 5.5A), whereas the 72h triple injection dosing paradigm (Fig. 
4.7A) did not, despite having a significant effect on DA turnover (Fig. 4.7D-F). It is 
unknown why this is, but as stated previously, the results obtained in Fig. 4.7A may be 
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due to some type of compensatory effect [349], which was not affected by the single 
dose administrations (Fig 5.5A).  
 Further, although direct statistical comparisons were not done, three doses of PZ 
or PG (Fig 4.3) caused more monoamine oxidase inhibition than single doses (Fig. 5.1). 
For example, in regards to NE a single dose of PG or PZ led to a mean (± standard 
deviation) tissue level (ng/g) of 852.90 ± 57.23 and 980.10 ± 186.30, respectively, 
whereas three doses of PG or PZ led to a mean (± standard deviation) tissue level (ng/g) 
of 940.2 ± 90.58 and 1155 ± 242.9, respectively. In regards to 5-HT, a single dose of PG 
or PZ led to a mean (± standard deviation) tissue level (ng/g) of 394.10 ± 87.92 and 
580.60 ± 69.98, respectively, whereas three doses of PG or PZ led to a mean tissue 
level of 499.20 ± 49.01 and 855.00 ± 180.00, respectively. In regards to 5-HT turnover, a 
single dose of PG or PZ led to a mean (± standard deviation) turnover ratio of 0.57 ± 
0.18 and 0.34 ± 0.08, respectively, whereas three doses of PG or PZ led to a mean (± 
standard deviation) turnover ratio of 0.28 ± 0.03 and 0.13 ± 0.04, respectively. Further, 
this effect is most evidenced in the (DOPAC + HVA) / DA turnover ratios in which a 
single dose of PG or PZ led to a mean (± standard deviation) turnover ratio of 0.54 ± 
0.29 and 0.39 ± 0.16, respectively, whereas three doses of PG or PZ led to a mean (± 
standard deviation) turnover ratio of 0.053 ± 0.013 and 0.035 ± 0.002, respectively. In 
fact, the change in DA turnover ratios were so great between the single and triple dosing 
paradigms that the scale of the x-axis in the triple dosing paradigm (Fig. 4.7D-F) had to 
be decreased by a factor of 4 from the scale of the x-axis for the single dosing paradigm 
(Fig. 5.5D-F). However, it should be noted that this was also true for the saline and HZ 
groups as well (Fig. 4.7 and Fig. 5.5). Therefore, it is possible that the very large 
change in DA turnover seen between the single dosing paradigm (Fig. 4.7D-F) and triple 
dosing paradigm (Fig. 4.7D-F) may be due to a technical or collection issue between 
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HPLC experiments or due to the total number of injections given (1 vs 3), as stress has 
been shown to increase endogenous inhibition of monoamine oxidase [379]. However, 
the latter may not be the case because the effect of saline on NE (Fig. 4.5 and Fig. 5.3) 
and 5-HT (Fig. 4.6 and Fig. 5.4) do not widely differ between the single and triple dosing 
paradigms.  
CCI Time Course HPLC Monoamine and Metabolite Tissue Levels and Turnover 
Ratios in Penumbral Cortical Tissue 
 As discussed in “Chapter Four” the PZ dosing paradigm utilized in the current 
study had previously been shown to be not only safe but beneficial in non-CCI models 
such as SCI and ischemic-reperfusion injury [74, 76]. However, as shown in “Chapter 
Four”, for the current study the PZ dosing paradigm utilized was not only unable to 
improve reference memory (Fig. 4.10) or cortical tissue sparing (Fig. 4.12), but it also 
led to significant weight loss (Fig. 4.11), qualitative behavioral concerns, and PZ animals 
were unable to make significant improvements during the MWM acquisition phase (Fig. 
4.8). One possible explanation for these findings is that after severe CCI monoamine 
levels are significantly elevated or monoamine oxidase is significantly inhibited, and that 
administration of PZ after injury, particularly multiple doses of PZ, is exacerbating these 
effects, leading to negative consequences. Therefore, we hypothesized that over the first 
24h following CCI monoamine tissue levels would be significantly elevated and 
monoamine turnover ratios would be significantly decreased.  
 However, the results indicate the contrary. In fact, at 3h and 24h after severe CCI 
the monoamines NE (Fig. 5.6), 5-HT (Fig. 5.7A), and DA (Fig. 5.8A), are significantly 
decreased compared with sham. Interestingly, there was not a significant difference in 
any of the neurotransmitter tissue levels between sham and the 12h post-CCI time point. 
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This is similar to other post-CCI processes such as mitochondrial dysfunction which 
increase 3h after CCI before recovering and then beginning to decline again at 24h [73]. 
However, it should be noted that all sham tissue was collected at the midway time point 
of 12h (Fig. 5.2). It is therefore possible that technical or tissue collection issues could 
have also influenced these results.  
In regards to monoamine turnover (i.e. MAO inhibition), the only significant 
change from sham was seen at 24h in which there was an increase in 5-HT turnover to 
5-HIAA (Fig. 5.7C). However, as both a significant decrease in tissue level of 5-HT (Fig. 
5.7A) and a non-significant decrease in tissue level of the 5-HT metabolite, 5-HIAA (Fig. 
5.7B) were also seen at this time point the increase in the 5-HIAA / 5-HT ratio is likely 
due to the larger of the two decreases being seen in the denominator (5-HT). Although it 
is possible the significant increase seen in the 5-HIAA / 5-HT ratio 24h post-CCI is in fact 
due to an decrease in MAO inhibition, the more likely explanation is that due to injury 5-
HT has been depleted or serotonergic neurons have degenerated in the penumbral area 
analyzed, whereas the metabolite 5-HIAA has not been removed to a such a degree. 
Additionally, it should be noted that 5-HT may come from other sources, such as platelet 
activation. However, platelets only contain MAO-B [380], whereas MAO-A selectively 
metabolizes 5-HT [186], so platelets should not be a large source of the 5-HT metabolite 
5-HIAA. 
 Although our data did not indicate any CCI-induced monoamine elevations, it 
should be noted that this study was limited to analysis of the penumbral tissue directly 
lateral to the epicenter of injury. It is possible that other brain regions would have shown 
increases either in monoamine tissue levels or MAO inhibition as previous studies have 
demonstrated that tissue levels of monoamines vary after experimental TBI depending 
region [154, 173, 174, 178, 182, 363-365]. It is also possible that increases in tissue 
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levels of monoamines or MAO inhibition occur at later time points still relevant to our CCI 
+ drug studies (Fig. 4.4), such as 48h-72h post-CCI. However, we forewent conducting 
experiments at these later time points based upon the results obtained over the first 24h 
(Fig. 5.6-5.8).  
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration 
(HPLC Experiments) 
Overall the results indicate that in uninjured animals two doses of PZ led to a 
significant amount of weight loss compared with both saline and PG. Although HZ also 
led to weight loss, it was not significant (Fig. 5.9). This is similar to what was seen in 
CCI, in which three doses of PZ led to a significant amount of weight loss following 
MWM compared with all other groups including sham, vehicle (saline), PG and HZ (Fig. 
4.11). As stated previously in regard to PZ it is possible that the weight loss seen in the 
current experiment was due to an increase in monoamine levels (Fig. 4.5 and 4.6A), as 
monoamines are capable of inducing weight loss through a variety of mechanisms [350], 
an effect which has been previously seen with non-PZ MAOIs [158, 351]. However, as 
weight loss was not observed in the other MAOI group, PG, it is possible that PZ causes 
weight loss through another mechanism, such as formation of the metabolite, 
phenethylamine (PEA) [189], itself an MAO substrate with amphetamine-like stimulatory 
effects [207].  
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CHAPTER SIX: 
 
Final Discussion and Concluding Remarks  
 
Summary of Results and Conclusions  
 TBI represents a significant health crisis in the United States and worldwide. 
However, currently there are no FDA-approved pharmacological agents capable of 
attenuating the devastating neurologic consequences that occur after TBI [1]. As central 
mediators of the TBI secondary injury cascade, mitochondria and LP-derived neurotoxic 
aldehydes, such as 4-HNE and acrolein, make promising therapeutic targets (Fig 1.2). In 
fact, CsA, an FDA-approved immunosuppressant capable of inhibiting the mPTP has 
been shown to be neuroprotective in experimental TBI [110, 122-124, 135, 136, 223-
227]. Additionally, PZ, an FDA-approved non-selective irreversible MAOI-class 
antidepressant has also been shown to be neuroprotective in experimental TBI due to 
the presence of a hydrazine (-NH-NH2) moiety allowing for the scavenging of LP-derived 
neurotoxic aldehydes [71, 72, 334].  
Due to the complex pathophysiology that occurs following TBI it is imperative that 
robust neuroprotective drugs be developed. It is possible that robust neuroprotection 
could be achieved through effective targeting of vulnerable mitochondrial 
subpopulations, such as synaptic mitochondria, the combining of two partially 
neuroprotective drugs, or through use of single agents which have dually protective 
mechanisms of action. Therefore, the overall goal of this dissertation was to further 
examine the neuroprotective efficacy of the mPTP inhibitor CsA and the LP-derived 
neurotoxic aldehyde scavenger PZ using a severe CCI model in 3-month old male 
Sprague-Dawley rats. Specifically, we evaluate 1) the protective effects of CsA on 
isolated synaptic and non-synaptic mitochondria, 2) the ability of a novel 72h 
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subcutaneous continuous infusion of PZ combined with CsA to improve mitochondrial 
respiration, attenuate mitochondria-aldehyde conjugate formation, and prevent 
cytoskeletal spectrin degradation compared to monotherapy, and 3) the effects of PZ 
(MAOI, aldehyde scavenger) on learning and memory and cortical tissue sparing 
following CCI compared to the effects of PG (MAOI, non-aldehyde scavenger) and HZ 
(non-MAOI, aldehyde scavenger). 
Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria 
after Traumatic Brain Injury and are Protected by Cyclosporine A 
 In order to test the hypothesis that CsA has a differential protective effect on 
isolated synaptic and non-synaptic mitochondrial bioenergetics following experimental 
TBI, 3mo male Sprague-Dawley rats were administered an intraperitoneal dose of CsA 
(20mg/kg) 15min after a severe controlled cortical impact injury (2.2mm), cortical 
synaptic and non-synaptic mitochondria were isolated 24h post-CCI, and respiratory 
rates were measured using a Clark-type oxygen electrode. 
 Results indicate that 24h after severe CCI synaptic mitochondria are more 
damaged than non-synaptic mitochondria, particularly in regard to RCR (Fig. 2.4). In 
fact, statistical analysis revealed a significant interaction between injury and population 
for this measure, indicating that synaptic mitochondria are indeed more susceptible to 
injury. There are several possibilities for why synaptic mitochondria are more vulnerable 
to injury than non-synaptic mitochondria, including increased susceptibility to calcium-
induced permeability transition due to high cyclophilin D content [38], increased 
exposure to oxidative damage [37, 38], and decreased respiratory chain activity and 
subunit content [296]. Further, non-synaptic mitochondria can tolerate larger 
impairments to respiratory complex activity before ATP production is significantly 
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decreased [35].  Impressively, these results also indicate that the more significantly 
damaged synaptic mitochondria are protected by intraperitoneal administration of CsA 
(20mg/kg) 15min post-CCI (Fig. 2.1 – 2.6). In fact, significant protection is achieved for 
respiratory states II (Fig. 2.1), III (Fig. 2.2), V(II) (Fig. 2.6), and the RCR (Fig. 2.4). 
Additionally, CsA improved non-synaptic respiration (Fig. 2.1 – 2.6). However, the 
improvements were non-significant likely due to the fact non-synaptic mitochondria are 
less severely damaged 24h after severe CCI (Fig. 2.4) [322].  
  This was the first study to investigate the effects of CsA on isolated and purified 
synaptic and non-synaptic mitochondria after experimental TBI and the results are 
important for several reasons. First, synaptic mitochondria represent a more purely 
neuronal population [37-39], have been implicated in neuronal and synaptic 
degeneration absent overt cell death [37, 48, 49], and are essential for proper 
neurotransmission and synaptic plasticity [44-46]. Therefore, it is critically important that 
synaptic mitochondrial function be protected after TBI. Yet, synaptic mitochondria are 
more vulnerable to damage after experimental TBI [41, 322] and previous studies in SCI 
have demonstrated that synaptic mitochondria often respond less favorably to 
pharmaceutical intervention than their non-synaptic counterparts [50]. As such, the 
ability of a previously optimized CsA dose [225, 294] to significantly protect the more 
vulnerable synaptic mitochondria population after experimental TBI, despite high 
cyclophilin D concentrations (i.e. CsA binding partner) [37], strengthens the growing 
body of evidence that CsA is protective in TBI and that its clinical translation should be 
pursued. 
 In fact, several clinical trials have shown that CsA is safe for use in patients with 
severe TBI with a trend toward improved outcomes [234, 235]. Unfortunately, due a 
biphasic dose-response curve [227] and concerns over the toxicity of cremophor, the 
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vehicle in which the currently available commercial preparation of CsA (Sandimmune®) 
is provided, [381, 382], larger CsA clinical trials have not been conducted. Although 
concerns over cremophor toxicity may be overblown and limited to chronic or in-vitro 
administrations [300-302], recently a novel cremophor-free lipid emulsion CsA 
preparation (NeuroSTAT®) was shown to be neuroprotective in a porcine model of TBI 
[381] as well to be bioequivalent to Sandimmune®. Therefore, future clinical trials 
investigating the neuroprotective effects of the non-cremophor CsA preparation 
NeuroSTAT® are planned [383].   
 As future clinical trials investigating the neuroprotective effects of CsA in TBI are 
likely to use non-cremophor preparations of CsA, the use of cremophor-CsA in the 
current study does represent a limitation and future experimental TBI studies of CsA 
may want to consider alternately using non-cremophor CsA. This study was additionally 
limited by several other factors such as the inability to further separate non-synaptic 
mitochondria into neuronal and non-neuronal cell types. Previous studies have 
demonstrated that mitochondria isolated from cultured neurons and glia have differing 
properties [38, 296]. Therefore, it is likely that in regards to synaptic mitochondria, the 
results of this study were influenced both by cell type (neuronal) and subcellular location 
(pre-synaptic). As techniques to isolate mitochondria from various cell types improve, 
future studies could offer insight into the differential properties of synaptic neuronal vs 
non-synaptic neuronal vs non-neuronal mitochondrial populations following experimental 
TBI, as well as their response to CsA. Additionally, this study was limited to one outcome 
measure (i.e. respiration), time point (i.e. 24h post-CCI), and dosing paradigm (20mg/kg 
CsA i.p. 15min post-CCI). Utilization of additional outcome measures such as calcium 
buffering capacity, enzyme activity, or formation of aldehyde-mitochondrial conjugates 
could have offered more specific insight into the differential effects of CCI and CsA on 
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synaptic and non-synaptic mitochondrial function. Further, evaluation of synaptic and 
non-synaptic mitochondrial function at a later time point, such as 48h, in which non-
synaptic mitochondria have sustained further damaged [322], may have shown CsA to 
have an enhanced protective effect on the non-synaptic mitochondrial population. Last, 
delaying CsA administration beyond 15min post-CCI may have revealed that synaptic 
and non-synaptic mitochondria have different therapeutic windows, an effect which has 
been previously seen in SCI [50], and one which may explain the finding that although 
CsA remains neuroprotective when administration is delayed 8h, it is most effective 
when administered within 3h of TBI [122].   
Continuous Infusion of Phenelzine, Cyclosporine A, or Their Combination: 
Evaluation of Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal 
Degradation Following Severe Controlled Cortical Impact Traumatic Brain Injury in 
Rats 
 To date all monotherapy clinical trials for TBI have failed [1]. Based upon the 
complex secondary injury cascade that occurs following TBI combinational therapies 
may offer more complete neuroprotection after injury than single agent therapies [213]. 
Therefore, the purpose of this study was to test the hypothesis that a 72h subcutaneous 
continuous infusion of PZ combined with CsA would improve mitochondrial respiration, 
attenuate formation of LP-derived aldehyde mitochondrial protein conjugates, and 
maintain cytoskeletal integrity following experimental TBI to a greater degree than 
monotherapy. Following a severe controlled cortical impact injury (2.2mm) in 3mo male 
Sprague-Dawley rats, subcutaneous osmotic pumps containing PZ (10mg/kg/day/3d), 
CsA (10mg/kg/day/3d), or PZ + CsA were implanted. Animals also received loading 
doses of PZ (10mg/kg s.c.), CsA (20mg/kg i.p.), or PZ + CsA 15min post-CCI (Table 
3.1). At 72h post-injury cortical mitochondria (total) respiratory rates were assessed 
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using a Clark-type oxygen electrode and cortical mitochondria (total) bound 4-HNE and 
acrolein were assessed using Western blot. Additionally, Western blot was used to 
assess cortical tissue for 145kD (calpain-only) and 150kD (calpain/caspase 3) αII-
spectrin breakdown as a marker for cytoskeletal integrity. Further, Western blot of 
spectrin breakdown products was used to compare a 72h subcutaneous continuous 
infusion PZ dosing paradigm to a dosing paradigm in which bolus PZ doses were 
administered every 12h over the first 72h following CCI (Table 3.2). 
Our results (Table 3.3) indicate that a 72h subcutaneous continuous infusion of 
PZ (10 mg/kg subcutaneous loading dose 15 min post-injury + 10 mg/kg/day 
subcutaneous infusion of PZ for 3 days) maintained mitochondrial RCR and cytoskeletal 
integrity, and decreased binding of 4-HNE and acrolein to mitochondrial proteins 72h 
following severe CCI. In fact, continuous infusion of PZ was able to maintain cytoskeletal 
integrity, whereas 12hr intermittent dosing of PZ was not (10 mg/kg PZ subcutaneous 
loading dose 15 min post-injury + 5 mg/kg PZ subcutaneous maintenance bolus every 
12h up to and including 60h) was not.  Additionally, continuous infusion of CsA (20 
mg/kg CsA intraperitoneal loading dose 15 min post-injury + 10 mg/kg/day subcutaneous 
infusion of CsA for 3 days) decreased binding of 4-HNE and acrolein to mitochondrial 
proteins. Although the combination of PZ + CsA was able to maintain cytoskeletal 
integrity, it did so to a similar degree as PZ alone, suggestive of a purely PZ effect, and 
was unable to attenuate other outcome measures. In fact, once combined the protective 
effect PZ and CsA individually had on formation of mitochondrial bound 4-HNE and 
acrolein was lost. 
Although enhanced protection was not seen with the combination PZ + CsA and 
the protection that was seen with each individual therapy was limited, it should be noted 
that this study had several limitations. First, only one dosing paradigm was investigated. 
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This study was designed to combine an optimized CsA dosing paradigm [122] with a PZ 
dosing paradigm previously demonstrated to be neuroprotective in experimental TBI 
[72]. However, the results were similar to previous combinational therapy studies in 
which utilization of drug doses optimized for monotherapy did not result in enhanced 
protection once combined [280]. A better approach likely would have been to either 
combine sub-therapeutic doses of PZ and CsA or to conduct a dose-response of the 
combined therapy.  
Second, the study was limited to one time point (i.e. 72h post-CCI) and only a 
few biochemical outcome measures (i.e. total mitochondrial respiration, mitochondria-
aldehyde conjugate formation, spectrin degradation). It is possible that a greater degree 
of neuroprotection was achieved with the dosing paradigms utilized, but that such 
neuroprotection was not seen in the specific outcome measures evaluated. For example, 
as the CsA dosing paradigm utilized has previously been shown to improve cortical 
tissue sparing [225, 294], it is possible that the same dosing paradigm did have a 
protective effect on mitochondrial respiration, but that the effect was masked in the total 
mitochondrial preparations (synaptic and non-synaptic mitochondria) because CsA has a 
greater effect on synaptic mitochondria than non-synaptic mitochondria (Fig. 2.1 – 2.6) 
[309], but at 72h post-injury synaptic mitochondria make up a minority of the 
mitochondrial population [121, 128, 321]. On the other hand, the inability of CsA to 
improve mitochondrial respiration makes sense physiologically as CsA inhibition of the 
mPTP allows mitochondria to sequester calcium, causing the mitochondrial membrane 
potential to decrease and respiration to slow. Although neither of these scenarios may 
be the case, as continuous infusion of CsA was also unable to prevent cytoskeletal α-
spectrin degradation (Fig. 3.5). However, it should be noted that pharmacologic-
dependent neurologic improvements have been documented absent attenuation of 
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spectrin degradation [132]. Further, based upon the preponderance of studies 
demonstrating CsA to be protective in experimental TBI, including its effects on synaptic 
mitochondria (Fig. 2.1 – 2.6) [309], we do not believe the absence of protective effects 
seen here preclude its future development as a translational therapy for TBI.  
Similar to CsA, it is possible that the mitochondria isolation technique utilized has 
also masked PZ protective effects to individual states of mitochondria respiration. For 
example, PZ binds mitochondrial aldehyde-protein conjugates [79, 262], but it is 
unknown what effect this has on post-injury mitochondrial dynamics, such as fission, 
fusion and mitophagy. It is possible that binding of PZ to mitochondria which are beyond 
saving is preventing these mitochondria from being degraded by normal post-injury 
processes and at the same time significantly improving the bioenergetics of the less 
damaged mitochondria. The unusual presence of these considerably damaged 
mitochondria in the mitochondria preps could mask improvements to individual states of 
mitochondrial respiration. Additionally in that regard, if aldehyde-scavengers are going to 
be pursued as therapeutic agents for TBI it will be important for future studies to 
investigate their effects on post-injury homeostatic mechanisms such as mitochondrial 
dynamics, mitophagy, and protein degradation. Also of note is the possibility that the 
significant decrease seen in aldehyde-mitochondrial conjugates following PZ 
administration (Fig. 3.4) is due to the inability of the 4-HNE and acrolein antibodies to 
recognize ternary drug-aldehyde-protein complexes. However, this is likely not the case 
as the continuous PZ dosing paradigm did demonstrate partial protective effects as 
evidence by the maintenance of RCR (Fig. 3.3) and cytoskeletal integrity (Fig. 3.5).  
Additionally, this study may have been complicated by the choice of drug 
combination. For example, CsA and PZ both physically bind mitochondria [79, 218, 258], 
which may have resulted in too many non-physiologic interactions for mitochondria, 
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particularly damaged mitochondria, to handle (Fig. 3.9). Additionally, CsA has a biphasic 
dose-response curve [294] and is metabolized by cyp3A4 [246], an enzyme which can 
be inhibited by PZ [266, 267]. In fact, although CsA has been previously identified as a 
good candidate for combination drug therapies [213], because it is metabolized by 
cyp3A4 [246], has a biphasic dose-response curve [294], and is a calcineurin inhibiting 
immunosuppressant [316], the number and types of drugs it could be safely combined 
with may be severely limited. In fact, a previous experimental TBI study which combined 
CsA with the antibiotic minocycline resulted in a 100% lethality rate [215, 283]. 
Therefore, clinical translation of CsA for use in TBI may hold the most promise if its use 
is restricted to that of a monotherapy agent. Similarly, given the complicated 
pharmacokinetics of PZ, an irreversible MAOI and MAO substrate, with several active 
metabolites [169, 189], PZ also may not represent the optimal choice for combinational 
drug therapy. 
However, several combinational therapy experimental designs do exist that avoid 
the above complications. First, two drugs that are mechanistically complementary but 
spatially distinct could be combined. For example, a blood brain barrier penetrable drug 
could be combined with tirilazad, as tirilazad’s primary effects are localized to the 
vasculature [1, 256]. Second, although the use of FDA-approved drugs such as CsA and 
PZ potentially makes clinical translation for TBI easier, faster, and cheaper than the use 
of experimental agents, combining drugs with less complicated mechanisms of action, 
such as the non-immunosuppressive mPTP inhibitor, NIM811, or a pure aldehyde-
scavenger, may limit confounding factors and offer a more straightforward approach. 
Finally, a drug could be combined with a non-pharmacological therapy such as stem cell 
administration or environmental enrichment. In fact, such pharmacologic + non-
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pharmacologic combinational designs seem to have a higher success rate than purely 
pharmacologic combinational approaches [215, 280].  
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and 
Memory and Cortical Tissue Sparing Following Experimental Traumatic Brain 
Injury 
Several studies have indicated that PZ can offer protection in experimental brain 
injury [71, 72, 76, 333, 334]. However, in order for PZ to be further developed for use in 
clinical TBI, the effect its MAOI properties have on TBI pathophysiology must be 
considered. Therefore, this study was designed to test the hypothesis that PZ, a LP-
derived neurotoxic aldehyde scavenger and MAOI, and hydralazine (HZ), an LP-derived 
neurotoxic aldehyde scavenger non-MAOI would improve cognitive function and cortical 
tissue sparing following experimental TBI, whereas pargyline (PG), a MAOI non-
aldehyde scavenger would not. Following severe controlled cortical impact injury 
(2.0mm), 3mo male Sprague-Dawley rats received an intraperitoneal dose of PZ 
(15mg/kg), HZ (5mg/kg), or PG (15mg/kg) at 15min, 24h, and 48h following injury. Morris 
water maze testing was conducted on day 3 – day 7 post-CCI and cortical tissue sparing 
was analyzed on post-CCI day 8. Additionally, the effects of the PZ, HZ, and PG dosing 
paradigms on tissue levels of monoamines and metabolites were evaluated via HPLC in 
uninjured cortical tissue as a surrogate marker of MAO inhibition. 
This was not only the first study to evaluate the effects of PG and HZ in 
experimental TBI, but it was also the first study to assess the behavioral effects of PZ in 
experimental TBI. Contrary to the hypothesis, the results indicate that PZ (15mg/kg, 
MAOI, aldehyde scavenger) and HZ (5mg/kg, non-MAOI, aldehyde scavenger), as well 
as PG (15mg/kg, MAOI, non-aldehyde scavenger),  were unable to attenuate reference 
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memory deficits (D7 post-CCI) (Fig. 4.10) or improve cortical tissue sparing (D8 post-
CCI) (Fig. 4.12) when administered intraperitoneal 15min, 24h, and 48h after a severe 
CCI (2.0mm) in 3mo male Sprague-Dawley rats. However, although non-significant, HZ 
led to the most improvement to cortical tissue sparing (Table 4.1). Of concern, following 
CCI PZ animals lost a significant amount of weight (Fig. 4.11), and their MWM 
acquisition performance did not significantly improve across time (D3-6 post-CCI), 
possibly indicating deficits to working memory, (Fig. 4.8), and perhaps being caused by 
PZ-induced high monoamine tissue levels as was seen in uninjured cortical tissue (i.e. 
NE, 5-HT) utilizing the same PZ dosing paradigm (Fig. 4.5 – 4.7). Similarly, qualitative 
behaviors observed in the PZ group following CCI may have also been suggestive of 
elevated monoamine levels. However, the effects of excessive aldehyde savaging or 
other PZ mechanisms of actions, such as inhibition of GABA-T or formation of PEA, 
cannot be ruled out as factors effecting outcome. 
There are several possible reasons for why, contrary to the original hypothesis, the 
hydrazine (-NH-NH2) containing aldehyde scavengers PZ and HZ were unable to provide 
significant protection in the current study. In regards to PZ, it is possible that at higher 
doses additional PZ mechanisms of action (MAO inhibition, GABA-T inhibition, PEA 
formation, etc.) or excessive aldehyde scavenging are detrimental and negate protective 
effects. It does seem that in the context of experimental TBI, lower doses of PZ may be 
more protective as they have been shown to improve cortical tissue sparing [71] and 
individual states of mitochondrial respiration [334], whereas higher PZ doses do not (Fig. 
3.2 and Fig. 4.12) [333]. However, this dose effect may also be outcome specific as 
continuous infusion of PZ is able to maintain cytoskeletal integrity better than bolus 
dosing (Table 3.4) [333, 334]. Although a different PZ dosing paradigm may have 
resulted in better outcomes, inclusion of additional experiments, such as HPLC analysis 
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of CCI + PZ tissue, measurement of GABA levels, and additional quantitative behavioral 
testing may also have led to a greater understanding of the effects PZ’s non-aldehyde 
scavenging mechanisms of action are having after TBI. Additionally, although a PG 
concentration equal to that of PZ was utilized as an extension of previous ex-vivo studies 
[72], because equal concentrations of PG and PZ are not necessarily pharmacologically 
equivalent, specifically in regards to MAO inhibition [189], choosing an alternate PG 
dosing concentration or a different MAOI for comparison to PZ may have led to a better 
understanding of MAO effects on TBI pathophysiology.  
Similarly, in regards to HZ, as this was the first study to evaluate HZ in experimental 
TBI, it is possible than an alternate dosing paradigm would have led to different results. 
It may be that the HZ dosing paradigm utilized was too low to achieve significant 
aldehyde scavenging and protective effects. Alternately, it is possible that as an anti-
hypertensive [268], the concentration of HZ utilized induced hypotension and negated 
any protective effects. Admittedly, this study would have been strengthened by the 
inclusion of blood pressure measurements after drug administration.  
On the other hand, it is possible that the PZ and HZ dosing paradigms utilized can 
provide protection, but that such protection was not observed in the single early 
behavioral task or in the single histological method analyzed. It is possible that delay of 
behavioral analysis, use of alternative behavioral tasks, or inclusion of additional 
histological methods may have yielded different results.  
Although it is unfortunate that the hydrazine (-NH-NH2) containing aldehyde 
scavengers, PZ and HZ, were unable to provide significant protection in the current 
study, both have shown extensive promise as neuroprotective agents in previous 
experimental studies of CNS injury [71, 72, 74-76, 333, 334, 361, 362]. Therefore, 
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aldehyde scavengers likely still offer a valid approach to neuroprotection after TBI and 
their development should continue to be pursued. However, based upon the results 
obtained in the current study, the PZ dosing paradigm has clearly not been optimized. 
Although the limitations of the current study make it impossible to say for sure if the 
effects of PZs MAOI mechanism of action are detrimental following TBI, the weight loss 
(Fig. 4.11), MWM acquisition performance (Fig. 4.8), qualitative behavioral 
observations, and uninjured HPLC data (Fig. 4.5 – 4.7) are concerning and suggestive 
of an MAOI effect. These observations, combined with the knowledge that MAOIs can 
lower seizure threshold [265], PZ is both an irreversible MAO inhibitor and substrate with 
complicated pharmacokinetics and several active metabolites [189], may make clinical of 
translation of PZ for use in human TBI difficult even if dosing paradigms are optimized in 
experimental rodent models. Similarly, HZ’s antihypertensive properties may limit its 
clinical translation. Therefore, if hydrazine (-NH-NH2) containing aldehyde scavengers 
are going to be further pursued as neuroprotective agents for TBI, it may be beneficial 
for future studies to develop hydrazine (-NH-NH2) compounds which lack confounding off 
target mechanisms of action. 
Further, it is interesting that the PZ dosing paradigm utilized in the current study was 
not only unable to provide protection but also resulted in significant weight loss (Fig. 
4.11) and negative behavioral effects (Fig. 4.8, qualitative observation), whereas 
similar dosing paradigms were safe and beneficial in other models of CNS injury such as 
SCI and ischemic-reperfusion [74-76]. One hypothesis for this is that PZ exacerbated 
severe CCI-induced monoamine elevations or monoamine oxidase inhibition. Although 
HPLC analysis of penumbral tissue did not show elevated monoamine levels post-CCI 
(Fig. 5.6 – 5.8), previous studies have found elevated monoamine levels after TBI 
depending on time point and brain region [154, 173, 174, 178, 182, 363-365]. However, 
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there is a dearth of information regarding the monoaminergic system acutely after TBI. 
Additionally, despite the central role mitochondria have in TBI and the known damage to 
mitochondrial function that occurs after TBI, little is known about the function of the 
mitochondrial enzyme, MAO, following injury. In fact, in general, controversy exists as to 
whether monoamines and monoamine oxidase inhibition are neuroprotective or toxic 
[154, 170, 181, 193, 194]. Therefore, such topics may be interesting areas of 
investigation for future TBI studies to pursue.  
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APPENDIX: 
Abbreviations  
2-propenal: acrolein  
2,4-DNP: 2,4-dinitrophenol  
3-HPMA: N-acetyl-S-3-hydroxypropylcysteine  
3-MP: 3-aminopropanal  
3-MT: 3-methoxytyramine  
3-NT: 3-nitrotyrosine  
4-HNE: 4-hydroxynonenal  
5-HIAA: 5-hydroxyindolacetic acid  
5-HT: 5-hydroxytryptamine (i.e. serotonin) 
ADP: adenosine diphosphate  
AIF: apoptosis inducing factor  
ALA-T: alanine transaminase  
ALDH: aldehyde dehydrogenase  
ANT: adenine nucleotide translocase  
ANOVA: analysis of variance  
APP: amyloid precursor protein  
ARE: antioxidant responsive element  
ATP: adenosine triphosphate  
CCI: controlled cortical impact traumatic brain injury  
CHI: closed head traumatic brain injury 
CMIA: continuous multiple trial inhibitory avoidance task  
CNS: central nervous system 
CO2: carbon dioxide  
CO●-3: carbonate radical  
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COMT: catechol-O-methyl transferase  
CsA: cyclosporine A  
CSF: cerebral spinal fluid  
CT: computerized tomography 
CyD: cyclophilin D 
DA: dopamine 
DHBA: dihydroxybenzylamine  
DOPAC: 3,4-dihydroxyphenylacetic acid  
eNOS: endothelial nitric oxide synthase 
EPI: epinephrine  
ER: endoplasmic reticulum  
ETC: electron transport chain 
FAD+ / FADH2: flavin adenine dinucleotide 
FCCP: carbonyl cyanide-p-trifluoromethoxyphenylhydrazone  
FDA: Federal Drug Administration 
Fe2+: ferrous iron 
Fe3+: ferric iron  
FPI: fluid percussion traumatic brain injury  
GABA: gamma-aminobutyric acid  
GABA-T: GABA transaminase 
GCEE: gamma-glutamylcysteine ethyl ester  
GCS: Glasgow coma scale  
GPx: glutathione peroxidase 
GSH: glutathione  
GST: glutathione-S-transferase  
H2O2: hydrogen peroxide   
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HPLC: high performance liquid chromatography  
HO-1: heme oxygenase-1 
HVA: homovanillic acid  
HZ: hydralazine  
iNOS: inducible nitric oxide synthase 
i.p.: intraperitoneal  
K+: potassium cation   
L•: lipid radical 
L1CAM: neuronal cell adhesion molecule L1 
LOO•: lipid peroxyl radical  
LP: lipid peroxidation 
MAO: monoamine oxidase 
MAOI: monoamine oxidase inhibitor  
MAP: microtubule associated protein   
Mito: mitochondria 
Mn-SOD: mitochondrial superoxide dismutase 2 (i.e. manganese superoxide dismutase)  
mPT: mitochiondrial permeability transition  
mPTP: mitochondria permeability transition pore 
MR: magnetic resonance 
mtNOS: mitochondrial nitic oxide synthase  
MWM: Morris water maze  
NAC: n-acetylcysteine  
NACA: n-acetylcysteine amide  
NAD+ / NADH: nicotinamide adenine dinucleotide 
NAD(P)H: nicotinamide adenine dinucleotide phosphate  
NE: norepinephrine 
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NH-NH2: hydrazine moiety  
NIH: National Institutes of Health  
NIM811: n-methyl-4-isoleucine cyclosporine  
NMDA: n-methyl-D-aspartic acid  
nNOS: neuronal nitric oxide synthase  
NO●: nitric oxide radical  
NO●2: nitrogen dioxide oxide radical  
NOS: nitric oxide synthase  
NqO1: NAD(P)H quinione oxidoreductase 1 
Nrf2: nuclear factor (erythroid-derived 2) 
NS: non-synaptic  
O2: molecular oxygen 
O2•
-: superoxide radical  
OCD: ornithine decarboxylase  
OH•: hydroxyl radical  
OH-: hydroxyl anion 
ONOO-: peroxynitrite anion 
ONOOCO2
-: nitrosperoxocarbonate  
ONOOH: peroxynitrious acid  
ORN-T: ornithine transaminase  
Pi: inorganic phosphate  
PBS: phosphate buffered saline 
PEA: phenethylamine  
PEG-SOD: polyethylene glycol superoxide dismutase  
PEH: phenylethyldenehydrazine  
PFA: paraformaldehyde  
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PG: pargyline  
PKC: protein kinase C 
PN: peroxynitrite 
psi: pounds per square inch  
PUFA: polyunsaturated fatty acid  
PZ: phenelzine 
RCR: respiratory control ratio 
ROS: reactive oxygen species 
RNS: reactive nitrogen species 
SBDP: spectrin breakdown products  
s.c.: subcutatenous  
SCI: spinal cord injury  
SNK: Student-Newman-Keuls  
SNRI: serotonin-norepinephrine-reuptake inhibitor 
SOD: superoxide dismutase  
SSRI: selective serotonin reuptake inhibitor  
Syn: synaptic  
TCA: tricarboxylic acid cycle (i.e. citric acid cycle, Krebs cycle) 
TBI: traumatic brain injury 
TBS: tris-buffered saline  
TBST: tris-buffered saline with tween  
VDAC: voltage-dependent anion channel  
WD: weight drop traumatic brain injury  
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(2016). Journal of Neurotrauma: 33(13): A-1-A-139 (2016) 
 
Kulbe JR, Hill RL, Singh IN, Wang JA, and Hall ED “Temporal profile of non-synaptic 
and synaptic mitochondrial bioenergetics following severe controlled cortical impact 
traumatic brain injury in rats” Poster presented at 3rd Annual Molecular Psychiatry 
Meeting, San Francisco, CA (2015) 
 
Regional, Local, Institutional Posters and Abstracts  
 
Kulbe JR, Dunkerson JA, Huettl PF, Wang JA, Smith R, and Hall ED “Phenelzine, 
pargyline, and hydralazine: the effects of lipid-peroxidation-derived aldehyde scavenging 
and monoamine oxidase inhibition on learning and memory and cortical tissue sparing 
following experimental TBI” Poster presented at 14th Annual Center for Clinical and 
Translational Sciences Spring Conference, Lexington, KY (2019) 
 
Kulbe JR, Singh IN, Dunkerson JA, Wang JA, Hill RL, Smith R, Huettl PF, and Hall ED 
“Neuroprotective strategies following experimental traumatic brain injury: inhibition of 
mitochondrial permeability transition, lipid peroxidation-derived aldehyde formation, and 
monoamine oxidase” Poster presented at University of Kentucky Department of 
Neurology Resident and Trainee Research Day, Lexington, KY (2018) 
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Kulbe JR, Singh IN, Dunkerson JA, Wang JA, Hill RL, Smith R, Huettl PF, and Hall ED 
“Neuroprotective strategies following severe controlled impact traumatic brain injury: 
lipid peroxidation-derived neurotoxic aldehyde scavenging and inhibition of 
mitochondrial permeability transition” Poster presented at 24th Annual KSCHIRT 
Symposium, Lexington, KY (2018) 
 
Kulbe JR, Singh IN, Dunkerson JA, Wang JA, Hill RL, Smith R, Huettl PF, and Hall ED 
“Neuroprotective strategies following severe controlled impact traumatic brain injury: 
lipid peroxidation-derived neurotoxic aldehyde scavenging and inhibition of 
mitochondrial permeability transition” Poster presented at 13th Annual Center for 
Clinical and Translational Sciences Spring Conference, Lexington, KY (2018) 
 
Kulbe JR, Singh IN, Wang JA, and Hall ED “Neuroprotective evaluation of the 
combination phenelzine and cyclosporine A following severe controlled cortical impact 
traumatic brain injury” Poster presented at 23rd Annual KSCHIRT Symposium, 
Louisville, KY (2017) 
 
Kulbe JR, Singh IN, Wang JA, and Hall ED “Evaluation of the combinational therapy 
cyclosporine A and phenelzine on protection of mitochondrial respiratory function 
following severe controlled cortical impact injury in rats” Poster presented at 12th 
Annual Center for Clinical and Translational Sciences Spring Conference, Lexington, 
KY (2017) 
 
Kulbe JR, Hill RL, Singh IN, Wang JA, and Hall ED “Cyclosporine A protects synaptic 
and non- synaptic mitochondria following severe controlled cortical impact injury in rats” 
Poster at Kentucky Neuroscience Institute Clinical-Translational Research Symposium, 
Lexington, KY (2016) 
 
Kulbe JR, Hill RL, Singh IN, Wang JA, and Hall ED “Cyclosporine A protects synaptic 
and non-synaptic mitochondrial bioenergetics 24h following severe controlled cortical 
impact injury” Poster presented at 31st Annual Bluegrass Society for Neuroscience 
Spring Neuroscience Research Day, Lexington, KY (2016) 
 
Kulbe JR, Hill RL, Singh IN, Wang JA, and Hall ED “Cyclosporine A protects synaptic 
and non-synaptic mitochondria and attenuates calpain-mediated cytoskeletal 
degradation 24h following severe controlled cortical impact traumatic brain injury in rats” 
Poster presented at University of Kentucky AOA Groves Memorial MD/PhD Student 
Research Day, Lexington, KY (2016) 
 
Kulbe JR and Geddes JW “Identification of novel serum biomarkers for mild 
traumatic brain injury using phage display” Poster presented at University of Kentucky 
AOA Groves Memorial MD/PhD Student Research Day, Lexington, KY (2015) 
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Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, and Bayer KU “Excitotoxic 
glutamate insults block autophagic flux in hippocampal neurons” Poster presented at 
University of Kentucky AOA Groves Memorial MD/PhD Student Research Day, 
Lexington, KY (2014) 
 
Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, and Bayer KU “Excitotoxic 
glutamate insults block autophagic flux in hippocampal neurons” Poster presented at 
University of Kentucky AOA Groves Memorial MD/PhD Student Research Day, 
Lexington, KY (2013) 
 
Oral Conference Presentations 
 
“A pharmacologic neuroprotective approach to experimental TBI: targeting 
mitochondria & lipid peroxidation-derived aldehydes” 3rd Annual Neuroscience Clinical-
Translational Research Symposium, Lexington, KY (2018) 
 
“Multi-Mechanistic Attenuation of Mitochondrial Dysfunction and Lipid Peroxidation 
Following Experimental Traumatic Brain Injury” 13 th Annual Center for Clinical and 
Translational Sciences Spring Conference, Lexington, KY (2018) 
 
“Continuous Infusion of Phenelzine, Cyclosporine A, or the Combination: Evaluation of 
Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal Degradation 
Following Severe Cortical Impact Traumatic Brain Injury in Rats” 2nd Annual University 
of Michigan Massey TBI Summit Invited Mentee Research Presentation, Ann Arbor, MI 
(2017) 
 
“Cyclosporine A Protects Synaptic Mitochondria Following TBI”, NIMH MD/PhD Student 
Conference Data Blitz, San Francisco, CA (2015) 
 
Oral Department Presentations  
 
“Multi-Mechanistic Attenuation of Mitochondrial Dysfunction and Lipid Peroxidation 
Following Experimental Traumatic Brain Injury” Center for Clinical and Translational 
Sciences Seminar, University of Kentucky, Lexington, KY (2018) 
 
“Neuroprotective Evaluation of 72h Subcutaneous Continuous Infusion of Phenelzine, 
Cyclosporine A, and the Combination Following Severe Controlled Cortical Impact 
Injury” Department of Neuroscience Seminar, University of Kentucky, Lexington, KY 
(2017) 
 
“Cyclosporine A Improves Synaptic and Non-Synaptic Mitochondrial Respiration 
following TBI”, Department of Neuroscience Seminar, University of Kentucky, Lexington, 
KY (2016) 
  
 
 
298 
“Identification of Novel Serum Biomarkers for Mild Traumatic Brain Injury Using Phage 
Display”, Center for Clinical and Translational Sciences Seminar, University of Kentucky, 
Lexington, KY (2015) 
 
Journal Club Presentations 
 
Journal Club Paper Presentation: “Cyclic head rotations produce modest brain injury in 
infant piglets (Coats et al. 2016)”, University of Kentucky Spinal Cord and Brian Injury 
Research Center Journal Club, Lexington, KY (2016) 
 
Journal Club Paper Presentation: “Neurobehavioral, neuropathological and biochemical 
profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild 
traumatic brain injury (Ojo et al. 2014)”, University of Kentucky Spinal Cord and Brian 
Injury Research Center Journal Club, Lexington, KY (2016) 
 
Course Lectures 
 
“Chronic traumatic encephalopathy-integration of canonical traumatic                       2018 
brain injury 22018secondary injury mechanisms with tau pathology”  
ANA 605 / PGY605 Neurobiology of CNS Injury and Repair, University of Kentucky 
 
“Programmed Cell Death Mechanisms: Role in CNS Injury”                             2016, 2018                                       
ANA 605 / PGY605 Neurobiology of CNS Injury and Repair, University of Kentucky 
 
Funding 
 
NIH F30 (NINDS) NRSA pre-doctoral Fellowship (F30NS096876)         07/2016 – Present 
“Multi-mechanistic protection of mitochondria following traumatic brain injury”   
 
Honors & Awards  
 
P.E.O. Scholar Award            2019 
Merit-based scholarship awarded for scholarly excellence, academic  
achievement, & worthwhile career goals by the International Chapter of the P.E.O. 
 
University of Kentucky Graduate School Incentive Award                            2018 
Awarded for receipt of a nationally competitive fellowship, i.e. NRSA F30 
 
Society for Neuroscience Trainee Professional Development Award                2018 
Awarded to attend the 2018 Society for Neuroscience Annual Meeting, 
San Diego, CA 
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University of Kentucky Graduate School Travel Award                   2018 
Awarded to attend the 3rd Joint Symposium of the International and National 
Neurotrauma Societies, Toronto, Canada  
 
2nd Annual University of Michigan Massey TBI Summit Invited Mentee                        2017 
Invited mentee, Ann Arbor, MI  
 
EMBO-FEBS Lecture Course “Mitochondria in Life, Death, and Disease”         2017 
Selected attendee, Brindisi, Italy  
 
National Neurotrauma Symposium Sensor Travel Grant Award                 2017 
Awarded to attend the “Environmental Sensor Use for Quantifying Neural  
Exposure to Inertial and Blast Forces” Pre-Meeting Workshop,  
35th Annual National Neurotrauma Symposium, Snowbird, UT  
 
University of Kentucky Graduate School Travel Award                 2017 
Awarded to attend the 2017 AAP/ASCI/APSA Joint Meeting, Chicago, IL 
 
University of Kentucky Graduate School Incentive Award                  2016 
Awarded for receipt of a nationally competitive fellowship, i.e. NRSA F30 
 
AUPN/NINDS Travel Award                                             2016 
Awarded to attend the Combining Clinical and Research Careers in  
Neuroscience Symposium, Washington, DC 
 
Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) Travel Award     2016 
Awarded to attend the 34th Annual National Neurotrauma Symposium, 
Lexington, KY 
 
NIMH Travel Award                                   2015 
Awarded to attend the NIMH MD/PhD Student Conference & 3rd Annual Molecular 
Psychiatry Meeting, San Francisco, CA 
 
University of Kentucky College of Medicine (M1 and M2) 
 Promoted with High Distinction            2013 – 2014 
Promoted with High Distinction                                                   2012 – 2013 
Highest Academic Achievement: Behavioral Basis of Medicine                      2013 
Distinguished Portfolio Award: Introduction to Clinical Medicine I                2013 
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Undergraduate                        2001 – 2004 
 Magna cum laude 
 Phi Beta Kappa 
 Alpha Epsilon Delta and Golden Key National Honor Societies 
 Dean’s List, National Dean’s List and Hornbeck Scholar 
 Outstanding Student Achievement, Department of Chemistry 
 
Service 
Ad hoc reviewer, Headache: The Journal of Head and Face Pain 
University of Kentucky MD-PhD Internal Advisory Committee                         2015 – 2017 
Teaching Assistantship 
Neuroscience Department Proctor 
 Principles of Human Anatomy                  2018 – 2019 
 Anatomy and Physiology for Nursing        2016 – 2017 
 Principles of Human Anatomy                   2014 – 2015 
  
Neuroscience Department Teaching Assistant  
 Anatomy and Physiology for Nursing        2015 – 2016 
 
Membership  
Society for Neuroscience                    
American Physician Scientist Association                 
National Neurotrauma Society                                                                                  
Women in Neurotrauma Research                                                                           
Bluegrass Chapter of the Society for Neuroscience                                                 
American Medical Student Association                                                                       
 
 
